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Summary 
RNA polymerase II (RNAPII) has been identified almost 40 years ago, but the molecular 
details of its regulation and fine tuning during messenger RNA (mRNA) synthesis are 
still far from understood. Subsequently to RNAPII six general transcription factors 
(GTFs; TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH) were discovered of which all except 
TFIIA are necessary and sufficient for promoter-dependent basal transcription initiation. 
In addition to the GTFs activator-dependent transcription requires the presence of a 
transcription cofactor, the Mediator complex. Mediator serves as a link between 
transcription activators, enhancers and the general transcription machinery. Initial studies 
revealed that Mediator stimulates the activity of the TFIIH associated kinase CDK7 and 
thereby facilitates RNAPII C-terminal domain (CTD) phosphorylation. Furthermore the 
Mediator complex interacts functionally with several signal transduction pathways and 
serves as an signal integration platform.  
In order to dissect the process of transcription initiation, early studies made use of in vitro 
transcription systems reconstituted from recombinant or highly purified GTFs and 
RNAPII. In this system basal, activator-independent transcription does not require the 
presence of the Mediator complex. If however a more physiological nuclear extract 
transcription system is used, our laboratory and others have established previously that 
basal transcription becomes critically dependent on Mediator. Another difference 
between both transcription systems is that the first is insensitive to the kinase inhibitor H8 
whereas in the second transcription can be inhibited by H8. This suggests that only the 
second transcription system is regulated by RNAPII CTD phosphorylation. In this thesis 
the interplay between Mediator, RNAPII, GTFs and transcription cofactors was studied 
using immobilized promoter template assays in combination with various 
immunodepleted nuclear extracts and recombinant factors.  
Negative cofactor 2 (NC2) is an evolutionary conserved general cofactor that binds to 
many active genes in vivo. Previous studies in our laboratory had shown with 
recombinant proteins that NC2 competes with TFIIA and TFIIB for binding to TATA-
binding protein (TBP) at a promoter in vitro. Genetic studies in yeast provided evidence 
that Mediator acts antagonistically to NC2. Here I have studied the role of NC2 on 
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preinitiation complex (PIC) formation and transcription in nuclear extracts. I observed 
rapid association of TFIID with promoters whereas NC2 enters PICs with a slow kinetic 
which is similar to that of TFIIB recruitment. My data indirectly suggest that TBP binds 
to DNA in a yet to be defined inactive form (perhaps as a TFIID complex) which is then 
slowly converted into an active TBP-TATA complex that is rapidly recognized by GTFs 
or NC2. My data support the notion that NC2 and TFIIB compete for binding to a PIC 
also in immobilized promoter assays under physiological conditions. NC2 concentrations 
in nuclear extracts appears to be tightly controlled. Doubling the NC2 concentration in a 
nuclear extract by adding recombinant NC2 (rNC2) abolished functional PIC formation 
and transcription. However, the in vitro analysis also showed that upstream of NC2 PIC 
formation is fully dependent on Mediator. Hence, TFIID binds to a promoter in a nuclear 
extract in vitro transcription system but we have no indication that a transcription 
competent PIC is formed in the absence of Mediator.  
In yeast studies it was reported that upon transcription initiation in vitro several GTFs 
dissociate from the promoter DNA template whereas the Mediator complex is retained in 
a reinitiation complex. In the human system I recapitulate this observation for TFIIB and 
CDK7. In addition I provide evidence that Mediator partially dissociated from the 
promoter template upon transcription initiation. Upon transcription initiation the middle 
module subunit MED7 was retained on a promoter template, whereas the tail module 
subunit MED15 and CDK8 did dissociate. This data suggest that upon transcription 
initiation a head/middle module Mediator subcomplex is retained at the promoter 
whereas the tail and CDK8 modules dissociate.  
Previous studies have established that Mediator promotes CDK7-dependent 
phosphorylation of the RNAPII CTD at serine-5 (ser-5). Various studies found that CTD 
ser-5 phosphorylation does coincide with transcription initiation. Using new monoclonal 
antibodies I observed two functionally distinct modes of CTD ser-5 phosphorylation in 
vitro: Hypo- and hyperphosphorylation of the largest RNAPII subunit Rpb1. I observed 
that CTD ser-5 hypophosphorylation is established already before complex opening by 
TFIIH. I found CTD ser-5 hypophosphorylation to be critically dependent on TBP, 
Mediator, TFIIB and CDK7. In addition I noted that CTD ser-5 hypophosphorylation 
correlates with the transcription potential of a PIC. CTD ser-5 hyperphosphorylation was 
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established in a Mediator-dependent fashion but independent of productive transcription. 
Immunodepletion of CDK7 did not led to a reduction in CTD ser-5 
hyperphosphorylation. However, immunodepletion of CDK8 caused a reduction but not a 
loss of CTD ser-5 hyperphosphorylation upon transcription initiation indicating that 
another yet to be identified kinase might be involved in this process. These data suggest 
that CTD ser-5 hypophosphorylation is established only in the PIC context on RNAPII 
located at bona fide promoter regions but not on RNAPII complexes bound to DNA 
outside of promoter regions, e.g. in an open reading frame.   
 Recently phosphorylation of the RNAPII CTD at serine-7 (ser-7) was reported. In that 
study the entire coding region of the TCRβ locus was found to be associated with 
RNAPII CTD phosphorylated at ser-7. Starting from there I found that establishment of 
CTD ser-7 phosphorylation in the process of transcription initiation can be recapitulated 
in an immobilized template assay system in vitro. I confirmed the in vitro finding that 
establishment of CTD ser-7 phosphorylation correlates with transcription initiation with 
chromatin immunoprecipitation experiments on an inducible model gene system in vivo. 
Similar to CTD ser-5 phosphorylation, I observed two modes of CTD ser-7 
phosphorylation: CTD ser-7 hypo- and hyperphosphorylation. In contrast to CTD ser-5 
hypophosphorylation, which was established before complex opening, I observed 
establishment of CTD ser-7 hypophosphorylation predominantly after complex opening 
by TFIIH. Both, CTD ser-7 hypo- and hyperphosphorylation were found to be Mediator-
dependent. A mass spectrometric screen for PIC associated kinases (in collaboration with 
the laboratory of Gerhard Mittler) yielded 13 kinases. Seven of the identified kinases 
were further tested for their potential to phosphorylate the RNAPII at ser-7 in an 
immobilized template assay.  
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A. Introduction 
A.1 Transcription Overview 
More than 30 years ago Robert Roeder and William Rutter purified RNA polymerase I, II 
and III (Roeder and Rutter, 1969). Since then six general transcription factors and several 
positive and negative cofactors have been identified but still the exact molecular 
mechanism of transcription initiation remains elusive. Messenger RNA biogenesis is a 
complex and highly interconnected process in which large protein complexes devoted to 
RNA synthesis, elongation, capping, splicing, polyadenylation and RNA export act 
simultaneously in the context of chromatin. Phosphorylation of the RNAPII CTD has 
been described in great detail but several mechanistic explanations are missing in 
particular with respect to CTD ser-5 phosphorylation. Till the present day it could not be 
conclusively resolved whether RNAPII moves along a DNA template during 
transcription, or whether the DNA is pulled through a large protein assembly called the 
transcription factory. Another mystery represents the mechanism by which RNAPII 
manages to transcribe through chromatin. (Hirose and Manley, 2000; Maniatis and Reed, 
2002; Orphanides and Reinberg, 2002; Proudfoot et al., 2002). For the development and 
maintenance of an organism it is of paramount importance to regulate and coordinate all 
of the above processes properly. Gene expression can be controlled at several levels: The 
access of transcription activators to promoters is regulated by chromatin, transcription 
initiation by an complex interplay of transcription factors being recruited to promoters 
and enhancers. Before RNAPII switches to productive mRNA synthesis, abortive 
transcripts are produced. In addition transcription at many promoters appears to be 
regulated at the elongation step, as many genes are found to be associated with initiated 
but paused polymerases (Guenther et al., 2007). Furthermore is the stability of a 
particular mRNA subject to regulation by various mechanisms within the cell.  
A.1.1 The Transcription Cycle 
The transcription cycle of RNAPII can be divided into six subsequent steps: (1) Pre- 
initiation complex (PIC) formation, (2) transcription initiation and (3) promoter 
clearance, (4) elongation, (5) 3’end formation and finally (6) termination of transcription 
(Fig. 1). The first step in transcription initiation complex formation is the recruitment of 
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the transcription machinery to the promoter to form a preinitiation complex (PIC). The 
efficiency of this step is determined by the accessibility of the chromatin-embedded 
promoter, promoter specific regulatory factors and the core promoter elements (TATA 
box, initiator (INR), TFIIB recognition element (BRE) and downstream promoter 
element (DPE)). Two models were proposed: A stepwise assembly pathway and a 
holoenzyme model. In the stepwise assembly model the GTFs and RNAPII are recruited 
sequentially. This model describes the situation well if purified or recombinant proteins 
are used in an in vitro transcription assay (Orphanides et al., 1996). The holoenzyme 
model states that GTFs and RNAPII are recruited together with coactivators like 
Mediator in a preassembled complex to the promoter. This model is based on in vitro data 
in which nuclear extracts instead of purified or recombinant factors were used (Chang 
and Jaehning, 1997; Myer and Young, 1998).  The yeast holoenzyme complex contains 
the GTFs TFIIB and TFIIH (Wilson et al., 1996). TFIID and TFIIA are not found in 
holoenzyme complexes. Upon PIC assembly components are recruited the ATP-
dependent DNA helicase activity XPB, which is part of the TFIIH complex, catalyses the 
formation of the open complex. During open complex formation 11-15 bp of double-
strand DNA close to the transcription start site are melted and the template strand is 
positioned into the active site of RNAPII (Wang et al., 1992). Formation of the open 
complex can be inhibited by ATPγS, which inhibits the TFIIH associated helicase 
(Stelzer et al., 1994). After formation of a 4 nt RNA, transcription is no longer sensitive 
to ATPγS, indicating that the TFIIH helicase is only required for the initial DNA melting 
(Stelzer et al., 1994). In several transcription systems multiple short RNAs (3-10 nt in 
length) are generated as so called abortive transcripts before RNAPII productively 
initiates synthesis of full length transcripts (Holstege et al., 1996; Luse and Jacob, 1987).       
During promoter clearance RNAPII is released from the PIC. Based on the finding that 
the Mediator complex does interact with unphosphorylated but not with 
hyperphosphorylated RNAPII CTD (Svejstrup et al., 1997) it is likely that CTD 
hyperphosphorylation plays a crucial role in promoter clearance. During PIC formation or 
transcription initiation CTD ser-5 phosphorylation is established but it has not been 
resolved in the literature at which point it is established. Furthermore it is not definitely 
solved to which degree the promoter associated CTD ser-5 kinases CDK7 and CDK8  
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Figure 1: The pathway of transcription initiation and reinitiation for RNAPII. Taken from a review by 
Steven Hahn (Hahn, 2004).   
 
contribute to CTD ser-5 phosphorylation of RNAPII (Lee and Young, 2000; Liu et al., 
2004). Upon transcription initiation in vitro the PIC does partially dissociate. In yeast  
TFIIA, TFIID, TFIIE and p62 of TFIIH and several Mediator subunits remain associated 
with the promoter template whereas RNAPII, TFIIB and TFIIF do not. Notably the tail 
Mediator subunit MED15 (Gal11) appears to dissociate whereas the head middle subunits 
MED17 (Srb4), MED20 (Srb2) and MED6 remain attached to the promoter DNA 
template upon transcription initiation (Yudkovsky et al., 2000). RNAPII that managed to 
escape the promoter will finally switch to the elongation mode, which is associated with 
phosphorylation of the RNAPII CTD at ser-2, which in turn is mediated by CDK9 (Price, 
2000). Upon reinitiation of transcription at the promoter RNAPII, TFIIB and TFIIF are 
recruited again to the promoter, and the transcription cycle starts over again with PIC 
formation (Hahn, 2004). 
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A.2. Regulation of RNA Polymerase II 
Timing and location of RNAPII transcription initiation is tightly regulated by a variety of 
accessory factors such as general transcription factors, positive and negative cofactor 
complexes and chromatin modifying enzymes. These factors guide RNAPII to bona fide 
transcription start sites and facilitate transcription initiation. A particular regulatory 
surface is the C-terminal domain (CTD) of the largest subunit of RNAPII. It acts as a 
binding surface for transcription related protein complexes. Post-translational 
modifications of the CTD ensure recruitment of these complexes in the correct order 
(Meinhart et al., 2005).   Furthermore transcription regulation by CTD post-translational 
modifications is proposed to occur in a combinatorial fashion, as stated in the CTD-code 
hypothesis (Buratowski, 2003). A common view on RNAPII function is that it travels 
along the DNA template during transcription. Given the fact that the assembled RNAPII 
transcription machinery represents a complex of several megadalton, it is also possible 
that the DNA is moved though a stationary transcription factory. Evidence for this 
scenario comes from a combination of three-dimensional fluorescence in situ 
hybridization, immunofluorescence and chromosome conformation capture (3C) 
experiments. They revealed that active genes are clustered in the nucleus and that these 
genes are recruited to sites of active transcription, and not vice versa (Cook, 1999; Faro-
Trindade and Cook, 2006). 
A.2.1. RNA Polymerase II 
RNAPII is a 500 kDa multiprotein complex composed of 12 subunits. The subunits can 
be classified into three groups:  (i) subunits that are shared between RNAPI, II and III 
(Rpb5, 6, 8, 10, 12); (ii) RNAPII specific core subunits (Rpb1, 2, 3, 11) and (iii) the 
RNAPII specific subunits Rpb 4 and 7 that are not essential for transcription elongation 
in vitro (Cramer et al., 2000). A unique feature of RNAPII is the presence of  several 
repeats of the heptapeptide YSPTSPS in the C-terminal region of Rpb1. All amino acids 
of the heptarepeats have the potential to be post-translationally modified. The RNAPII 
CTD is part of the largest subunit of RNAPII, Rpb1, and attached to the body of RNAPII 
by a flexible linker region. In x-ray structures of RNAPII the CTD is not visible and 
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therefore may exhibit an unstructured conformation. Binding of transcription cofactors 
may induce distinct CTD structures (Meinhart and Cramer, 2004; Noble et al., 2005). 
 
A.2.1.1. CTD  
The C-terminal domain of RNAPII can be seen as regulatory switchboard for RNAPII  
transcription activity. It interacts with components of the preinitiation complex, e.g. the 
Mediator complex (Naar et al., 2002), as well as with factors required for RNA 
processing, e.g. the capping enzyme complex (Komarnitsky et al., 2000). By now it is 
established that RNAPII can be phosphorylated at ser-2, -5 and -7 of a heptarepeat. 
During the transcription cycle, RNAPII is incorporated into the PIC in the 
unphosphorylated form, and then sequentially phosphorylated at ser-5 and, as the 
polymerase switches to the elongation mode, at ser-2. The physiological significance of 
CTD ser-7 phosphorylation has not been elucidated in detail (Chapman et al., 2007; 
Phatnani and Greenleaf, 2006). Interestingly, in vitro transcription reactions involving 
highly purified or recombinantly expressed factors are not dependent on CTD 
phosphorylation, whereas in vitro transcription in the nuclear extract system is dependent 
on CTD phosphorylation and sensitive to the kinase inhibitor H8 (Serizawa et al., 1993).  
A.2.1.2. CTD kinases 
Several kinases have the potential to phosphorylate the CTD of RNAPII at least in vitro. 
Most CTD kinases belong to the class of cell-cycle dependent kinases (CDKs) and 
require a cyclin as cofactor for full activation. The largest subgroup within the CTD 
kinases represent the CDK1-related CDC2-like kinases CDK1, CDK9, CDK11, CrkRS 
and CDK13. The Mediator complex can be associated either with CDK8 or the CDK8-
like kinase CDK11. Another PIC associated CTD kinase is CDK7. DNA-PK and ERK 
have been identified as CTD kinases, however little is know about the physiological 
significance of their particular CTD phosphorylation activities (Table 1).  
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CDK CTD-P 
specificity 
General 
function 
Cyclins/ 
Cofactors 
Reference 
CDK1 ser-2, ser-5  mitosis A, B (Cisek and Corden, 1989; Gebara 
et al., 1997) 
CDK2 ser-2, ser-5 mitosis E (Deng et al., 2002) 
CDK7 ser-5 mitosis/ 
transcription 
H (Trigon et al., 1998) 
CDK8 ser-5  transcription C (Hengartner et al., 1998) 
CDK8-like   
(aka CDK11) 
 transcription C (Tsutsui et al., 2008) 
CDK9 ser-2, ser-5 transcription T, K (Price, 2000) 
CDK11  alternative 
splicing 
L (Hu et al., 2003) 
CDK12/CrKRS/ 
CDC2L7 
 transcription/ 
splicing 
L (Chen et al., 2006) 
CDK13/CDC5L  splicing  (Chen et al., 2007) 
CKII  ubiquitous  (Trembley et al., 2003) 
DNA-PK ser-2, ser-7 transcription 
reinitiation 
Ku80, Ku86 (Trigon et al., 1998) 
ERK1/2 ser-5 signal 
transduction 
 (Trigon et al., 1998) 
 
Table 1: CTD kinases and their CTD phosphorylation specificity as reported in the literature  
 
CDK1 
In yeast the CDK1 homologue CDC2 (S. pompbe) or CDC28 (S.cerevisiae) are required 
for the G1-S and the G2-M transition. CDC2 is involved in the coordination of cell-cycle 
dependent gene transcription (Wittenberg and Reed, 2005). CDK1 is responsible for cell 
cycle-dependent CTD hyperphosphorylation during M-phase. As a consequence 
RNAPII-dependent transcription is shut down. During mitosis the hypophosphorylated 
IIa form of RNAPII virtually disappears and the hyperphosphorylated, inactivated form 
predominates (reviewed in (Bregman et al., 2000)). Purified CDC2/cyclin B kinase is 
sufficient to inhibit transcription in reconstituted transcription reactions with biochemical 
purified and recombinant basal transcription factors (Long et al., 1998). Yu and 
colleagues described CDK1 in S.cerevisiae as essential for GAL1 transcription. However, 
they find that the kinase activity of CDK1 is not essential for transcription initiation (Yu 
et al., 2005). CDK1 is activated by T-loop phosphorylation and a substrate of CDK7 
within the CAK complex (Larochelle et al., 2007).  Based on in vitro kinase assays with 
CTD peptides as substrates, CDK1 phosphorylates ser-2 and ser-5 within the  CTD of 
RNAPII (Gebara et al., 1997). 
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CDK9 (CDC2L4) 
CDK9 acts in conjunction with T-type cyclins and is the catalytic subunit of the positive 
transcription elongation factor (pTEFb) (Price, 2000). P-TEFb acts at the level of 
elongation and is regulated by reversible association of the regulator 7SK RNA and an 
RNA binding protein, HEXIM1 or HEXIM2 (Byers et al., 2005). The p-TEFb activity is 
required to overcome a transcription arrest during early elongation which is imposed by 
the DSIF and NELF complexes. In this process the RNAPII CTD is critical (Marshall et 
al., 1996; Marshall and Price, 1995) and phosphorylated predominantly by pTEFb 
associated CDK9 at ser-2. Another substrate of pTEFb is the hSpt5 subunit of DSIF 
(Price, 2008). CTD ser-2 phosphorylation increases towards the 3’end of a transcribed 
gene in vivo (Chapman et al., 2007).  
    
CDK11 (CDC2L1/CDC2L2)  
CDK11, formerly known as PITSLRE, is a member of the CDK1-related kinases. It is 
encoded by two different, but highly similar, genes CDC2L1 (cell devision control like 1) 
and CDC2L2 (cell devision control like 2) (Kahle et al., 2005). Three variants of CDK11 
are found in a cell, CDK11(p110), CDK11(p58) and CDK11(p46). All isoforms are 
associated with L-type cyclins. A yeast two-hybrid screen found CDK11(p46) to interact 
with the CCR4-NOT complex component NOT2 (Shi and Nelson, 2005). The 
CDK11(p110) isoform has been implicated in splicing, as immunodepletion of CDK11 
from a splicing extract reduces the appearance of spliced products in an in vitro system 
(Hu et al., 2003; Loyer et al., 2008). CDK11 co-purifies and is tightly associated with 
casein kinase II (CKII). CDK11 associated CKII phosphorylates the CTD of RNAPII as 
well as CDK11(p110) (Trembley et al., 2003). CDK11(p110) was found to be a substrate 
of CDK7 in vitro (Larochelle et al., 2006).  
 
CrkRS (CDK12/CDC2L7) 
CrkRS, also named CDK12 or CDC2L7 (cell devision control like 7), is a CDK1-related 
kinase that contains an arginine- and serine-rich domain, a feature that is found in several 
SR protein family splicing factors. CrkRS interacts with L-type cyclins and has been 
shown to regulate alternative splicing of an E1A minigene. (Chen et al., 2006). Anti-
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CrkRS antibodies stain nuclei in a pattern that overlaps with that of splicosomal 
components and hyperphosphorylated RNAPII. Anti-CrkRS immunoprecipitations 
phosphorylate the RNAPII CTD in vitro (Ko et al., 2001). Human CDK9 is orthologous 
to S.cerevisiae BUR1, whereas the CTD kinase CTDK-I is more closely related to human 
CDK13 and CrkRS (Guo and Stiller, 2004). 
 
CDK13 (CDC2L5) 
CDK13, also known as CDC2L5 (cell devision control like 5), is like CrkRS involved in 
the regulation of alternative splicing. It interacts with L-type cyclins (Chen et al., 2007).  
 
CDK7 
CDK7 is a kinase with a dual function, depending on the complex it is associated with. 
The trimetric CAK complex is required for cell cycle progression (Larochelle et al., 
2007). Genetic studies in yeast indicated that the S.cerevisiae CDK7 homologue Kin28 is 
essential for RNAPII gene expression (Cismowski et al., 1995; Valay et al., 1995, 
Holstege et al., 1998). A recent study using a chemical inhibitor raised specifically 
against an engineered Kin28 protein found that the kinase activity of Kin28 is 
dispensable for transcription (Kanin et al., 2007).  CDK7 is part of the TFIIH complex 
and has been shown to phosphorylate RNAPII CTD at ser-5. Furthermore CDK7 has 
been shown to be required for the assembly of CDK1/cyclin B complexes as well as for 
activation of CDK2 (Larochelle et al., 2007). 
 
CDK8/CDK11 
CDK8 is component of the Mediator complex. It is a RNAPII CTD kinase that 
phosphorylates the CTD at ser-5 (Hengartner et al., 1998). A close homologue of CDK8 
is the CDK8-like (CDK8L) kinase (Sato et al., 2003). Like CDK8 it is associated with the 
Mediator complex. In some publications this kinase is referred to as CDK11, however it 
is not identical to the CDK1-related CDK11 kinase (Tsutsui et al., 2008).  
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DNA Protein Kinase (DNA-PK)  
DNA-PK is associated with PICs formed on immobilized promoter templates in vitro. In 
this context DNA-PK acts as a CTD kinase (Peterson et al., 1995). Inhibition of DNA-PK 
with wortmannin does not have an effect on in vitro transcription (Woodard et al., 1999).   
 
Casein Kinase II (CKII) 
Casein kinase II is a ubiquitous kinase involved in various processes. It was found to be 
the CTD kinase activity present in a CDK11 immunoprecipitation (Trembley et al., 
2003). Furthermore it is required for downstream-promoter element (DPE) dependent 
transcription in vitro (Lewis et al., 2005).  
A.2.1.3. CTD phosphatases 
CTD phosphorylation is counteracted by at least two particular CTD phosphatases, Fcp1 
and Ssu72. Fcp1 has been described as CTD ser-2 and ser-5 phosphatase and is 
associated with the general transcription factor TFIIF (Lin et al., 2002). The CTD also 
can be dephosphorylated at ser-5 by the Ssu72 phosphatase, which is associated with the 
cleavage and polyadenylation factor complex and also does interact with the general 
transcription factor TFIIB (Dichtl et al., 2002; Krishnamurthy et al., 2004). A model is 
proposed in which the Ssu72 phosphatase catalyzes ser-5 dephosphorylation after 
pre-mRNA capping in a manner that facilitates the transition of RNAPII from the 
initiation to the elongation stage of the transcription cycle (Reyes-Reyes and Hampsey, 
2007).   
A.2.3. General Transcription Factors 
In in vitro transcription systems composed of only recombinant or highly purified 
proteins, a strict order of incorporation of general transcription factors into the PIC could 
be determined. The first factor to bind the TATA box of DNA in such a system is TFIID, 
then TFIIB is recruited to the DNA-IID complex. After that RNAPII is recruited together 
with TFIIF, and finally TFIIE and TFIIH are recruited into the PIC. TFIIA is not 
absolutely required for transcription initiation and therefore not considered a general 
transcription factor. In yeast, TFIIA acts at an early step of PIC assembly by enhancing 
the stable recruitment of TFIID. TFIIA was found to increase the rate of PIC formation, 
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but has no influence on the stability of a PIC (Ranish et al., 1999). If a more complex in 
vitro transcription system is used, e.g. the nuclear extract transcription system it is not 
clear whether PIC assembly follows the scheme above.  
Several laboratories purified a RNAPII holoenzyme complex, a pre-assembled complex 
composed of RNAPII, Mediator and the general transcription factors TFIIB, TFIIE, 
TFIIF and TFIIH. TFIID was not found in the holoenzyme complex (Chang and 
Jaehning, 1997; Maldonado et al., 1996; Ossipow et al., 1995; Wilson et al., 1996). In 
addition components of the hnRNP and SWI/SNF complexes were described as 
constituent of the holoenzyme complex (Kim and Nikodem, 1999; Wilson et al., 1996). 
Which PIC assembly model holds true in vivo, the stepwise GTF assembly model or the 
holoenzyme model is not conclusively determined till the present day.  
A.2.3.1. TFIID 
TBP, the TATA-box binding protein is a universal transcription factor required by all 
three eukaryotic RNA polymerases (Hernandez, 1993). The RNAPII-associated TFIID 
complex is composed of 14 TBP-associated proteins (TAFs) and about 700 kDa in size 
(Albright and Tjian, 2000; Tora, 2002). X-ray studies revealed that the core domain of 
TBP binds to a TATA box in a saddle-like conformation (Burley and Roeder, 1996). TBP 
binds the 8 bp TATA box unwinds it about a third of a helical turn and thereby bends the 
DNA in an 80 degree angle (Kim et al., 1993a; Kim et al., 1993b). The TBP molecule is 
not symmetric in itself and does not bind to TATA elements with high orientation 
specificity. TBP requires other promoter elements and initiation factors in order to 
assemble the transcription machinery in the right orientation (Cox et al., 1997).  
A.2.3.2. TFIIB 
TFIIB is recruited to the PIC after TBP. It interacts with DNA and can recognize the 
BRE-core promoter element (Imbalzano et al., 1994). TFIIB is at least in part responsible 
for transcription start site selection by RNAPII (Hawkes and Roberts, 1999). There are 
reports suggesting that TFIIB might be recruited by transcriptional activators such as 
VP16 (Roberts et al., 1993). Recently it was demonstrated that TFIIB helps to form a 
loop between the promoter and the polyA region of a gene (Singh and Hampsey, 2007).  
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A.2.3.3. TFIIF 
TFIIF consists of two subunits Rap30 and Rap74. TFIIF binds tightly to RNAPII, 
suppresses unspecific DNA binding of RNAPII and stabilizes the PIC (Conaway and 
Conaway, 1993). TFIIF also has a function during elongation. It prevents pausing of 
RNAPII (Bengal et al., 1991). TFIIF has been shown to be associated with a 
serine/threonine kinase activity which may modulate TFIIF function (Rossignol et al., 
1999).  
A.2.3.4. TFIIE 
TFIIE consists of two subunits, α and β, which form an α2β2heterotetramer (Ohkuma et 
al., 1991). TFIIE interacts directly with the unphosphorylated form of RNAPII, TFIIF 
and TFIIH  (Flores et al., 1989). TFIIE stimulates TFIIH recruitment as well as its 
helicase activities (Ohkuma, 1997). 
A.2.3.5. TFIIH 
TFIIH is a complex composed of nine polypeptides with four enzymatic activities: A 
DNA-dependent ATPase (Roy et al., 1994) two ATP dependent helicases (Schaeffer et 
al., 1993) and a kinase activity (Lu et al., 1992). The TFIIH complex consist of two 
distinct domains: a six subunit core complex, which contains the two DNA helicase 
activities and the CAK (CDK activated kinase) domain, consisting of the CDK7 kinase, 
cyclin H and MAT1 (Coin and Egly, 1998). The XPB DNA-helicase activity is essential 
for the formation of an open promoter complex (Holstege et al., 1996; Moreland et al., 
1999; Wang et al., 1992). The CDK7 kinase activity is important for promoter clearance, 
the transition from transcription initiation to elongation (Dvir et al., 1997). Recently it has 
been demonstrated that the kinase module of TFIIH is recruited in a Mediator-dependent 
fashion to a promoter (Esnault et al., 2008). The CDK7 kinase activity is stimulated by 
the Mediator complex (Kim et al., 1994). The TFIIH complex is not only important in 
transcription initiation, but also part of the nucleotide excision repair pathway (Svejstrup 
et al., 1995).  
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A.2.4. Positive transcription cofactors 
Most transcription cofactors were purified from the upstream stimulatory activity (USA) 
fraction. This fraction represses transcription in the absence of activators and stimulates it 
in the presence of activators (Meisterernst et al., 1991). The USA fraction contains six 
positive cofactors (PC1: PARP-1 (Meisterernst et al., 1997), PC2: Mediator complex 
(Kretzschmar et al., 1994; Malik et al., 2000), PC3: Topoisomerase I (Kretzschmar et al., 
1993; Merino et al., 1993), PC4 (Kaiser et al., 1995), PC5 and PC6. PC1, PC3, PC4 and 
HMG2 are all non-sequence specific DNA binding proteins suggesting that these 
cofactors function by affecting the accessibility of RNAPII to promoters in the chromatin 
context (Kaiser and Meisterernst, 1996). PC3/Topoisomerase I has been reported to 
comprise an intrinsic kinase activity that phosphorylates splicing factors (Rossi et al., 
1996). In addition two negative cofactors (NC) were identified in the USA fraction – 
NC1 and NC2 (see chapter A.2.5.). In addition the Integrator complex was described as a 
RNAPII cofactor which is essential for transcription of small nuclear RNAs (Baillat et 
al., 2005). 
A.2.4.1. Mediator complex 
Initially the Mediator complex was purified as the activity that is required for activator-
dependent in vitro transcription in a system reconstituted from recombinant and highly 
purified factors.  To do so, the Mediator complex functionally connects promoter- and 
enhancer-bound transcription activators to the general transcription machinery. 
Subsequently it was discovered that the Mediator has functions in transcription initiation 
beyond that. In vitro, transcription can be observed from a DNA template even in the 
absence of an activator, and termed basal transcription (Blazek et al., 2005). In a 
transcription system reconstituted from recombinant and purified factors no Mediator 
complex is required basal transcription. If however the more physiological nuclear extract 
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Figure 2: Schematic representation of the yeast Mediator (without the CDK8 module) and an EM 
micrograph (taken from (Asturias et al., 1999)) of Mediator attached to RNAPII. The black spot indicates 
the CTD attachment point; c indicates the location of the DNA binding channel.  
 
transcription system is used, also basal transcription becomes dependent on the Mediator 
complex. The fact that basal in vitro transcription can occur with recombinant or purified 
factors, but not in the nuclear extract system (which contains all factors present in the 
minimal transcription system) indicates that Mediator is required to inactivate a 
regulatory mechanism that acts negatively on transcription initiation. In the course of this 
study it was published that Mediator is required for the recruitment of the general 
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transcription factor TFIIB in the nuclear extract system (Baek et al., 2006). In addition 
Mediator was also discovered by means of yeast genetics. Mediator components were 
discovered in genetic screens for suppressors of CTD truncation mutants (Hengartner et 
al., 1995; Kim et al., 1994; Thompson et al., 1993). Five of these Srb-genes,  are essential 
for yeast cell growth (Nonet and Young, 1989; Thompson et al., 1993).  In addition 
Mediator was found to counteract the effects of the negative cofactors NC2 and the 
CCR4-NOT complex (Lee et al., 1998). In early studies Mediator was found to facilitate 
CTD phosphorylation by stimulating the TFIIH-associated kinase CDK7 (Kim et al., 
1994). Due to its complexity, the Mediator complex also serves as an integration platform 
for intracellular signaling pathways (Blazek et al., 2005).  
A.2.4.1.1. Head module 
In S.cerevisiae the head module consist of the MED6, MED8, MED11, MED17 (Srb4), 
MED18 (Srb5), MED19, MED20 (Srb6) and the MED22 (Srb6) polypeptides and can be 
assembled from recombinant proteins as a distinct module (Takagi et al., 2006). Within 
the head module a MED8-18-20 submodule was identified to interact with TBP 
in vitro (Lariviere et al., 2006; Lariviere et al., 2008).  
A.2.4.1.2 Midle module 
The middle module comprises the MED1, MED4, MED5, MED7, MED9, MED10, 
MED21, and MED31 Mediator subunits. Like the head module it possesses several 
contact points with RNAPII (Davis et al., 2002).    
A.2.4.1.3. Tail module 
In yeast the tail module is composed of the MED2, MED3, MED14, MED15 and MED16 
subunits. The Mediator tail can be deleted without loss of yeast cell viability (Li et al., 
1995) or destruction of the overall Mediator structure as determined by electron 
microscopy (Dotson et al., 2000).  
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A.2.4.1.4. CDK8 module  
The CDK8 module consist of the MED12 (Srb8), MED13 (Srb9), CDK8 (Srb10) and 
cyclin C (Srb11) subunits. It is found in large (e.g. ARC-L) but not in small Mediator 
complexes (e.g. CRSP). The CDK8 module containing Mediator has been shown to be 
inert in activator-dependent transcription in vitro (Taatjes et al 2002, Sune et al 1998). An 
electron microscopy (EM) study revealed that binding of RNAPII and the CDK8 module 
to Mediator is mutually exclusive (Elmlund et al., 2006).  CDK8 has been shown to 
phosphorylate the CTD of RNAPII at ser-5 (Borggrefe et al., 2002) and in addition the 
regulatory subunit of CDK7, cyclin H. Phosphorylation of cyclin H leads to decreased 
amounts of transcript generated in in vitro transcription assays (Akoulitchev et al., 2000). 
At least for some genes transcription activation is dependent on the loss of the CDK8 
module from the promoter in vivo. The loss of the CDK8 module, which coincides with 
transcription activation appears to be dependent on PARP-1 (Pavri et al., 2005). There is 
evidence that the CDK8 module may also contain the CDK8-like CDK11 kinase instead 
of CDK8 (Sato et al., 2003).  
A.2.4.1.5. MED25-Mediator 
The MED25 subunit of the Mediator complex is exclusively found in higher eukaryotes 
(Blazek et al., 2005; Bourbon, 2008). It was discovered as a subunit that strongly 
interacts with the activation domain of the viral activator VP16. However, the MED25 
containing Mediator complex is dispensable for Sp1 activated in vitro transcription 
(Mittler et al., 2003). In vivo, MED25 is required for retinoic acid receptor (RAR)-
activated transcription (Lee et al., 2007).  
A.2.4.1.6. Mediator and RNAPII interactions  
The Mediator complex has several physical interaction sites with RNAPII (Chadick and 
Asturias, 2005). Critical for the interaction of RNAPII and the Mediator complex appears 
to be the CTD of RNAPII. Nine Mediator subunits were initially discovered in genetic 
screens for suppressors of CTD truncation mutants (Hengartner et al., 1995; Thompson et 
al., 1993). Antibodies against the unphosphorylated RNAPII CTD displace Mediator 
from RNAPII (Svejstrup et al., 1997). Mediator is unable to stimulate transcription of a 
CTD-less RNAPII (Myers et al., 1998). Apparently CTD phosphorylation upon 
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transcription initiation leads to a break-up of the RNAPII-Mediator complex, allowing 
RNAPII to start transcription (Liu et al., 2004). The Tjian laboratory identified a 
particular Mediator dubbed CRSP by its ability to interact with GST-CTD in a pulldown 
assay. Addition of an excess of recombinant GST-CTD to an in vitro transcription assay 
inhibits CRSP-dependent transcription (Naar et al., 2002). In EM studies demonstrate that 
CRSP adopts a distinct structure upon GST-CTD binding which is different from the 
three dimensional structure of free CRSP complex. Furthermore its been shown that 
CRSP that is bound to the transcription activator VP16 does adopt the same structure as it 
does when bound to GST-CTD (Taatjes and Tjian, 2004). The CTD may bind to yeast 
Mediator between the head and middle modules, since recombinant head and middle 
modules independently interact with the CTD (Kang et al., 2001). EM studies with 
human Mediator complexes map the RNAPII CTD to a small region between the head 
and the middle module. This region is close to, but not identical to the VP16 binding site 
(Naar et al., 2002). The Gnatt laboratory described a particular Mediator responsive form 
of RNAPII which contains an additional thirteenth RNAPII subunit termed Gdown1. In 
in vitro transcription experiments Gdown1-containing RNAPII is selectively dependent 
on and responsive to Mediator (Hu et al., 2006).  
A.2.5. Negative transcription cofactors 
Over the past two decades a number of negative transcription cofactors have been 
described. Negative cofactor 2 (NC2) and the CCR4-NOT complex were found to be 
antagonists of Mediator complex function in a genetic screen (Lee et al., 1998). The 
ATPase BTAF-1 which is known in yeast as Mot1 acts like NC2 in a complex with TBP. 
NC2 and BTAF-1 act as negative transcription cofactors in in vitro transcription 
experiments, however they are recruited to transcriptional active genes in vivo (Albert et 
al., 2007; van Werven et al., 2008). DSIF and NELF act in conjunction after transcription 
initiation. These complexes pause RNAPII 20 to 50 nucleotides downstream of the 
transcription start site. This block appears to be another mode of RNAPII regulation and 
can be overcome by pTEFb which comprises the CDK9 kinase (Price, 2008). 
Furthermore DSIF has been reported to be involved in capping enzyme recruitment 
(Mandal et al., 2004). 
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A.2.5.1. NC2 
NC2 is an evolutionary conserved heterodimer complex composed of the NC2α and 
NC2β subunits. It binds TBP-promoter complexes from the bent underside of the TATA-
element. NC2 and TBP form a ring-like structure around the DNA which sterically 
occludes association of TFIIA and TFIIB with the PIC (Goppelt et al., 1996; Kamada et 
al., 2001; Mermelstein et al., 1996). The NC2 complex facilitates TBP interaction with 
promoters irrespective whether they contain a TATA box or not. Based on a ChIP on chip 
study NC2 is associated with a substantial fraction of active human promoters
in vivo (Albert et al., 2007). Genetic studies have revealed both negative and positive 
effects of NC2 on gene expression. In in vitro transcription experiments only a negative 
function of NC2 could be detected. Recently it was found that the promoter bound  DNA-
TBP-NC2 complex exhibits a substantial mobility along the  DNA template. This study 
suggested that by this mechanism NC2 may help to position TBP properly at the 
promoter (Schluesche et al., 2007). This represents the first molecular explanation for the 
apparent positive NC2 function in vivo. Furthermore NC2 is subject to post-translational 
modifications during Mitosis (E. Piaia and M. Meisterernst, unpublished). 
A.2.5.2. BTAF-1 
BTAF1 and its yeast orthologue Mot1 are general repressors of RNAPII-dependent 
transcription (Davis et al., 1992). BTAF-1 and Mot1 are able to dissociate TBP from 
DNA with their intrinsic ATPase activity (Chicca et al., 1998; Pereira et al., 2003). In 
mammalian cells/nuclear extract the majority of TBP is not found in TFIID but in a 
complex with BTAF1 dubbed B-TFIID (Timmers and Sharp, 1991). However recent 
genome wide gene expression profiling studies revealed that Mot1 affects gene 
expression negatively as well as positively (Andrau et al., 2002; Dasgupta et al., 2002; 
Geisberg et al., 2002). The proposed hypothesis for a BTAF-1 mechanism of action states 
that BTAF-1/Mot1 displaces TBP from non-promoter regions and deliver it thereby to 
promoter regions (Geisberg et al., 2002; Muldrow et al., 1999). 
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A.2.5.3. DSIF 
DRB-sensitivity inducing factor (DSIF) was initially discovered as a factor, that renders 
an partially reconstituted in vitro transcription system (comprising the 0.5 M and 0.85 M 
P11 fractions) sensitive to the inhibitors DRB or H8 (Wada et al., 1998a). DSIF is 
conserved from yeast to man and composed of two subunits hSpt4 and hSpt5 
(Yamaguchi et al., 1999). Subsequently DSIF was found to be an essential factor in 
switching the RNAPII into the elongation mode. The mechanism involves binding of 
DSIF to RNAPII during promoter escape (Yamaguchi et al., 1999), which in conjunction 
with the NELF complex induces pausing. The inhibition can be overcome by the factor 
pTEFb and the kinase activity of CDK9. If a nuclear extract is used to examine DSIF 
effects, hexokinase-treated nuclear extracts are used (Wada et al., 1998b). Notably, DSIF 
is unable to mediate DRB-induced transcription inhibition if the extract is treated with 
ATP during PIC formation (Wada et al., 1998b). Recently a function of DSIF in early 
transcription initiation was revealed by Malik et al. (Malik et al., 2007). It was shown 
that DSIF confers Mediator-dependence to an in vitro transcription system consisting of 
recombinant and highly purified transcription factors. This transcription system did not 
contain pTEFb or CDK9. Another hint that DSIF may have a function in early 
transcription initiation steps comes from the Fisher laboratory. This laboratory 
discovered that CDK7 is able to phosphorylate DSIF in vitro (Larochelle et al., 2006). 
Presumably DSIF has a second function prior to promoter escape. Another DSIF function 
appears to be the recruitment of capping factors that involves a direct interaction of the 
large DSIF subunit hSpt5 with capping enzyme (CE) (Mandal et al., 2004).  
A.3. Initiation and elongation control of transcription  
Based on their RNAPII occupancy and distribution three classes of genes can be 
distinguished: In the first class RNAPII is not detected throughout the gene and also no 
transcript is produced. The second class comprise genes that are transcribed in their entire 
length. They show a fairly uniform RNAPII distribution with many genes exhibiting a 
slightly higher polymerase occupancy at the 5’ and 3’ ends of the gene. The third class of 
genes, which appears to be larger than previously anticipated, includes genes at which 
transcription is initiated but no full-length transcript is produced. At this genes abortive 
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short transcripts are produced but the proximal DSIF/NELF imposed block on processive 
transcription can not be overcome (Price, 2008). Apparently a significant portion of 
developmental control genes are regulated by elongation control rather than by initiation 
control (Guenther et al., 2007). 
A.4. Chromatin and transcription regulation 
Transcription in vivo occurs in a chromatin context. A first layer of regulation is provided 
by regulation of chromatin compactation.  Transcription is controlled at this level by 
physical accessibility of promoters and enhancers for RNAPII and transcription factors. 
Once RNAPII has initiated transcription it still faces a physical barrier in from of histones 
on the DNA template. Several accessory factors are thought to assist RNAPII in making 
its way through DNA wrapped around nucleosomes. Histone post-translational 
modifications are associated with distinct transcription states of DNA. H3-K9 
trimethylation, which provides a docking site for the heterochromatin protein HP-1, is 
found at transcriptionally inert heterochromatin. H3-K4 trimethylation is found as a 
distinct peak close to the transcription start site of active RNAPII genes. In addition to 
that mark transcriptionally active genes are decorated with H3-K36 and H3-K79 
methylation (Guenther et al., 2007; Peters and Schubeler, 2005). Histone acetylation 
which is thought to make chromatin more accessible occurs predominantly on histone H4 
(Sterner and Berger, 2000).  
 A.5. Aim and scope of this work 
The main goal of this work was to further define Mediator as a general transcription 
factor. To further define the underlying molecular mechanisms of basal and activated 
in vitro transcription I used a twofold approach: In vitro assays such as immobilized 
promoter template and transcription assays to screen for molecular mechanisms and 
in vivo chromatin immunoprecipitation assays on an inducible model gene to confirm in 
vitro results.   
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B. Experimental Procedures 
B.1. Biochemistry 
B.1.1. Preparation of nuclear extract 
The difference between NAM and Dignam protocol is the salt concentration, at which the 
extraction takes place. Apparently the NAM protocol (210 mM NaCl) extracts more 
hypo- and less hyperphosphorylated RNAPII than the Dignam protocol (420 mM NaCl). 
All HeLa nuclear extracts were prepared according to the Dignam protocol, Jurkat 
nuclear extracts according to the NAM protocol. 
B.1.1.1. Dignam protocol for the preparation of HeLa nuclear extract 
HeLa nuclear extracts were prepared  according to a protocol published by Dignam and 
colleagues (Dignam et al., 1983). All steps were carried out on ice in the cold room. For 
the preparation of transcription competent nuclear extracts it is helpful to collect the cells 
during the logrhythmic growth phase at a density of about 5 x 105 cells per ml medium. 
HeLa cells for nuclear extracts were grown in spinner cultures. 10-15 liters of cell culture 
were processed in one extraction. HeLa cells were harvested by centrifugation in a 
Beckman J-6B centrifuge (10 min, 2500 rpm, 4ºC) and collected in 50 ml polypropylene 
tubes. About 5 ml packed cell volume (PCV) were aliquoted into each 50 ml tube. Cells 
were washed once with 45 ml ice-cold PBS and the cells pelleted by centrifugation in a 
Heraeus Multifuge 3L-R at 2500 rpm and 4ºC. Each 5 ml of PCV were resuspended in 
45 ml HB buffer. This hypotonic buffer leads to swelling of the cells. The swollen cells 
were pelleted by centrifugation (5 min, 2500 rpm, 4ºC) and the swollen cell volume 
(SCV) was determined. The supernatant was removed and the pellet resuspended in 2 x 
PCV HB buffer and further swelling was allowed by incubation for 10 min on ice. After 
that the cell suspension was transferred to a chilled glass homogenizer equipped with a 
loose type B pestle (Wheaton). Cell membranes were disrupted by 15 hard pestle strokes. 
After completion it was checked in the microscope that cell membranes were broken up 
efficiently and that the solution contained mainly nuclei. Then the suspension was 
centrifuged (15 min, 3900 rpm, 4ºC) and the cytosolic supernatant collected.  
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The pellet consisting of nuclei was resuspended in half a nuclear pellet volume  (NPV) 
low salt buffer and homogenized again in a glass homogenisator with a type B pestle (six 
hard strokes). The resulting suspension was transferred into a plastic beaker, a stir bar 
was added and over the period of 30 min half a NPV high salt buffer was added 
dropwise.  After the final potassium chloride concentration of about 420 mM was 
reached, the suspension was stirred for another 30 min. After that the suspension was 
centrifuged to clear the nuclear extract from debris (Sorvall centrifuge equipped with a 
SS34 rotor, 14 000 rpm, 30 min, 4ºC). The supernatant containing the nuclear extract was 
removed from the debris and dialyzed against BC0 buffer (supplemented with PMSF to a 
final concentration of 0.2 mM and β-mercaptoethanol to a final concentration of 1 mM) 
until the conductivity had reached that of BC100 (conductivity measurements were 
carried out on a Knick Konduktometer 703). After a final centrifugation step (Sorvall 
centrifuge equipped with a SS34 rotor, 14 000 rpm, 15 min, 4ºC) the nuclear extract was 
aliquoted and snap-frozen in liquid nitrogen and stored at -80ºC.  
 
 Hypotonic buffer (HB): 10 mM Tris-Cl, pH 6.8 at RT 
     1.5 mM MgCl2 
     10 mM KCl  
 
 Low salt buffer:  20 mM Tris-Cl, pH 6.8 at RT 
     25 % (v/v) glycerol 
     20 mM KCl 
     1.5 mM MgCl2 
     0.2 mM EDTA 
     1 mM β-mercapto-ethanol  
     0.2 mM PMSF 
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 High salt buffer:  20 mM Tris-Cl, pH 6.8 at RT 
     25 % (v/v) glycerol 
     1200 mM KCl 
     1.5 mM MgCl2 
     0.2 mM EDTA 
     1 mM β-mercapto-ethanol  
     0.2 mM PMSF  
B.1.1.2. NAM Protocol for Jurkat nuclear extract 
All steps were carried out at 4ºC and on ice in the cold room. DTT and PMSF were added 
to the buffers freshly prior to each extraction. Jurkat extracts in this work were prepared 
from isolated Jurkat nuclei (prepared by Cellex Biosciences Inc.). Nuclei were thawed on 
ice and after that resuspended in half a nuclear pellet volume (NPV) ice-cold NAM-
buffer A. The suspension was transferred to a chilled glass homogenizer equipped with a 
loose type B pestle (Wheaton) and the nuclei broken up by 10 soft pestle strokes. After 
that the suspension was poured into a plastic beaker and while steering 1 NPV NAM-
buffer C was added dropwise over a period of 30 min (final potassium chloride 
concentration: 210 mM). After another 30 min incubation the suspension was cleared 
from debris by centrifugation (Sorvall centrifuge equipped with a SS34 rotor, 
18 000 rpm, 20 min, 4ºC). The cleared nuclear extract was dialyzed against BC0 until the 
conductivity of BC100 was reached. After a final centrifugation step (Sorvall centrifuge 
equipped with a SS34 rotor, 18 000 rpm, 20 min, 4ºC) the nuclear extract was aliquoted 
and snap-frozen in liquid nitrogen and stored at -80ºC.   
 
 NAM-buffer A: 10 mM Tris-Cl, pH 7.3 at RT 
    1.5 mM MgCl2 
    10 mM KCl 
    0.2 mM EDTA 
    0.5 mM DTT 
    0.2 mM PMSF 
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 NAM-buffer C: 20 mM Tris-Cl, pH 7.3 at RT 
    25 % (v/v) glycerol 
    420 mM NaCl 
    1.5 mM MgCl2 
    0.2 mM EDTA 
    0.5 mM DTT 
    0.2 mM PMSF 
 
B.1.2. Expression and purification of recombinant proteins in E.coli 
B.1.2.1. Expression of recombinant proteins  
Recombinant proteins were expressed in the E.coli BL21 strain. The expression plasmid 
encoding the desired protein was transfected into the bacteria by heat-shock transfection. 
For protein expression, an overnight starter culture was diluted to an OD600 of 0.05 in LB 
medium to a total volume of 200 ml per shaker flask. Bacteria were grown at 37ºC to an 
OD600 of 0.6. Protein expression was induced by adding IPTG to a final concentration of 
0.5 mM. In order to enhance the yield of full length protein, the bacteria cultures were 
shifted to an incubation temperature of 30ºC after induction. Protein expression was 
allowed for 3 to 6 hrs, depending on the construct expressed. Subsequently bacteria were 
harvested by centrifugation for 15 min at 3500 rpm and 4ºC. All following purification 
steps of the recombinant proteins were carried out at 4ºC.    
B.1.2.2. Purification of recombinant GST-tagged proteins 
The bacteria pellet of 200 ml expression culture was resuspended in 10 ml ice-cold lyses 
buffer supplemented with 10 mg lysozyme. After 10 min incubation on ice the 
suspension was sonicated with a microtip and the following settings on a Branson 
sonifier: Output amplitude 30%; total sonication time: 2 min; sonication cycles: 10 sec 
on, 50 sec off. During the sonication, the suspension was cooled with an ice-water bath. 
Then the lysate was cleared by centrifugation (10 min, 10 000 x g, 4ºC).  
For the purification of the recombinant GST-tagged proteins 200 µl gluthathione-
sepharose 4B (Amersham, cat. no.: 17-0756-01) were equilibrated by washing the beads 
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three times in 30 CV lysis buffer. The lysate was incubated together with the equilibrated 
beads for at least 2 hours in the cold room at 4ºC on a rotating wheel. After binding of the 
GST-fusion proteins to the glutathione beads the beads were washed 5 times with 50 CV 
BC2000 buffer. GST-VP16 constructs as well as the GST-CTD fusion protein were 
stored bound to the beads in BC2000 buffer containing 0.03% NaN3. To determine the 
amount and purity of the GST-fusion proteins bound to the beads, a 10 µl aliquot of the 
beads was analyzed by SDS-PAGE and Coomassie staining of the gel. BSA protein 
solutions of known concentrations were used to determine the amount of protein bound to 
the beads.   
 
 Lysis Buffer:  20 mM HEPES-KOH pH 7.5 
    100 mM KCl 
    1 mM EDTA 
    10% (v/v) glycerol  
    0.1% (v/v) IGEPAL-CA-630 (NP-40) 
    0.1% (v/v) protease inhibitor cocktail (Sigma) 
B.1.3. Immunoprecipitations 
All centrifugation steps in this section were carried out for 3 min at 700 x g and 4ºC, if 
not indicated otherwise. 
B.1.3.1. Coupling of antibodies to sepharose beads 
Protein A (Amersham Biosciences, cat. no.: 17-0618-03) or protein G sepharose beads 
(Amersham Biosciences, cat. no.: 17-5280-03) were washed 3 times in 30 to 50  column 
volumes (CV) PBS. Usage of protein A or protein G IP-beads depended on the species in 
which the antibody that was to be bound to the IP-beads, was raised (protein A beads for 
rabbit antibodies, protein G beads for goat, rat and mouse antibodies).  IP beads were 
then blocked for at least 10 min in 10 CV of PBS containing 0.5% (w/v) BSA (Sigma, 
cat. no.: A3294). In case purified and concentrated antisera were to be bound to the IP-
beads the antiserum was added directly to the blocking buffer such that 1 μg antibody is 
added for each μl of IP-bead volume. If hybridoma supernatants were to be bound to IP-
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beads, the blocking buffer was removed and 10 μl hybridoma supernatant per 1 μl IP 
bead volume added. The beads were incubated together with the antibody for at least 
4 hrs at 4ºC. After binding the antibody coated beads were either equilibrated in 
immunoprecipitation buffer (for an immunoprecipitation) without a covalent crosslink of 
antibodies and beads, or forwarded to the covalent crosslink procedure (B.1.3.2.). 
B.1.3.2. Covalent crosslink of antibodies to sepharose beads 
Antibody-loaded IP-beads (see section B.1.3.1.) were washed twice in 10 column 
volumes (CV) 0.2 M sodium borate, pH 9.0. Then the beads were resuspended in 10 CV 
0.2M sodium borate, pH 9.0 containing 20 mM dimethyl pimelimidate (Sigma, cat. no.: 
D8388; the dimethyl pimelimidate degrades rapidly if dissolved, therefore it was added 
as powder immediately before the buffer was used). After 30 min incubation at RT on a 
roller, the IP beads were peletted by centrifugation and then washed once in 10 CV 0.2 M 
ethanolamine, pH 8.0. After that wash, the beads were resuspended in 10 CV 0.2 M 
ethanolamine, pH 8.0 and incubated for 2 hrs at RT on a roller. Finally the crosslinked IP 
beads were washed 3 times in 30 to 50 CV PBS. The beads were either used directly, or 
stored at 4ºC in PBS supplemented with 0.02% NaN3. 
B.1.3.3. Immunoprecipitation 
HeLa or Jurkat nuclear extracts (see section B.1.1.) containing 5-15 mg/ml of protein 
were supplemented with KCl to a final chloride ion concentration of 150 mM, 0.1 % 
(v/v) IGEPAL-CA-630 (NP-40), 0.2 mM PMSF and then incubated with the indicated 
antibody coupled to protein A (rabbit antibodies) or protein G Sepharose (rat, goat and 
mouse antibodies) beads for at least 3 hrs at 4°C. As an isotype control for the rat 
monoclonal antibodies (MED15, MED25) the 83M (9A12) rat monoclonal antibody was 
used, as an isotype control for the goat polyclonal CDK8 antibody normal goat serum 
(Santa Cruz, cat. no.: sc2043) was used and for the rabbit polyclonal antibodies normal 
rabbit serum (Santa Cruz, cat. no.: sc-2027) was used. Antibody loaded beads were 
prepared as described in sections B.1.3.1. and B.1.3.2. and equilibrated in BC150 / 0.1% 
(v/v) IGEPAL-CA-630 (NP-40) / 0.2 mM PMSF before the incubation with nuclear 
extract. Then the beads were washed either three times in 50 column volumes (CV) IP 
wash buffer 150 or three  times in 50 CV IP-wash buffer 800 and thereafter three times in 
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50 CV IP wash buffer 150. Protein-loaded IP beads were used to supplement 
immobilized template assays, in vitro transcription assays, in vitro kinase assays or were 
analyzed directly by immunoblot. In order to elute proteins from the beads for 
immunoblot analysis, three bead volumes 2 x SDS PAGE loading dye was added directly 
to the washed beads. Then the suspension was heated for 15 min at 60ºC in the heat 
block, the IP beads peletted by centrifugation and the supernatant loaded onto an SDS-
PAGE gel.   
 
 IP-wash buffer 150: BC150 containing 
    0.1% (v/v) IGEPAL-CA-630 (NP-40) 
    1 mM DTT 
    0.2 mM PMSF 
 
 IP-wash buffer 800: BC150 containing 
    0.1% (v/v) IGEPAL-CA-630 (NP-40) 
    1 mM DTT 
    0.2 mM PMSF 
B.1.4. Immunodepletion  
Immunodepletions were carried out essentially according to the immunoprecipiation 
protocol described in the previous sections. IP-beads were loaded as described in section 
B.1.3.1., except for the CDK1 immunodepletion. In that case 1 µl of IP bead (α-CDK1 as 
well as α-isotype beads) volume was loaded with 2.2 µg α-CDK1 antibody (Santa Cruz, 
cat. no.: sc-954). In order to immunodeplete 500 µl nuclear extract, two sequential 
incubations with 100 µl antibody-loaded IP-beads for each incubation was carried out. 
The first incubation step was carried out for 3, the second step for 2 hrs. In case of the 
CDK1 depletion, 100 µl of nuclear extract were immunodepleted with two sequential 
incubations with 50 µl CDK1 or isotype loaded beads. After completion of the depletion, 
nuclear extracts were centrifuged at high speed (5 min, 13200 x g, 4ºC) in order to 
remove remaining IP-beads. Then immunodepleted nuclear extracts were snap-frozen in 
liquid nitrogen and stored at -80ºC.  
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B.1.5. GST-pulldown experiments 
VP16 pulldown assays were performed essentially as described previously (Ikeda et al., 
2002). HeLa or Jurkat extracts containing between 5 and 15 mg/ml of protein were 
adjusted to 25 mM Hepes-KOH pH 7.6, 100 mM KCl, 0.1% NP-40, 1 mM DTT, 0.2 mM 
EDTA, 10% glycerol, 0.2 mM phenylmethylsulfonyl fluoride (PMSF) and incubated in 
siliconized Eppendorf tubes with VP16 derivatives fused to GST and immobilized on 
glutathione–Sepharose at concentrations of 1 mg/ml for 16 hrs at 4°C. After 4 washes 
with 50 column volumes HEGN-100 buffer (25 mM Hepes-KOH pH 7.6, 100 mM KCl, 
0.1% NP-40, 1 mM DTT, 0.2 mM EDTA, 10% glycerol, 0.2 mM PMSF) the bound 
proteins were eluted with 500 mM KCl in HEGN buffer (2CV) and analyzed by 
immunobloting. 
B.1.6. In vitro transcription assays 
In vitro transcription experiments were carried out essentially as described previously 
(Gilfillan et al., 2003; Malik and Roeder, 2003). In vitro transcription reactions were 
carried out either with an SmaI linearized major-late (ML) promoter fragment, that was 
purified by CsCl-gradient centrifugation, or on a isolated PIC that was formed prior to the 
in vitro transcription experiment on an immobilized template (as described in section 
B.1.6.). In reactions in which SmaI linearized ML promoter templates were used, 50 ng 
template were added to each 25 µl reaction. In cases there VP16-activated transcription 
was studied, 10 ng of GAL4-VP16 was added to each 25 µl reaction on a SmaI linearized 
major-late promoter template. If nuclear extracts were used in in vitro transcription 
experiments directly, 75 µg HeLa or 25 µg Jurkat nuclear extract were used per 25 µl 
reaction. The reaction was composed such that the criteria defined in table 2 were 
matched. On an immobilized promoter template formed PICs were washed, and then 
resuspended in a buffer that fulfilled the criteria defined in table 2. 
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Reaction volume 25 µl 
Chloride ion concentration 60 mM 
DTT 10 mM 
Total BC-buffer content 40-50% 
MgCl2 5 mM 
IGEPAL-CA-630 (NP-40) Max. 0.03% 
PEG-8000 0.1 mg/ml 
HEPES-pH8.2 20 mM 
RNase Inhibitor  
(Promega, cat. no.: N211A) 
10 units 
BSA (Roche, cat. no.: 711454) 0.5 mg/ml 
      Table 2: In vitro transcription parameters 
 
For typical in vitro transcription experiments, the components were mixed, and a PIC was 
formed in the presence of 1 µM ATP, if not stated otherwise. PIC formation was carried 
out for 45 min (if not indicated otherwise) at 30ºC in a reaction volume of 23.5 µl. After 
that 1.5 µl NTP mix was added, and the transcription reaction was allowed to proceed for 
45 min at 30ºC. The NTP mix consisted of 1 µl α-32P-UTP (3000 Ci/mmol, Amersham, 
cat. no.: PB10203) and 0.5 µl of 50 x NTP-low UTP mix. In case a template with a G-less 
cassette was used (e.g. the ML-promoter template) an 50 x NTP-low UTP OMG mix was 
used instead of the 50 x NTP-low UTP mix.  
In vitro transcription reactions were stopped by addition of 400 µl transcription stop 
buffer. The RNA was isolated by phenol-chloroform extraction and subsequent 
isopropanol precipitation at -20ºC. The RNA was pelleted by centrifugation (45min, 4ºC, 
13200 x g), washed once with 80% ethanol, air dried and resuspended in 10 µl RNA-
PAGE loading dye. RNA samples were incubated for 20 min at 60ºC and then loaded 
onto a 5% polyacrylamide-urea gel. The gel was run at a constant voltage of 250 V. The 
RNA was fixed in the gel by submerging it in 10% acetic acid for 10 min. Next the gel 
was washed three times in water, and dried on the vacuum gel dryer. Finally, the dried 
gel was exposed to either a phosphor-imager plate or to BioMax MR film (Kodak, cat. 
no.: 8736936). 
 
 
 
 
 
Experimental Procedures 
 37 
 50 x NTP-low UTP Mix:  5 mM ATP (Amersham, cat. no. 272056) 
      5 mM CTP (Amersham, cat. no. 272066) 
      5 mM GTP (Amersham, cat. no. 272076) 
      0.25 mM UTP (Amersham, cat. no. 272086) 
    
 50 x NTP-low UTP OMG-Mix: 5 mM ATP (Amersham, cat. no. 272056) 
      5 mM CTP (Amersham, cat. no. 272066) 
      0.25 mM OMG (3’-O-methyl-guanosine 
           triphosphat; Amersham, cat. no. 274675) 
      0.25 mM UTP (Amersham, cat. no. 272086) 
 
 Transcription stop buffer:  7 M urea 
      10 mM Tris-HCl, pH 7.8 
      10 mM EDTA, pH 8.0 
      300 mM sodium acetate 
      0.5 % (w/v) SDS 
      100 mM lithium chloride 
      0.4 mg/ml yeast tRNA 
 
 RNA-PAGE loading dye:  97% (v/v) formamide 
      20 mM Tris-Cl, pH 7.3 
      10 mM EDTA, pH 8.0 
      0.1% (w/v) Bromophenolblue 
      0.1% (w/v) Xylenecyanol 
 
 5 % Urea-PAGE Gel:   1 x TBE 
      8 M urea 
      5 % (v/v) acrylamide:bisacrylamide (19:1) 
      0.1 % (v/v) APS 
      0.01 % (v/v) TEMED 
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B.1.7. Immobilized template assays 
Immobilized template assays were performed on either a biotinylated MRG5 promoter 
construct or on a biotinylated major-late (ML) promoter construct. Early PIC formation 
studies were performed on the MRG5 promoter construct, later studies were carried out 
on the ML promoter template due to the fact that a more robust in vitro transcription 
results could be obtained by using this template. This immobilized template assay 
procedure is based on protocols published by the Hahn, Chiang and Carey laboratories 
(Black et al., 2006; Ranish et al., 1999; Wu et al., 2003). 
B.1.7.1. Promoter template preparation 
Biotinylated promoter templates were generated by PCR. The MRG5 promoter templates 
were amplified from the vector pGL2MRG5, that in turn stems from pMRG5 plasmid, 
which contains a Luciferase expression cassette in place of the G-free cassette of 
pMRG5. The promoter comprises 5 GAL4 bindings sites immediately upstream of a 
synthetic HIV/ML core promoter as described previously (Xie et al., 2000). The primers 
were: 5’- GCA TTC TAG TTG TGG TTT GTC CAA (biotinylated) and 5’- GCC GGG 
CCT TTC TTT ATG TT. To produce promoter templates with a mutated TATA box the 
same primer were used on plasmid pPHS99 in which the TATA box was mutated. The 
resulting 412 bp templates contain 91 bp of the luciferase coding region which in theory 
would generate a run-off transcript of that length. Biotinylated ML promoter templates 
were amplified from a 5xGAL4 site/major-late promoter/G-less cassete containing 
plasmid (pG5MLT) using the primers 5’- CGA TTC ATT AAT GCA GCT GG 
(biotinylated) and 5’- AAC TCG ACT GCA GCA TAT GTA TCA TAC ACA TAC G. 
The 700 bp template comprises five GAL4 binding sites upstream of the major late 
promoter and a 380 bp G-less transcription cassette downstream of the promoter region. 
The templates were purified on 0.7% agarose gels and recovered using a gel band 
extraction kit (Quiagen, cat. no.: 28704). 
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B.1.7.2. Coupling of promoter templates to paramagnetic beads 
Biotinylated DNA templates were coupled to paramagnetic streptavidin beads (Promega, 
cat. no.: Z548C) as follows: paramagnetic beads were washed three times in binding and 
washing (B&W) buffer.  Beads were resuspended in B&W buffer, and 8.5 ng biotinylated 
MRG5 promoter template or 15 ng biotinylated ML promoter template (in TE 
supplemented with 1 M NaCl) was added for each µg magnetic beads. After shaking for 
30 min at room temperature, beads were washed once in B&W buffer containing 0.5 
mg/ml BSA (Sigma, cat. no.: A3294). For blocking, beads were resuspended at a 
concentration of 1 mg/ml in blocking buffer. After that the paramagnetic beads were 
washed three times in TXN wash buffer and finally resuspended in TXN wash buffer at a 
concentration of 10 µg paramagnetic beads per microliter TXN wash buffer.  
 
 B&W buffer: 5 mM Tris-HCl, pH7.5  
  1 mM EDTA 
  1 M NaCl 
   0.003% (v/v) IGEPAL-CA-630 (NP-40) 
 
 Blocking buffer: 20 mM Hepes-KOH, pH 8.2 
   5 mM MgCl2 
   50 % (v/v) BC120 
   0.1 mg/ml PEG-8000 
   1 mM DTT 
   0.025% (v/v) IGEPAL-CA-630 (NP-40) 
  5 mg/ml BSA (Sigma, cat. no.: A3294) 
  5 mg/ml polyvinylpyrolidone (Sigma, cat. no.: 81420) 
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 TXN Wash buffer: 20 mM Hepes-KOH, pH 8.2 
 5 mM MgCl2 
 50% (v/v) BC120 
 0.1 mg/ml PEG-8000 
 0.025% (v/v) IGEPAL-CA-630 (NP-40) 
 1 mM DTT 
 0.2 mM PMSF 
B.1.7.3. PIC formation reaction 
PIC formation reactions were conducted such that the conditions resembled those of a 
classical in vitro transcription experiment and carried out in lubricated tubes. A typical 
PIC formation reaction was conducted in a total volume of 200 µl and adjusted to meet 
the following criteria: 
Basic components 70 µg paramagnetic beads coupled to 2.4 pmol promoter template 
10-20% (v/v) nuclear extract, recombinant proteins       or IP-beads in  BC-buffer 
40-50% (v/v) total BC-buffer content 
60 mM total chloride ion concentration 
20 mM Hepes-KOH, pH 8.2 
5 mM MgCl2 
0.5 mg/ml BSA (Roche, ca. no.: 711454) 
0.025 % (v/v) IGEPAL-CA-630 (NP-40) 
0.1 mg/ml PEG-8000 
40 units RNase inhibitor (Promega, cat. no.: N211A) 
25 ng/µl poly(dG:dC) (Amersham, cat. no.: 27-7890-02) 
10 mM DTT 
0.2 mM PMSF 
Optional components 1 µM ATP or 1 µM ATPγS or 500 µM H8 
200 ng GAL4-VP16 or GAL4-Sp1 or GAL4-TA1 
 
Table 2: PIC formation conditions for immobilized template assays 
  
Typically, the reaction mixture was prepared without adding nuclear extract, recombinant 
proteins or IP-beads, then activator proteins (GAL4-VP16 or GAL4-Sp1 or GAL4-TA1) 
were added, and finally extracts, recombinant proteins and IP-beads were added as 
indicated in the figures. ATP, ATPgS or H8 were added to the PIC formation reaction as 
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indicated in the figures. PICs were formed by incubation for 45 min at 30ºC in the 
shaking block (1400 rpm). After PIC formation, the paramagnetic beads were 
concentrated with a magnet and washed three times with TXN wash buffer. Depending 
on the experiment, the magnetic beads were then eluted with 2 x SDS-PAGE loading dye 
in order to analyze the PIC by immunoblot or the template bound PICs were forwarded to 
a second incubation step under in vitro transcription conditions (see section B.1.6.). The 
buffer for the second incubation step was composed as described in table 2 and the 
reaction volume was reduced to 50% of that during the PIC formation. At this stage either 
an in vitro transcription experiment was performed (to test the in vitro transcription 
potential of a particular PIC population) or it was analyzed how the PIC protein 
composition changed if incubated with NTPs as indicated in the respective figures by 
immunoblot. In order to monitor proteins that remained associated with the DNA 
template and those that dissociated from it both fractions were analyzed separately by 
immunoblot. The DNA-bound proteins were eluted with 2 x SDS-PAGE loading dye, the 
dissociated proteins were analyzed by collecting the supernatant of the second incubation 
step and adding ¼ volume 5 x SDS-PAGE loading dye to it.   
B.1.8. In vitro kinase assay 
All in vitro kinase assays in this study were performed under the same buffer conditions 
as an in vitro transcription reaction (see section B.1.6.). Kinases were 
immunoprecipitated with appropriate antibodies, washed in BC150 buffer containing 
0.1% IGEPAL-CA630 (NP-40) and then applied to the reaction mixture. Up to 10 µl 
kinase loaded IP-beads were added to a 50 µl kinase assay reaction. In terms of reaction 
composition the bead volume was calculated as if it would be the same volume BC150/ 
0.1% NP-40 buffer. In vitro kinase assays were carried out in a first stage that resembled 
a PIC formation reaction, and a second stage that resembled the conditions of an in vitro 
transcription reaction. During the first stage ATP at a final concentration of 1 µM was 
included into the reaction (30 min incubation at 30ºC), then NTPs were added to a final 
concentration of 100 µM for each NTP, and the reaction was incubated for another 30 
min at 30ºC. The reaction was stopped by addition of 5 x Laemli buffer and boiled 
immediately afterwards at 95ºC.  
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B.1.9. SDS-PAGE, Coomassie staining and Westernblotting 
B.1.9.1. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Prior to analysis by Coomassie staining or immunoblot proteins were separated according 
to their molecular weight by SDS-PAGE. In most cases 12/18% step gels were used, in 
rare cases gels with an acrylamide content ranging from 8 to 18%. In order to obtain 
better results when immunoblotting big proteins, an acrylamide mix containing 
acrylamide and bisacrylamide in a ratio of 170:1 was used. The stacking gel was prepared 
as a 5% gel. Before loading to the gel, protein samples were supplemented with 5 x SDS-
PAGE loading dye such that the loading dye was diluted 5-fold by adding the sample. 
The samples were boiled at 95ºC, centrifuged briefly, and loaded onto the gel which was 
submerged in 1 x SDS-PAGE running buffer. Proteins were separated at a current of 
25 mA per minigel, or 50 mA for big gels, with the voltage restricted to a maximum of 
170V. As a molecular weight standard either Biorad high- or lowrange maker was used.    
 
Gel-mixtures    12%  18%  stacking gel 
Gel A (Roth, cat. no.: 3037.1): 4 ml  6 ml  0.85 ml 
Gel B (Roth, cat. no.: 3039.1): 0.35 ml 0.52 ml 0.35 ml 
1.5 M Tris HCl, pH 8.8  2.5 ml  2.5 ml  - 
1 M Tris-Cl, pH 6.8   -  -  0.63 ml 
water     2.95 ml 0.78 ml 3.1 ml 
10% SDS    0.1 ml  0.1 ml  50 µl 
10% APS    0.1 ml  0.1 ml  50 µl 
TEMED    4 µl  4 µl  5 µl 
  
 
 5 x SDS-PAGE loading dye: 250 mM Tris-HCl pH 6.8 
     10% (v/v) SDS 
     50% (v/v) glycerol 
     500 mM DTT 
     0.2% Bromphenolblue 
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 SDS-PAGE running buffer: 25mM Tris-HCl 
     190 mM Glycine 
     1% (w/v) SDS  
B.1.9.2. Coomassie staining 
To visualize proteins directly in a SDS-PAGE gel the gel was incubated with Coomassie 
staining solution for at least 1 hr on a rocking platform. After that gels were incubated 
with destaining solution for at least 1 hr. For documentation gels were scanned and then 
dried between cellophane films at RT.  
 
 Coomassie staining solution: 40% (v/v) Methanol 
     10% (v/v) Acetic acid 
     0.025% (w/v) Coomassie R-250 
B.1.9.3. Immunoblot 
Together with a piece of nitrocellulose membrane (Biorad, cat. no.: 162-0115) that 
matched the size of the gel, SDS-PAGE gels were equilibrated for 15 min in semi-dry 
blotting buffer. For the semi-dry protein transfer, the gel and the membrane were 
sandwiched between 4 pieces of semi-dry buffer soaked thick Whatman papers (2 pieces 
below, 2 above gel and membrane). The protein transfer was carried out in a Hoeffer 
TE77 blotting apparatus at a constant voltage of 18 V for 45 min.  
After the transfer proteins were visualized by PonceauS staining on the membrane, and 
the position of the molecular weight standards were indicated with a pencil. Before 
antibody incubation, the membrane was blocked by incubation in a solution containing 
1% dry milk powder in TBS-T for at least 1 hr. Then the membrane was incubated with a 
specific antibody dissolved in 1% milk TBS-T solution and incubated overnight at 4ºC. 
Following that incubation the membrane was washed 4 times within 1 hr with plain 
TBS-T and then incubated with appropriate horse reddish peroxidase (HRP) conjugated 
secondary antibodies dissolved 1 to 5000 (v/v) in 1 % mild TBS-T solution. After 45 min 
incubation at room temperature the membrane was washed again 4 times within 1 hr with 
plain TBS-T.  After a brief final wash with water the enzymatic activity associated with 
Experimental Procedures 
 44 
the HRP-conjugated secondary was detected with an enhanced chemiluminescence 
detection system (Perkin Elmer, cat. no.: NEL105) and the processed membranes were 
exposed to BioMax MR film (Kodak, cat. no.: 8736936). 
 
 Semi-dry blotting buffer: 190 mM glycine 
     50 mM Tris-Cl 
     0.25 % (w/v) SDS 
     20 % methanol 
 
 Ponceau S solution:  0.1 % (w/v) PonceauS 
     5 % (v/v) acetic acid 
     
 TBS-T:   150 mM NaCl 
     100 mM Tris-HCl, pH 7.6 
     0.1 % (v/v)Tween-20 
     
Secondary Antibodies Cat. no. Provider Conjugate 
anti-rat 112-035-044 Jackson Immunoresearch HRP 
anti-goat Sc-2020 Santa Cruz HRP 
anti-mouse W402B Promega HRP 
anti-rabbit W401B Promega HRP 
 
Table 3: Secondary antibodies 
B.1.10. DE52 column chromatography 
B.1.10.1. Preparation of the column material 
DEAE-cellulose DE52 (Whatman, cat. no.: 4057050) was washed three times in water 
and then equilibrated over night at 4ºC in DE52-buffer. The next day, the column 
material was washed twice in BC100 containing 1 mM DTT, 0.5 mM PMSF and poured 
into Biorad Econo column.   
   
  DE52 buffer: 0.5 M Tris-HCl pH 7.3 at RT 
    0.5 M ammonium sulfate, pH 7.9 
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B.1.10.2. Protein separation by DE52 chromatography 
The freshly prepared DE52 column was washed extensively with BC100 / 1 mM DTT, 
0.5 mM PMSF and then loaded with 2 mg protein per ml column volume at a flow rate of 
1 column volume (CV) per hour. After that the column was washed with 3 CV BC100 / 
1 mM DTT / 0.5 mM PMSF and then the  KCl concentration was raised in linear gradient 
over 5 CV to 300 mM KCl. Finally the column was washed with BC300 / 1 mM DTT / 
0.5 mM PMSF until no more protein could be detected in the column fractions.  
B.1.11. Crosslink-restriction digest immunoprecipitation (CRIP) assay 
The CRIP assay, which represents an adaptation of the in vivo chromatin 
immunoprecipitation technique allows to monitor the binding site of a particular epitope 
on a DNA template in an in vitro assay. In brief, a in vitro assay is performed on a 
radiolabelled DNA template, e.g. the formation of a PIC or an in vitro transcription 
reaction, and the reaction is stopped by an formaldehyde crosslink.  Then the DNA 
template is digested with appropriate restriction enzymes, followed by an 
immunoprecipitation of the epitope of interest. If that epitope is crosslinked to an 
radiolabelled DNA fragment, it is coprecipitated and can therefore be detected in an 
autoradiography, without further amplification. Since the restriction pattern of the applied 
enzyme is known, it can be determined to which part of the DNA template the epitope 
was crosslinked.  
B.1.11.1. Preparation of the radiolabelled DNA-template 
Radiolabelled MRG5 promoter templates were generated by PCR and were amplified 
from the vector pGL2MRG5, that in turn stems from pMRG5 plasmid, which contains a 
Luciferase expression cassette in place of the G-free cassette of pMRG5. The promoter 
comprises 5 GAL4 bindings sites immediately upstream of a synthetic HIV/ML core 
promoter as described previously (Xie et al., 2000). The primers were: 
5’- GCA TTC TAG TTG TGG TTT GTC CAA (biotinylated) and 5’- GCC GGG CCT 
TTC TTT ATG TT.  
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The PCR reaction was carried out with the following reaction mix: 
  
10 X PCR buffer    5 µl 
MgCl2 (25 mM)    3 µl 
Template (10 ng/µl)    2 µl 
Primer A (10 µM)    2 µl 
Primer B (10 µM)    2 µl 
Taq (LC)    2 µl 
dNTP Mix (cold)    1 µl 
γ-32P-dCTP (3000 Ci/mmol) 1 µl 
Water    32 µl 
 
dNTP Mix (cold):  25 mM    dATP 
     25 mM    dGTP 
     25 mM    dTTP 
     6.25 mM dCTP 
 
After the PCR reaction, the templates were purified with a PCR purification kit (Qiagen, 
cat. no.: 28104) according to the manufacturer’s instructions.  
B.1.11.2. Preparation of the CRIP IP beads 
10 µl antibody loaded sepharose beads were prepared for one immunoprecipitation 
reaction. Any centrifugation step involving sepharose beads was carried out for 3 min at 
700 x g and 4ºC, if not stated otherwise. Protein A (for rabbit and goat antibodies) or 
protein G sepharose beads (for rat antibodies) were equilibrated by washing the beads 
three times in 20 column volumes (CV) 1 x TBS, pH 8.0. Unspecific binding sites on the 
beads were blocked by a 1 hr incubation with 10 CV blocking buffer at 4ºC. 
Concentrated antisera were added directly to the blocking buffer (2 µg antibody per 10 µl 
sepharose beads), hybridoma supernatants were added to the beads after removal of the 
blocking buffer (100 µl supernatant per 10 µl sepharose beads). The antibody binding 
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reaction was carried out for at least 2 hrs at 4ºC. Finally the beads were washed once in 
10 CV 1 x TBS-T, pH 8.0. 
B.1.11.3. CRIP assay on PICs 
Conditions of PIC formation were chosen similar to the ones used in a typical in vitro 
transcription experiment. For one CRIP assay immunoprecipitation a 25 µl reaction was 
prepared according to the following table: 
Basic components 150 ng (0.6 pmol) radiolabelled promoter DNA template     20-40% (v/v) nuclear extract 
40-50% (v/v) total BC-buffer content 
60 mM total chloride ion concentration 
20 mM Hepes-KOH, pH 8.2 
5 mM MgCl2 
0.5 mg/ml BSA (Roche, ca. no.: 711454) 
Maximal 0.025% (v/v) IGEPAL-CA-630 (NP-40) 
0.1 mg/ml PEG-8000 
40 units RNase inhibitor (Promega, cat. no.: N211A) 
25 ng/µl poly(dG:dC) (Amersham, cat. no.: 27-7890-02) 
10 mM DTT 
0.2 mM PMSF 
Optional components 1 µM ATP or 1 µM ATPγS or 500 µM H8 
50 ng GAL4-VP16 
 
Table 4: CRIP Conditions 
  
For PIC formation, the reaction mixture was incubated for 45 min at 30ºC. Prior to the 
formaldehyde crosslink, a TATA-box containing double stranded DNA oligo nucleotide 
(5’- CCT GAA GGG GGG TAT AAA AGG GGG TGG GGG CGC G) was added to a 
final concentration of 0.6 mM. Exact 1 min after addition of the competition TATA-
oligonucleotide, the reaction was crosslinked by addition of 5% (v/v) formaldehyde 
solution (diluted in PBS) to a final concentration of 0.25% (v/v) in the reaction. 
Crosslinking was allowed for 10 min at RT and stopped by addition of one reaction 
volume 300 mM glycine, pH 7.5. For the restriction digest, the samples were diluted with 
3 reaction volumes of water. Then the restriction digest buffer as well as the restriction 
enzyme indicated in the figures were added to the reaction and incubated for 2 hrs at 
37ºC. Finally the samples were placed on ice.    
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B.1.11.4. CRIP immunoprecipitation 
For the immunoprecipitation the samples were diluted 1:5 in 5 x CRIP IP buffer and 
protease inhibitors (Roche, cat. no.: 11697498001) were added. To reduce unspecific 
binding of proteins and DNA to the IP beads, each sample was pre-cleared with 10 µl 
plain protein A or G sepharose beads, which were equilibrated in TBS, pH 8.0. Pre-
clearing was carried out for 2 hrs in the cold room on a rotating wheel. For the 
immunoprecipitation, the pre-cleared samples were transferred to the antibody-coated IP 
beads and incubated for 16 hrs in the cold room on the rotating wheel.  The next day, the 
IP-beads were washed 3 times with 500 µl  ice-cold 1 x TBS-T (CRIP), then once with 
TE containing 50 mM NaCl. For elution of immunoprecipitated complexes the IP-beads 
were incubated with 30 µl ChIP-EB buffer containing 0.1 µg/ml proteinase K (Roche, 
cat. no.: 03115887001) for 15 min at 65ºC in a shaking block. Then the IP-beads were 
peletted by centrifugation (1 min, 13200 x g, RT) and the supernatant was transferred to a 
fresh Eppendorf tube. For reversal of the formaldehyde crosslink the samples were 
incubated overnight at 65ºC. Remaining proteins were then digested by adding 15 µg 
proteinase K (Roche, cat. no.: 11697498001) to each sample followed by an incubation 
for 2 hrs at 55ºC. The immuoprecipitated radiolabelled DNA fragments were then 
separated by native polyacrylamide gel electrophoresis on a 6% gel, the gel was dried and 
exposed to BioMax MR film (Kodak, cat. no.: 8736936). 
 
  TBS, pH 8.0:   150 mM NaCl 
      100 mM Tris-HCl 
      pH to 8.0 
   
  1 X TBS-T (CRIP):  1 X TBS 
      0.05% Tween-20  
 
  Blocking Buffer:  1 X TBS pH 8.0 
      0.5% BSA 
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  300 mM Glycine pH 7.6: 300 mM Glycine 
      pH adjusted to 7.6  
 
  5 x CRIP IP Buffer:  100 mM Hepes-KOH pH 7.5 
      0.5% NP-40 
      0.5% Trition X-100 
      1 M NaCl 
      0.1% Polyvinylpyrolidone-40,000 
      0.1% FICOLL400 
      0.5% BSA 
      0.1 mg/ml tRNA 
      300 µg/ml sonicated salmon sperm DNA 
      2% PEG-8000 
      55 mM EDTA 
      200 µg/ml sonicated salmon sperm DNA 
 
   ChIP-EB:   50 mM Tris pH 7.5 
      10 mM EDTA 
      1% SDS 
B.1.12. Protein concentration determination 
To determine the total protein concentration of a sample the Bradford assay was used. A 
serial dilution of a BSA-solution with known concentrations (2 to 0.125 mg/ml) served as 
a standard in addition to the sample. The assay was carried out in 96 well plates. 5 µl of a 
sample or standard dilution were supplemented with 195 µl 1 x Bradford reagent solution 
(Bio-Rad, cat.no.: 500-0006). After 10 min incubation the absorbance at 595 nm was 
determined on a plate reader (BIO-TEK INSTRUMENTS INC., EL800 universal 
microplate reader).     
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 B.2. Cell Biology 
B.2.1. Cell culture 
B.2.1.1. Adherent cells 
HeLa adherent cell lines were grown in Dulbecco’s modified Eagle medium (DMEM, 
Invitrogen/Gibco, cat.no.: 15140-122) supplemented with 10% fetal bovine serum (FCS; 
Invitrogen/Gibco, cat. no.: 15140-122) and  Penicillin (1000 u/l)-Streptomycin (100 mg/l) 
(Invitrogen/Gibco, cat. no.: 15140-122). Cells were cultured in plastic dishes (10 or 15 
cm in diameter) or in 6 or 12 well plates (Nunc, cat. no.: 157150, 150350, 140675 and 
150628, respectively). Cells were grown in tissue culture incubators in the presence of 
5% CO2 at 37ºC. In order to detach cells from cell culture dishes, the medium was 
removed, the cells were rinsed with 1 x PBS and then incubated with 0.25% trypsin / 
0.2% EDTA (Invitrogen/Gibco, cat. no.: 25050-014) for 3 – 5 minutes. Cells were 
splitted at a ratio of 1:4.  
B.2.1.2. Suspension cells 
Jurkat and HeLaS3 cells were grown in RPMI 1640 containing L-glutamine 
(Invitrogen/Gibco, cat. no.: 21875-034), supplemented with 10% fetal bovine serum 
(FCS; Invitrogen/Gibco, cat. no.: 15140-122) and Penicillin (1000 u/l)-Streptomycin 
(100mg/l) (Invitrogen/Gibco, cat. no.: 15140-122). Suspension cells were grown in 25 to 
175 cm2 cell culture flasks and maintained at a density between 3 to 9 x 106 cells per 
milliliter medium. 
B.2.1.3. Spinner cultures 
HeLaS3 cells were grown in 3 liter glass spinner flasks (Wheaton, cat. no.: 356886) and 
stirred at a constant rate of 42 rpm. Cells were cultured similar to suspension cells as 
described in the previous chapter, except that the medium was supplemented with only 
5% FCS. Spinner cultures were grown in a humidified incubator in the presence of 5% 
CO2. 
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B.2.1.4. Freezing of eukaryotic cells 
0.5 to 1 x 107 cells were collected and pelleted by centrifugation (500 x g, room 
temperature). Cells were resuspended in freezing medium. Cells were frozen in 0.5 to 1 
ml aliquots at -80ºC in a freezing box and subsequently transferred to a liquid nitrogen 
tank for storage.   
 
 Freezing medium: 90% (v/v) FCS 
    10% (v/v) DMSO  
B.2.1.5. Thawing of eukaryotic cells 
In order to take frozen cells into culture, the vial containing the frozen cells was thawed 
in a water bath at 37ºC. After completion of the thawing process cells were resuspended 
immediately in 10 ml of prewarmed cell culture medium.  
B.2.2. Luciferase assay 
CMV-HeLa cells were tested for reporter gene induction 16 hours after addition of 
doxycycline to the cell culture medium. For each luciferase assay reading one well of a 
12 well plate was used. Immediately prior to cell lysis, the cell culture medium was 
removed, the cells rinsed once with 1 x PBS and then lysed by addition of 100 µl 
1 x passive  lysis buffer (Promega, cat. no.: E194A). After 10 min incubation on ice the 
lysate was collected in an Eppendorf tube and centrifuged for 10 min (16200 x g, RT). 
20 µl of this supernatant was used in the luciferase assay according to the manufacturer's 
instructions (Promega; cat. no.: E1501). Luciferase readings were normalized to the 
protein content of each sample. The protein concentration of each luciferase sample was 
measured with a Bradford assay (see section B.1.12.).  
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B.2.4. Chromatin immunoprecipitation 
This ChIP protocol is based on a protocol published by the Young lab (Odom et al., 
2004).  
B.2.4.1. Crosslinking of adherent cells 
CMV HeLa cells were crosslinked on 15 cm diameter cell culture dishes by adding 37% 
formaldehyde solution (Roth, cat. no.: 4979.1) to a final concentration of 1% (v/v) 
directly to the medium. After exact 10 min incubation on a rotating platform at RT the 
crosslink was stopped by addition of 2 M glycine solution to a final concentration of 
125 mM in the cell culture dish. All subsequent steps were carried out in the cold room at 
4ºC. Crosslinked cells were rinsed 3 times with ice-cold PBS containing 0.2 mM PMSF 
and then harvested from the cell culture dishes with a rubber scrapper. Cells were 
collected in polypropylene tubes, peletted by centrifugation (5 min, 500 x g, 4ºC) and 
then either processed directly or snap-frozen in liquid nitrogen and stored at -80ºC.  
B.2.4.2. Cell lysis and sonication 
For the lysis, a crosslinked cell pellet comprising about 108 cells was resuspended in 5 ml 
lysis buffer LB1 supplemented with protease inhibitors (Roche, cat. no.: 11697498001). 
The suspension was incubated on a roller for 10 min at 4ºC. After centrifugation (10 min, 
4000 rpm, 4ºC) the pellet was resuspended in LB2 and incubated on a roller for 10 min at 
4ºC. Then the cells were pelleted by centrifugation (10 min, 4000 rpm, 4ºC) and 
resuspended in LB3 supplemented with protease inhibitors (Roche, cat. no.: 
11697498001). In addition a spatula tip of acid-washed glass beads (Sigma, cat. no.: 
G1277) was added to each sample prior to sonication. Sonication of the crosslinked 
extracts was carried out on a Branson 250 sonifier with the tubes being cooled in a 
ice/ethanol bath during sonication. The sonication settings were: 40% output amplitude, 
total sonication time: 6 min, sonication cycles: pulse on: 30 sec, pulse off: 10 sec. After 
sonication the average DNA fragment size was checked by agarose gel electrophoresis 
(Before loading the samples onto the agarose gel proteins were digested and the crosslink 
reverted). Typically, the fragment size was between 300 and 600 bp. The sheared 
chromatin was then centrifuged (5 min, 5500 rpm, 4ºC) and the supernatants were 
transferred into fresh Eppendorf tubes. Debris was removed by another centrifugation 
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step (15 min, 13200 x g, 4ºC), then the double strand (ds) DNA concentration was 
determined in a spectral photometer and the samples were diluted with LB3 to a ds DNA 
concentration of 1 mg/ml. Before aliquoting and freezing of the ChIP samples in liquid 
nitrogen, 80% glycerol was added to each sample such that the final glycerol 
concentration was 5 % (v/v). ChIP samples were stored at -80ºC. 
B.2.4.3. Immunoprecipitation 
25 µl antibody-coupled protein A or G sepharose beads were prepared as described in 
section B.1.3.1. for each chromatin immunoprecipitation sample and equilibrated in LB3 
buffer. Crosslinked chromatin extract was allotted such that each chromatin 
immunoprecipitation contained the equivalent of 200 µg double-strand DNA. Typically, 
an immunoprecipitation was carried out in a total volume of 400 µl LB3 containing a 
final concentration of 0.5% (v/v) Triton X-100, 0.25% (v/v) N-lauryl sarkosyl and 0.1% 
(v/v) deoxycholate. Each chromatin immunoprecipitation mix was supplemented with 
protease inhibitors (Roche, cat. no.: 11697498001). Before the immunoprecipitation with 
the specific antibody, each sample was precleared by incubation with 25 µl plain protein 
A or G sepharose beads equilibrated in LB3 containing 0.5% Triton X-100, 0.25% 
N-lauryl sarkosyl and 0.1% deoxycholate for 2 hrs at 4ºC on the rotating wheel. After that 
the supernatant was transferred to the antibody coupled IP beads and incubated overnight 
at 4ºC on the rotating wheel. The next day the IP beads in each sample were washed 6 
times with 1 ml ice-cold ChIP wash buffer supplemented with protease inhibitors. After a 
final wash with 1 ml TE containing 50 mM NaCl the IP-beads of each sample were 
eluted by addition of 100 µl ChIP-EB buffer. For the elution, the samples were incubated 
for 15 min at 65ºC in a thermo mixer. Finally the beads were pelleted by centrifugation (1 
min, 13200 x g, RT) and the supernatant was transferred to a fresh Eppendorf tube. For 
reversal of the crosslink samples were incubated overnight at 65ºC. The next day 1 
volume TE was added to each sample. Then RNase A (Ambion, cat. no.: 2272) was 
added to a final concentration of 10 µg/ml and the samples were incubated at 37ºC for 2 
hrs. After that proteinase K (Roche, cat. no.: 03115887001) was added to each sample to 
a final concentration of 150 µg/ml and the samples were incubated at 55ºC for 2 hrs. 
Then the immunoprecipitated DNA fragments were prepared by phenol-chloroform 
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extraction and ethanol precipitation with glycogen as a coprecipitant. Dried DNA pellets 
were resuspended in 50 µl 10 mM Tris-HCl, pH 8.0 at room temperature.
 
 Lysis buffer 1 (LB1):  50 mM Hepes-KOH, pH 7.5 
     140 mM NaCl 
     1 mM EDTA 
     10% (v/v) Glycerol 
     0.5% (v/v) IGEPAL CA630 (NP-40) 
     0.25% (v/v) Triton X-100    
   
 Lysis buffer 2 (LB2):  200 mM NaCl 
     1 mM EDTA 
     0.5 mM EGTA 
     10 mM Tris-Cl, pH 8.0 at RT 
 
 Lysis buffer 3 (LB3):  140 mM NaCl 
     1 mM EDTA 
     0.5 mM EGTA 
     20 mM Tris-Cl, pH 8.0 at RT 
     0.5% N-lauryl sarkosyl 
     0.1 % Sodium deoxycholate 
 
 ChIP-Wash buffer:  25 mM HEPES-KOH, pH 7.6 
     0.5 mM EDTA 
     0.5% (v/v)  IGEPAL CA630 (NP-40) 
     0.25 M LiCl 
     0.7% (v/v) sodium deoxycholate 
 
 ChIP-EB:   50 mM Tris pH 7.5 
     10 mM EDTA 
     1% SDS 
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B.2.5. Quantitative real-time PCR 
Quantitative real-time PCR were carried out on a  Gene Amp 5700 (Applied Biosystems) 
machine. The subsequent data analysis was performed with the Microsoft Excel software.  
A typical 25 µl PCR reaction was composed as follows 
 
      4 µl  sample in 10 mM Tris pH 8.0 or TE 
 12.5 µl  2X  SYBR Green PCR Mastermix  
   (Applied Biosystems, Cat. no.: 4367659) 
     1 µl  10 mM Primer Mix 
   7.5 µl  water   
B.3. Basic buffers and solutions 
 BC-buffers 20 mM Tris-HCl pH 7.3 (RT) 
   0.2 mM EDTA, pH 8.0 
   0 – 2000 mM KCl 
   20% (v/v) glycerol 
 
 HEGN  25 mM Hepes-KOH, pH 7.6 
   0.2 mM EDTA 
   0 – 2000 mM KCl 
   10% (v/v) glycerol 
   0.1% (v/v) IGEPAL CA630 (NP-40) 
 
 10 x TBE 1 M Tris-HCl 
   1 M Boric acid 
   20 mM EDTA, pH 8.0 
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 10 x PBS 1.37 M NaCl  
   78 mM Na2HPO4 
   15 mM KH2PO4 
   27 mM KCl 
   pH 7.4 
 
 1 x TE  10 mM Tris HCl, pH 7.5 
   1 mM EDTA, pH 8.0 
B.4. Material 
B.4.1. Antibodies 
Primary antibody Number Provider Species 
AF-10 sc-27083 Santa Cruz goat 
CPSF1 sc-17289 Santa Cruz goat 
Brd4 sc-27975 Santa Cruz goat 
CstF-64 sc-16473 Santa Cruz goat 
PARP-1 sc-1561 Santa Cruz goat 
CDK7 sc-529 Santa Cruz rabbit 
CDK8 sc-1521 Santa Cruz goat 
CDK9 sc-8338 Santa Cruz rabbit 
CBP/HAT 6D6 E.Kremmer rat 
cyclin T1 sc-10750 Santa Cruz rabbit 
GAL4-DBD sc-577 Santa Cruz rabbit 
H3-K79me2 05-835 Upstate rabbit 
H3 ab1791 Abcam rabbit 
H3-K9-me3 07-523 Upstate rabbit 
Ku sc-466 Santa Cruz mouse 
TRAP220 sc-8998 Santa Cruz rabbit 
TRAP150 sc-5378 Santa Cruz goat 
MED6 sc-9433 Santa Cruz goat 
MED7 3E12 E.Kremmer rat 
MED15 6C9 E.Kremmer rat 
MED15 1H7 E.Kremmer rat 
MED25 VC1 E.Kremmer rat 
NC2-alpah 4G7 E.Kremmer rat 
TRAP95 sc-5366 Santa Cruz goat 
TRAP95 sc-5363 Santa Cruz goat 
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TRAP240 sc-5369 Santa Cruz goat 
PolII (N20) sc-899 Santa Cruz rabbit 
Leo1  T. Albert rabbit 
Sur2 550429 BD mouse 
TFIIB sc-225 Santa Cruz rabbit 
TFIIB sc-23875 Santa Cruz mouse 
TFIIH p62 sc-292 Santa Cruz rabbit 
TAFII100 1C2 L.Tora mouse 
TAFII80  L.Tora mouse 
TAFII250 sc-735 Santa Cruz mouse 
TBP SI-1 sc-273 Santa Cruz rabbit 
Cdc2 p34 sc-54 Santa Cruz mouse 
Cdc2 p34 sc-954 Santa Cruz rabbit 
hSpt5 sc-28678 Santa Cruz rabbit 
CTD Ser-7 P 4E12 E.Kremmer/D.Eick rat 
CTD Ser-5 P 3E8 E.Kremmer/D.Eick rat 
CTD Ser-2 P 3E10 E.Kremmer/D.Eick rat 
Paf1  T. Albert rabbit 
PC4  M.Meisterernst rabbit 
 
Table 5: Primary antibodies 
B.4.2. Plasmids 
Plasmid Insert Purpose Provider Reference 
pSB1 GST-VP16 
Protein 
expression T. Stuehler 
(Ikeda et al., 
2002) 
pSB2 GST-H1 
Protein 
expression T. Stuehler 
(Ikeda et al., 
2002) 
pSB3 GST-H1mt 
Protein 
expression T. Stuehler 
(Ikeda et al., 
2002) 
pSB4 GST-H2 
Protein 
expression T. Stuehler 
(Ikeda et al., 
2002) 
pSB5 GST-H2mt 
Protein 
expression T. Stuehler 
(Ikeda et al., 
2002) 
pSB6 GST-CTD 
Protein 
expression Dynan lab 
(Peterson et 
al., 1992) 
 
Table 6: Plasmids 
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B.4.3. Primers 
Oligo 
ID 
Name Sequence Modi-
fication 
Use Provider/ 
Reference  
oSB1 bio-pGL2-
MRG5 
 
GCA TTC TAG 
TTG TGG TTT 
GTC CAA 
 
5’-Biotin IMTA T.Uhlmann 
oSB2 Luc-bio-dw-
MRG5 
 
GCC GGG CCT 
TTC TTT ATG 
TT 
 
 IMTA T.Uhlmann 
oSB3 oriP_FW 
 
TGA TAC CCA 
GTA GTA GAG 
TGG 
 
 ChIP T.Uhlmann 
oSB4 oriP_BW 
 
CAG CAG GAA 
AAG GAC AAG 
CAG 
 
 ChIP T.Uhlmann 
oSB5 TRE1 
 
AGG CG GTA 
CGG TGG GAG 
GCC 
 ChIP T.Uhlmann 
oSB6 TRE2 
 
AGG CTG GAT 
CGG TCC CGG 
TGT 
 ChIP T.Uhlmann 
oSB7 Bio-H2B-
FW 
 
GAC GTG TTG 
TTG GTT AGG 
GCT 
5’-Biotin IMTA T.Albert 
oSB8 H2B-SP-Bac 
 
CAGAGG AGG 
AAT ACA AGC 
ACC 
 IMTA T.Albert 
oSB9 MRG5-
IMTA_long
_3' 
AT ACG ACG 
ATT CTG TGA 
TTT G 
 IMTA T.Uhlmann 
oSB10 bio-G5ML-
IMTA 
 
CGA TTC ATT 
AAT GCA GCT 
GG  
5' Biotin 
 
IMTA Wu et al., 
2003 
oSB11 G5ML-
Reverse-
IMTA 
 
AAC TCG ACT 
GCA GCA TAT 
GTA TCA TAC 
ACA TAC G 
 IMTA Wu et al., 
2003 
 
Table 7: Primers 
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B.4.4. Cell lines 
HeLa S3: HeLa derived cell line that has been adapted for growth in suspension culture. 
HeLa: Human epithelial cell line originating from a cervical carcinoma. Adherent cells.  
CMV-HeLa: HeLa cell line carrying the episomal plasmid pEBNA-SVP-GL-EµCAG-
rtTA  
Jurkat J6: Human T lymphoblastoid cell line 
B.4.5. Standards 
B.4.5.1. DNA ladders 
1 kB DNA-ladder (Gene ruler), Fermentas. Fragment lengths in bp: 10 000, 8000, 6000, 
5000, 4000, 3500, 3000, 2500, 2000, 1500, 1000, 750, 500, 250. 
 
100 bp DNA-ladder (Gene ruler), Fermentas. Fragment lengths in bp: 1031, 900, 800, 
700, 600, 500, 400, 300, 200, 100, 80.   
 
B.4.5.2. Protein standards 
SDS-PAGE protein standard high and low range (Biorad): 
Molecular weight Protein High range 
(Biorad, cat. no.: 161-
0303) 
Low range 
(Biorad, cat. no.: 161-
0304) 
200 Myosin x  
116 β-Galactosidase x  
97 Phosphorylase B x x 
66 Serum albumin x x 
45 Ovalbumine x x 
31 Carboanhydrase  x 
21 Trypsininhibitor  x 
14 Lysozyme  x 
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C. Results 
C.1. Mediator modules and Mediator subpopulations 
The  Mediator complex in a nuclear extract does not present itself as a homogeneous 
entity. Based on its composition several distinct Mediator forms can be distinguished. In 
the first chapter I describe my efforts to further characterize the Mediator populations 
defined by the presence of the CDK8 module and the MED25 subunit respectively. In 
terms of function I focused on the role of Mediator as a basal transcription factor.  
C.1.1. Characterization of Mediator subpopulations in nuclear extracts 
Chromatin immunoprecipitation (ChIP) experiments revealed that CDK8 is lost at the 
promoter region upon transcription induction in a doxycycline inducible tet-VP16 model 
system in vivo (Uhlmann et al., 2007). Previous biochemical studies of VP16-Mediator 
interactions had not revealed a selectivity of VP16 for a CDK8-less Mediator population 
that seems to mediate transcription activation in vivo. (Ito et al., 1999; Mittler et al., 
2003). Solutions to this apparent contradiction could be either the substochiometric 
distribution of CDK8 in Mediator or a mechanism that leads to its removal i.e. during 
transcription initiation. Monoclonal antibodies directed against MED15 and MED25 and 
polyclonal antibodies against CDK8 and MED1 were used to deplete standard Dignam 
HeLa nuclear extracts for the complexes associated with them. TBP served as a loading 
control (Fig. 3A). MED15 depletion reproducibly removed all MED25 as well as other 
Mediator core subunits but retained a minor fraction of CDK8. This initially implies that 
most of the CDK8 exists in a Mediator-bound form. CDK8 depletion, while being highly 
efficient for the antigen, removed a smaller fraction of MED25 and of other Mediator 
subunits. MED25 depletion retains a larger fraction of CDK8. MED1 depletion removed 
all MED7 but retained a fraction of MED15, MED25 and CDK8. These findings indicate 
that the extracts contain minimally a MED15-MED25 containing subcomplex that lacks 
MED7. This could be a free head module or another complex. The data further 
qualitatively suggest that CDK8 is underrepresented in MED25 and MED1 associated 
Mediators. 
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Figure 3: Biochemical and functional analyses of extracts depleted for variant Mediator complexes. 
A, Western blot analysis of immunodepleted HeLa extracts using antibodies against the indicated Mediator 
subunits. Jurkat nuclear extracts led to an essentially identical picture (data not shown). B, Westernblot 
analysis of factors bound to immobilized templates upon immunodepletion with antibodies against the 
indicated Mediator subunits in the absence and presence of the activator GAL4-VP16 using Jurkat extracts. 
Lane 1 (NEX) shows a nuclear extract control. PIC (preinitiation complex) indicates analysis of complexes 
bound to and washed on the immobilized templates (lane 2 to lane 11). In vitro transcription analyses 
(TXN) of isotype and the indicated Mediator-subunit depleted Jurkat nuclear extracts on a adenovirus 
major-late promoter carrying five upstream GAL4 binding sites in the presence and absence of Gal4-VP16 
as indicated.  
C.1.2. CDK8 is dispensable for basal and VP16-dependent in vitro transcription 
To address the question whether CDK8 is necessary or inhibitory to Mediator 
recruitment by VP16 I employed the immobilized promoter template technology. Jurkat 
nuclear extracts were incubated with an immobilized promoter template comprising five 
consecutive GAL4 binding sites upstream of a synthetic core promoter and part of the 
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luciferase reporter gene. Transcription complexes were formed in the absence and 
presence of GAL4-VP16 using extracts (NEX) and extracts depleted for Mediator 
variants (Δ). Bound complexes were washed, proteins eluted, separated on SDS-PAGE 
gels and analyzed by immunoblot (Fig. 3B). The data argue for VP16-dependent binding 
of Mediator in mock-depleted extracts (ΔIsotype) and loss of Mediator binding if the 
extracts which were depleted with antibodies directed against MED15 or MED25. 
Conversely, depletion of CDK8 does not prevent recruitment of Mediator. Hence, CDK8 
is not necessary but - in the light of the reduced amount of Mediator in the ΔCDK8 
extract - the kinase is also not inhibitory to the interaction with VP16. Of note, TBP 
binding is independent of the activator and the presence of Mediators, and, thus, does 
serve here as a loading control. Next the analysis of transcription complex formation at 
immobilized promoter templates was extended to PICs which were exposed to a second 
incubation step under in vitro transcription conditions (Fig. 4B). Like TBP, TFIIH binds 
promoters independent of the presence of VP16 (a decrease of the TFIIH signal upon 
addition of VP16 was not generally seen). In agreement with previous studies (Johnson et 
al., 2004; Malik et al., 2005 and references therein) Mediator binding was strongly 
induced by VP16. Among the different Mediator subunits, the enrichment of MED25 by 
VP16 is most pronounced. This may be in part attributed to the fact that this factor is 
present in free and bound form both of which directly interact with VP16 (Mittler et al., 
2003). CDK8, although absent in vivo, was co-recruited with Mediator to the template as 
is MED1.  
To investigate the changes occurring in the template bound Mediator population upon 
transcription initiation washed PICs were incubated in a second step in transcription 
buffer supplemented with 500 µM NTPs (Fig. 4B). Afterwards the proteins bound to the 
immobilized templates were washed, eluted with Laemmli buffer and analyzed by 
immunoblot. The PIC is stable if incubated without any NTPs (Fig. 4B, lane 4). Addition 
of 500 µM ATP  alone is sufficient to dissociate the PIC (lane 5) and leads to a similar 
result as ATP and CTP (formation of the first phosphodiester bond is permitted; Fig. 4B, 
lane 6), or ATP, CTP and UTP were added (transcription proceeds till position 29 of the 
promoter template, Fig. 4B, lane 7) or all four NTPs were added (run-off transcription 
takes place, Fig. 4B, lane 8). The process of PIC dissociation appears to be independent 
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of productive transcription. In yeast a re-initiation Mediator has been described, which 
remains bound to the core promoter after transcription initiation (Yudkovsky et al., 
2000). I find that Mediator subunits dissociate to varying degrees. The MED7 
component, which is part of the middle module, remains attached to the promoter 
template. A slight loss is seen for the MED25 subunit. CDK8, a constituent of the 
 
 
Figure 4: Characterization of transcription complexes formed under the control of GAL4-VP16 on 
immobilized templates and influence of nucleotides on their composition. A, Schematic protocol of the 
immobilized template assay. PIC, preinitiation complex formation; NEX, nuclear extract. B, Western blot 
analysis of Jurkat extract (NEX) (25% of material relative to the bound fraction, lane 1) and factors bound 
to immobilized templates (PIC formation) in the absence and presence of saturating amounts of GAL4-
VP16 using the indicated antibodies. Several reactions (lanes 4–8) were subjected to a second incubation 
period with buffer only (lane 4), 500 µM ATP (A, open complex formation, lane 5), 500 µM ATP and 
500 µM CTP (AC, allowing transcription to position 2), 500 µM ATP, 500 µM CTP, and 500 µM UTP 
(ACU, allowing transcription to position 29) and all four NTPs at a final concentration of 500 µM (N, 91-
bp run-off transcript conditions). C, PICs were formed in the presence of 1 µM ATP, washed and incubated 
in a second step in the presence of 1, 10 and 100 µM of the casein kinase 2 (CKII) inhibitor TBB (lanes 3, 4 
and 5 respectively). In this case the second incubation step contained NTPs to a final concentration of 
100 µM.  
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CDK8 module is lost to a larger degree, as is MED15, which is part of the tail module. 
The amount of promoter bound TBP is modestly affected by NTP addition (Fig. 4C, 
compare lane 1 and 2). A modification of TBP is observed, which increases the apparent 
molecular weight of TBP in an SDS-PAGE gel by approximately 10 kDa (Fig. 4C, lanes 
2-5). As in the yeast study, a loss of CDK7 and TFIIB is seen, the TFIIH core subunit 
p62 is lost to a lesser degree (Fig. 4B, C) upon transcription initiation. This leads to the 
conclusion that in higher eukaryotes the reinitiation Mediator complex consists of the 
head and middle modules, but is devoid of the CDK8- and tail module components. 
C.1.3. The MED25-Mediator is sufficient for in vitro transcription 
MED25 lacks an apparent homologue in yeast (Blazek et al., 2005; Bourbon, 2008). To 
the present day the physiological role of this particular Mediator subunit is not 
understood. Earlier work by a former Ph.D. student, Gerhard Mittler, hinted that there 
might be two functionally distinct Mediator populations. One dubbed basal Mediator or 
B-MED, which acts similar to a general transcription factor and a second that is required 
for activator-dependent transcription (A-MED). It was reasoned, that the MED25 
Mediator might represent the A-MED variety (Mittler et al., 2001). I now asked whether 
the MED25 Mediator by itself is sufficient to support in vitro transcription or whether 
other Mediator complexes are required. A Jurkat nuclear extract was immunodepleted for 
all Mediator populations. Subsequently immunopurified MED25-Mediator was added 
back to the extract and tested for its ability to form a PIC and to support in vitro 
transcription (Fig. 5). The presence of the MED25 Mediator in a nuclear extract is 
sufficient to form a functional PIC (as measured by TFIIB and TFIIH recruitment) and to 
support in vitro transcription at levels comparable to an extract which had been mock-
depleted (ΔIso). This suggests that the MED25-associated complexes contain all 
functional elements required for VP16-dependent transcription initiation, even if washed 
under stringent (800 mM KCl) conditions.  
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Figure 5: The MED25-Mediator is sufficient for transcription in vitro. A, Immunoblot and in vitro 
transcription analysis (TXN) of immobilized promoter templates (lanes 3-9). Nuclear extracts were either 
mock-treated (ΔIso) or Mediator-depleted (ΔMED) and supplemented with immunoprecipitated MED25-
Mediator (MED25) or isotype immunoprecipitation (IP-) beads (Iso). IP-beads were washed either with 
low (150 mM KCl) or high stringency (800 mM KCl).  
C.1.4. Basal Mediator 
In previous studies our laboratory discovered that Mediator is absolutely required for 
activator-independent basal transcription in the nuclear extract in vitro transcription 
system. This requirement is not observed in a minimal in vitro transcription system 
composed of highly purified and recombinant components (Mittler et al., 2001). I set out 
to analyze the molecular mechanism behind this requirement and found that the basal 
Mediator acts at two distinct steps: in the nuclear extract transcription system Mediator 
acts on TFIIB, TFIIH, RNAPII recruitment and also is required to establish a ser-5 
phosphorylation of the IIa form of the CTD of RNAPII before complex opening. 
Notably, the nuclear extract transcription system is CTD-phosphorylation dependent, 
whereas the recombinant/purified transcription system is not (Serizawa et al., 1993).  
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C.1.4.1. Mediator promotes GTF recruitment to a TATA-TBP complex 
In the nuclear extract system the presence of Mediator is required for TFIIB and TFIIH 
recruitment to the promoter even though TFIIB is present in the nuclear extract in large 
excess compared with the amount finally recruited to the template ((Baek et al., 2006) 
and Fig. 5, compare lanes 3 and 4; Fig. 6A, compare lanes 4 and 5). First I compared the 
recruitment efficiency of TFIIB to a TATA-TBP complex using either a nuclear extract 
or recombinant TBP (rTBP) and recombinant TFIIB (rTFIIB) in similar concentrations as 
they are present in a nuclear extract (Fig. 6C, lanes 1 and 2). An immobilized template 
assay revealed that TFIIB is recruited in much larger amounts in case only rTFIIB/rTBP 
is used in the assay. Although the nuclear extract contains similar amounts of 
TBP/TFIIB, a significant lower amount of TFIIB is recruited to the immobilized 
promoter template (Fig. 6C, lanes 3 and 4). Furthermore I found that components of the 
0.1 M P11 phosphocellulose column fraction were able to interfere with recruitment of 
rTFIIB to an rTBP-TATA complex (Fig. 6C, lanes 5-8). However this effect could be due 
to unspecific DNA binding proteins present in the 0.1 M P11 fraction. In transcription 
system composed of nothing but recombinant and highly purified factors GTFs are 
recruited sequentially. To test whether this mechanism applies in this case I incubated the 
promoter DNA template with recombinant TBP and recombinant TFIIB prior to addition 
of mock-treated (ΔIso) or Mediator-depleted (ΔMED) nuclear extract (Fig. 6B). Even if 
massive amounts of TFIIB were bound to the promoter DNA template recruitment of 
TFIIH remained Mediator-dependent. This indicates that Mediator not only acts on TFIIB 
recruitment, but rather facilitates recruitment of GTFs such as TFIIB and TFIIH. This 
would be in line with the predictions of the holoenzyme model which states that 
Mediator, RNAPII and the GTFs TFIIB, TFIIE, TFIIF and TFIIH are recruited to an 
promoter in form of a holoenzyme complex. One can envision two modes for this GTF-
recruitment limiting mechanism that imposes the Mediator requirement on basal 
transcription: (i) Mediator is required so that TBP can adopt a conformation on the 
promoter that allows recruitment of TFIIB and TFIIH or (ii) Mediator counteracts the 
effect of a factor that blocks access of GTFs to their respective binding sites on the TBP-
DNA complex. To distinguish between the two possibilities I performed an immobilized 
template assay with the major-late promoter template in which I incubated the template 
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with either recombinant TBP (rTBP) alone (Fig. 6B lanes 12 and 13), or with TBP plus 
varying amounts of recombinant TFIIB (rTFIIB, Fig. 6B lanes 6-11). The amount of 
rTBP offered to the promoter template resembled that offered by a nuclear extract (see 
input, compare Fig. 6B lanes 1 and 2 to 3). The rationale behind this was that in the 
purified system rTBP binds without difficulties to the TATA box. If this binding is 
established prior to the presence of a nuclear extract factor that represents an obstacle to 
proper TBP positioning, TFIIB/TFIIH recruitment and in vitro transcription should 
become independent of a basal Mediator activity. After the pre-incubation step the 
templates were washed and incubated in a PIC formation reaction either with mock- 
(ΔIso) or Mediator-depleted (ΔMED) Jurkat nuclear extract in the presence of 1 µM ATP. 
After the PIC formation reaction, immobilized templates were washed and eluted in part 
with Laemmli buffer for immunoblot analysis of the PIC or were subjected to an in vitro 
transcription reaction (TXN). Binding of rTBP to the promoter template in a pre-
incubation step did not alleviate the Mediator requirement for TFIIB and TFIIH 
recruitment as well as the Mediator-requirement for basal transcription (compare Fig. 6B 
lanes 4 and 5 to l2 and 13). This led to the conclusion that TBP positioning is unlikely to 
be affected by a negative acting nuclear extract factor. Next it was tested whether TFIIB 
is actively recruited by basal Mediator or whether basal Mediator helps to overcome a 
factor that blocks TFIIB recruitment. In another PIC formation assay it was tested 
whether TFIIB recruitment might be dependent on a kinase or helicase activity. PICs 
were formed on an immobilized major-late promoter template in the presence of 500 µM 
of the broad spectrum kinase inhibitor H8, 1 µM of the helicase inhibitor ATPγS or 1 µM 
of ATP. TFIIB and CDK7 of TFIIH were recruited in similar quantities in each situation 
(Fig. 10A). Notably endogenous TFIIB was recruited by Mediator even if similar 
amounts of rTFIIB were recruited to the template bound rTBP during the pre-incubation 
(Fig. 6B, lanes 8 and 9). rTFIIB ran on a SDS page gel at a higher molecular weight due 
to its His-tag. Thus even massive recruitment of TFIIB to the promoter template in a 
TBP-TFIIB complex could not substitute for the Mediator-requirement for recruitment of 
TFIIH and basal transcription, as it would be predicted by the sequential GTF assembly 
model. This particular results rather argue in favor of the holoenzyme model.  
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Figure 6: Basal Mediator is required for TFIIB/TFIIH recruitment, establishment of CTD ser-5 
hypophosphorylation during PIC formation and transcription. A, Schematic protocol of the 
immobilized template assay. PIC, preinitiation complex formation. B, Immunoblot analysis and in vitro 
transcription (TXN) analysis of PICs formed on major-late promoter templates with mock depleted (ΔIso) 
or Mediator-depleted (ΔMED) Jurkat nuclear extracts in the presence of 1 µM ATP. Preincubations of the 
template with rTBP (TBP concentration similar to that found in a nuclear extract) and rTFIIB was carried 
out as indicated. Input lanes 1-3 display 20% of the protein offered to the immobilized templates analyzed 
in lanes 4-13. C, Immobilized template assay. PICs were formed with rTBP/rTFIIB, Jurkat nuclear extract 
(NEX) or the indicated P11 fractions supplemented with rTBP/rTFIIB. 
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C.1.4.2. Establishment of CTD ser-5 phosphorylation on the low-mobility form of 
RNAPII  Rpb1 during PIC formation is a distinct basal Mediator function  
As will be discussed in detail in sections C.2 I found that phosphorylation of the high 
mobility form of RNAPII (CTD hypophosphorylation) was established prior to complex 
opening by TFIIH and did correlate with the transcription potential of a PIC. In the above 
mentioned experiment it became evident, that CTD ser-5 hypophosphorylation was 
established in a strictly Mediator-dependent manner. Even recruitment of large amounts 
of TFIIB to the template did not bypass this dependency arguing that CTD ser-5 
hypophosphorylation did not occur by default after TFIIB recruitment. This provides 
evidence for the notion that CTD ser-5 hypophosphorylation is established only in the 
context of a transcription competent PIC. To further investigate the properties of 
Mediator as a general transcription factor I asked whether the transcription activation 
domains of VP16 and Sp1 are dependent on a basal Mediator function. I formed PICs on 
a major-late promoter template comprising five GAL4 binding sites with either mock- 
(ΔIso) or Mediator-depleted (ΔMED) nuclear extracts in the absence of activator (basal; 
Fig. 7, lanes 1 and 2) or in the presence of GAL4-VP16 (Fig. 7, lanes 3 and 4) or GAL4-
Sp1 (Fig. 7 lanes 5 and 6). Template bound VP16 led to an increase in template recruited 
Mediator and in turn to an increase in TFIIB and TFIIH recruitment. The increase of 
Mediator at the promoter template exceeded the one seen for TFIIB and TFIIH (Fig. 7, 
lanes 3 and 4). Sp1 did not lead to an increased Mediator recruitment, but efficient PIC 
formation remained Mediator-dependent (Fig. 7, lanes 5 and 6). CTD ser-5 
hypophosphorylation correlated with the amount of TFIIB and TFIIH recruited to the 
promoter template. TAF4 has been reported to be an essential cofactor of Sp1 
transcription activation (Hoey et al., 1993). A modest, Mediator-independent increase of 
TAF4 recruitment was seen in the presence of both activators. In summary, transcription 
activation by Sp1 did not lead to an increased Mediator recruitment, however, Sp1-
activated transcription proved to be dependent on a basal Mediator function that Sp1-
recruited factors could not bypass.  
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Figure 7: Recruitment of TFIIB and TFIIH to a PIC as well as establishment of CTD ser-5 
hypophosphorylation is dependent on Mediator in the presence of GAL4-VP16 and GAL4-Sp1. PICs 
were formed in immobilized template assays on the major-late promoter (ML) with mock- (ΔIso) or 
Mediator-depleted (ΔMED) nuclear Jurkat extracts. PICs were washed and either analyzed for their in vitro 
transcription potential (TXN) or by immunoblot. In lanes 3 and 4 the activator GAL4-VP16, in lanes 5 and 
6 the activator GAL4-Sp1 was included. The amount of both activators recruited to the five GAL4 binding 
sites on the ML-promoter template were comparable as shown by the GAL4 immunoblot. 
 
C.1.4.3. Negative cofactor 2 (NC2) is not responsible for the Mediator requirement 
in basal transcription 
A yeast genetic study found NC2 as well as the CCR4-NOT complex act as antagonists 
of the positive Mediator function (Lee et al., 1998). For NC2 it has been demonstrated 
with recombinant proteins that it has the ability to compete with TFIIA and TFIIB 
recruitment to a TATA-TBP complex in vitro (Goppelt et al., 1996). On this basis I tested 
the hypothesis that NC2 does impose the Mediator-requirement on basal transcription in 
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the nuclear extract system. Nuclear extracts were immunodepleted for Mediator (ΔMED), 
NC2 (ΔNC2), and the combination of both (ΔIsoΔMED). With these extracts PICs were 
formed in the presence of 1 µM ATP and the extent of TFIIB and TFIIH (CDK7) 
recruitment as well as the appearance of CTD ser-5 hypophosphorylation was scored by 
immunoblot (Fig. 8A). In parallel in vitro transcription reactions were carried out 
following the same scheme (Fig. 8, TXN). If NC2 would be the GTF-recruitment limiting 
factor, one would expect that taking out NC2 leads to increased TFIIB  and TFIIH 
recruitment, and that in the absence of both, Mediator and NC2, the positive as well as 
the negative transcription cofactor, basal in vitro transcription should be Mediator-
independent. Immunodepletion of NC2 indeed led to an increase of TFIIB and TFIIH 
recruitment to the promoter template in the basal as well as VP16-activated situation (Fig. 
8A, compare lanes 5 and 7 as well as 9 and 11). Correlated with NC2 immunodepletion 
an increase in basal and VP16-activated transcription was observed. However, 
immunodepletion of NC2 together with Mediator did not led to levels of functional PIC 
formation as were seen in the presence of both factors (Fig. 8A, compare lanes 5 to 8 and 
9 to 12). Thus transcription was even in the absence of NC2 Mediator-dependent. To 
further investigate how NC2 modulates TFIIB and TFIIH recruitment during PIC 
formation I performed an additional PIC formation assay and in parallel an in vitro 
transcription experiment in which I doubled the amount of NC2 in the nuclear extract by 
adding recombinant NC2 (rNC2) complexes. Addition of this extra amount of NC2 led to 
a reduction of TFIIB and TFIIH (CDK7) recruitment during PIC formation under basal 
and VP16-activated conditions. (Fig. 8B, compare lanes 3 and 7 and lanes 4 and 8 
respectively). In summary, NC2 appeared to fine tune GTF recruitment to the PIC. The 
fact that adding extra NC2 could suppress TFIIB and TFIIH recruitment might be 
explained by competition of TFIIB and NC2 for the binding to TATA-TBP complexes. 
This fact is supported by the notion that the recruitment kinetics of TFIIB as well as of 
NC2 were both much slower than that of Mediator or TFIID (Fig. 9). Notably, the 
amount of the CTD ser-5 hypophosphorylation correlated with the amount of transcripts 
produced by a given PIC (Fig 8A/B).   
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Figure 8: TFIIB and TFIIH (CDK7) recruitment during PIC formation is influenced by NC2, but 
NC2 does not impose the Mediator requirement on TFIIB/TFIIH recruitment. Immobilized template 
assays on MRG5 promoter templates. A, PICs were formed under basal conditions or in the presence of 
GAL4-VP16 using mock-treated (ΔIso), NC2-depleted (ΔNC2), Mediator depleted (ΔMED) or Mediator 
and NC2 depleted (ΔMEDΔNC2) nuclear extracts. In parallel an in vitro transcription experiment was 
carried out (TXN). After NC2 removal, TFIIB and CDK7 recruitment is still Mediator dependent in the 
basal (compare lanes 5 to 8) as well as the VP16-activated situation (compare lanes 9 to 12). B, PICs were 
formed in the absence of NC2 (lanes 5 and 6) or after doubling the amount of NC2 in the nuclear extract by 
adding recombinantly expressed NC2 (rNC2) complexes (lanes 7 and 8). 
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C.1.4.4. Basal Mediator activity is physically associated with MED25 
Next I wanted to address whether basal activity is physically associated with MED25 or 
whether an additional Mediator population is required for transcription. The experiment I 
performed was to immunodeplete all Mediator forms from a nuclear extract and to add-
back immunoprecipitated MED25 Mediator, the mediator population that binds to the 
transcription activator VP16. If there would be a requirement for another Mediator 
population in vitro transcription should be abolished in such a setting. In order to 
minimize the effect unspecifically MED25-associated proteins I included a stringent 
wash at 800 mM KCl before adding back the MED25-immunoprecipitation to the 
Mediator-depleted nuclear extract (Fig. 5). Proteins associated with a MED25 
immunoprecipitation were sufficient to restore TFIIB and TFIIH recruitment to a PIC, 
establishment of CTD ser-5 hypophosphorylation and transcription in a Mediator-
depleted nuclear extract (Fig. 5). Thus the basal Mediator function was physically 
associated with MED25 and no additional Mediator population was required for 
transcription initiation.  
C.2. Function of CTD ser-5 phosphorylation in transcription initiation 
CTD ser-5 phosphorylation is known to correlate with transcription initiation.  However 
the exact timepoint at which this mark is established during PIC formation or 
transcription initiation is unknown. My data suggest that phosphorylation of the high- 
mobility form of RNAPII at ser-5 does correlate with active PIC formation in various 
experimental settings. To characterize the underlying process further, I analyzed the 
conditions under which the mark is established. The kinase that mediates CTD 
phosphorylation at ser-5 of the high- but notably not of the low-mobility form of RNAPII 
in vitro is CDK7 (Fig. 15B). In the following chapters I provide evidence that in vitro at 
least two distinct forms of CTD ser-5 phosphorylation can be distinguished. In addition I 
provide evidence, that CDK7-dependent phosphorylation of the high-mobility form of 
RNAPII at ser-5 (CTD ser-5 hypophosphorylation) was established already before 
complex opening by TFIIH (Fig. 9B and 10A) as it is insensitive to the helicase inhibitor 
ATPγS. I found that CTD ser-5 hypophosphorylation correlates with the transcription 
potential of an in vitro formed PIC (Figures 5, 6B, 8, 11B, 12B, 13, 17, and 20). 
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C.2.1. RNAPII CTD ser-5 hypophosphorylation is established before complex 
opening by the TFIIH associated helicase 
The Eick laboratory has recently generated a set of new monoclonal antibodies against 
several phosphorylated RNAPII CTD residues (Chapman et al., 2007). In this work I 
used a monoclonal antibody against phosphorylated CTD ser-5 to determine the 
timepoint at which CTD ser-5 phosphorylation is established. Given that it has been 
reported that small amounts of ATP or ATPγS present during PIC formation do facilitate 
the subsequent in vitro transcription reaction (Safer et al., 1985; Serizawa et al., 1997) I 
made use of this reagents to determine the exact timepoint of CTD ser-5 phosphorylation. 
To address this question I made use of the immobilized template assay using major-late 
promoter templates and Jurkat nuclear extracts. PICs were prepared in presence of 
500 µM of the kinase inhibitor H8, 1 µM of the helicase inhibitor ATPγS or 1 µM of 
ATP. PICs were washed and either analyzed directly by immunoblot (Fig. 9B lanes 2 to 
4) or subjected to a second incubation step in transcription buffer supplemented with 
100 µM NTPs (Fig. 9B lanes 5 to 7); 100 µM ATPγS (Fig. 9B lanes 8 to 10); or 100 µM 
ATP (Fig. 9A lanes 11 to 13). Afterwards the  proteins that had dissociated during the 
incubation were collected and analyzed separately by immunoblot (Fig. 9C). The 
promoter templates were washed and also analyzed by immunoblot (Fig. 9B). Most 
notably CTD ser-5 phosphorylation appeared to be established on the RNAPII high- 
mobility form (CTD ser-5 hypophosphorylation) in the presence of 1 µM ATPγS 
although somewhat less efficient than in the presence of 1 µM ATP (Fig. 9B). ATPγS can 
not be hydrolyzed by helicases, but kinases can use it as a substrate and form a 
thiophosphorylated product on the target protein (Stelzer et al., 1994; Tazi et al., 1993). 
Since ATPγS efficiently inhibits the complex opening by TFIIH (Holstege et al., 1997; 
Stelzer et al., 1994) this is an indication that CTD ser-5 hypophosphorylation occurs 
before complex opening. Upon incubation of PICs with 100 µM NTPs most CTD ser-5 
and ser-7 phosphorylation is seen on IIo-like low-mobility forms of RNAPII (CTD ser-5 
hyperphosphorylation). CTD ser-7 phosphorylation was also seen on the high-mobility 
form of RNAPII but appeared to be established predominantly after complex opening, 
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Figure 9: PIC dissociation and CTD ser-5/7 hyperphosphorylation were dependent on an ATPase 
and occur before formation of the first phosphodiester bond. A, Reaction scheme. B, PICs were formed 
in the presence of 500 µM H8 (lanes 2, 5, 8 and 11), 1 µM ATPγS (lanes 3, 6, 9, 12) or 1 µM ATP (lanes 4, 
7, 10, and 13) on a major-late promoter template. PICs were washed and either analyzed directly by 
immunoblot (lanes 2-5) or incubated in transcription buffer together with 100 µM NTPs (lanes 5-7), 100 
µM ATPγS (lanes 8-10) or 100 µM ATP (lanes 11-13). The DNA-templates were washed and analyzed by 
immunoblot. C, The supernatant of the second incubation step (TXN) was also analyzed by immunoblot to 
monitor the RNAPII fraction that dissociated from the template during the TXN reaction. In: 20% input. 
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as it can be inhibited efficiently by the helicase inhibitor ATPγS (Fig. 9B/C and 10A). 
CTD ser-5 and -7 hyperphosphorylation was significantly decreased if PICs were 
incubated in the presence 100 µM ATPγS, in particular if during PIC formation 
establishment of CTD ser-5/7 hypophosphorylation was suppressed by the kinase 
inhibitor H8. Incubation of PICs in the presence of 100 µM ATP during the second 
incubation step gave rise to more CTD ser-5/7 hyperphosphorylation, but the overall 
amount remained below that seen when incubated in the presence of 100 µM NTPs. 
Nuclear extracts contain a small amount of NTPs. Therefore the observed CTD 
phosphorylation during PIC formation could be established by transcription engaged 
polymerases during the PIC formation reaction. To rule out this possibility I prepared 
PICs in the presence of the transcription inhibitor α-amanitin. Again PICs were formed 
without any supplement or in the presence of 500 µM H8, 1 µM ATPγS or 1 µM ATP 
during PIC formation (Fig. 10A, lanes 1-4). The incubations with 1 µM ATP and 
1 µM ATPγS were also supplemented with 2 µg/ml α-amanitin (Fig. 10A, lanes 5 and 6). 
The presence of α-amanitin did not alter the initial results, leading to the conclusion that 
hypophosphorylation of the RNAPII Rpb1 high-mobility form at ser-5 and -7 did indeed 
occur independent of processive transcription. Next I determined whether CTD ser-5/7 
hyperphosphorylation is established in a transcription-dependent fashion. In vitro 
transcription reactions were carried out without and with 2 µg/ml α-amanitin in the 
reaction. After the reaction was completed, the whole reaction was loaded onto an SDS-
PAGE gel and analyzed by immunoblot. Treatment with α-amanitin, which was tested in 
parallel for its ability to inhibit in vitro transcription, did not alter the pattern of generated 
CTD ser-5/7 phosphorylation in the reaction (Fig. 10B, compare lanes 3 and 4), 
indicating that these marks were established independent of processive in vitro 
transcription. Under the given experimental conditions I could not detect a significant 
increase in CTD ser-2 phosphorylation upon transcription initiation (Fig. 10B). In 
summary this experiments extends the timepoint window during which CTD ser-5 
phosphorylation is established. Phosphorylation of the high- and low mobility-form of 
RNAPII at ser-5 and -7 was established in this in vitro assay independent of processive 
transcription before transcription initiation.  
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Figure 10: CTD ser-5  and -7 hypo and hyperphosphorylation are established before RNAPII 
commits to processive transcription. A, PICs were formed for 45 min in the presence of the indicated 
supplements and the activator GAL4-VP16 (lanes 1-6), washed extensively and analyzed by immunoblot. 
α-amanitin was used at a concentration of 2 µg/ml. B, Standard in vitro transcription reactions were carried 
out on major-late promoter templates as indicated in the presence of 1 µM ATP. At the end the reactions 
were stopped by addition of Laemmli buffer and loaded onto a SDS-PAGE gel for protein analysis. The 
inhibitory effect of a-amanitin under these experimental conditions was verified by a RNA analysis of the 
resulting transcripts (TXN). Reactions in lane 1 and 2 were loaded on the gel without NTP incubation, 
reactions in lanes 3 and 4 were incubated with NTPs as indicated in the panel on the left.  
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C.2.2. Establishment of CTD ser-5 hypophosphorylation follows a slow kinetic and 
correlates with the transcription potential of a PIC  
In figures 6B and 7 it is shown that CTD ser-5 hypophosphorylation was established in a 
Mediator-dependent fashion in vitro. Next I examined the kinetics with which this 
modification is established during PIC formation. I carried out an immobilized template 
assay on major-late promoter templates and allowed PIC formation in the presence of 1 
µM ATP for  5 to 45 minutes. After PIC formation PICs were washed and either 
analyzed by immunoblot or forwarded to an in vitro transcription reaction. Recruitment 
of TFIIB and NC2 and establishment of CTD ser-5 hypophosphorylation followed a slow 
kinetic as compared to that of recruitment of TFIID (TBP, TAF5) and Mediator 
(Fig. 11B). Furthermore the amount of CTD ser-5 hypophosphorylation correlated to the 
amount of transcript produced by the respective PIC (Fig. 11).  Thus CTD ser-5 
hypophosphorylation may serve as a mark for an active, transcription competent PIC. 
 
 
Figure 11: TFIIB recruitment and formation of an active PIC is slow as compared to the recruitment 
of activator, TFIID and Mediator. CTD ser-5 hypophosphorylation correlates to transcription 
potential of the respective PIC. A, Schematic representation of the reaction. B,  PICs were formed for the 
indicated periods of time on a major-late promoter templates in the presence of 1 µM ATP, washed and 
analyzed in part by immunoblot and in part probed in an in vitro transcription reaction.  In: 20% input. 
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C.2.2.1. CTD ser-5 hypo phosphorylation is dependent on TFIIB 
In figure 6 I had shown that CTD ser-5 hypophosphorylation was dependent on Mediator 
even if TFIIB was recruited to the promoter template. Next I wanted to determine 
whether CTD ser-5 hypophosphorylation is dependent on TFIIB. I immunodepleted a 
Jurkat nuclear extract for TFIIB and tested in an immobilized template assay its capacity 
to establish CTD ser-5 hypophosphorylation. After TFIIB depletion a significant 
reduction in CTD ser-5 hypophosphorylation was observed during PIC formation (Fig 
12A, compare lanes 3 and 4 to 5 and 6). The absence of TFIIB during PIC formation led 
to decreased TFIIH recruitment (CDK7 and p62) in the VP16-activated situation. Overall 
NC2 recruitment was not affected by TFIIB depletion. Mediator was not co-depleted 
with TFIIB (Fig. 12A, compare lanes 1 and 2) and Mediator recruitment to the promoter 
template was not affected in the absence of TFIIB (Fig. 12A, compare lanes 3 and 4 to 5 
and 6).  
 
 
 
Figure 12: CTD ser-5 hypophosphorylation is dependent on TFIIB. A, Immobilized template assay on 
MRG5 promoter templates were carried out under basal conditions or in the presence of GAL4-VP16 with 
either mock-treated or TFIIB-depleted nuclear extracts (lanes 3-6). TFIIB-depletion did not co-deplete 
Mediator (compare lanes 1 and 2). In: 20% input. B, PICs were prepared on major-late promoter templates 
in the presence of 0.1 and 1 µM B2-RNA (lanes 2 and 3). PICs were washed and analyzed either by 
immunoblot or probed for their transcription potential (TXN).  
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Of note RNAPII associated mostly independent of TFIIB with the promoter template, 
both in the absence and presence of VP16. In addition I used the small non-coding B2-
RNA, which inhibits in vitro transcription in a transcription system composed of 
recombinantly expressed and purified factors prior to complex opening in the context of a 
PIC (Espinoza et al., 2004). In the nuclear extract in vitro transcription system the B2-
RNA present in a PIC formation reaction supplemented with 1 µM ATP interfered with 
TFIIB recruitment, CDK7 recruitment and establishment of the CTD ser-5 and -7 
hypophosphorylation states (Fig. 12B, compare lanes 1 to 2 and 3). Presence of the B2-
RNA during PIC formation also diminished the in vitro transcription potential of the 
formed PIC. Apparently, the B2-RNA limits TFIIB and TFIIH recruitment to the PIC but 
has no influence on TBP or Mediator recruitment. The B2-RNA used in this experiments 
was a kind gift of Florian Brueckner of the Cramer laboratory.  These experiments 
provide further evidence that the CTD ser-5 hypophosphorylation state correlates to an 
active, transcription competent state of the PIC.  
C.2.2.2. CTD ser-5 hypophosphorylation is dependent on TBP and a TATA box 
Next I asked whether establishment of CTD ser-5 hypophosphorylation is dependent on a 
TATA box in an immobilized promoter template assay. PICs were formed on MRG5 
promoter templates comprising five upstream GAL4 binding sites and a portion of the 
luciferase gene downstream of the core promoter. PICs were formed either on templates 
containing a wild type TATA box or on templates containing a mutated TATA box, 
which no longer supports basal as well as activated in vitro transcription (Fig. 13). PICs 
were formed under basal conditions or in the presence of the activator GAL4-VP16. CTD 
ser-5 hypophosphorylation was significantly reduced if a mutated TATA box was present 
in the core promoter. Again CTD ser-5 hypophosphorylation was seen to correlate with 
the in vitro transcription potential of the respective PICs. Also recruitment of RNAPII, 
TFIIB and TFIIH (p62, CDK7) correlated to the amount of transcript produced by the 
respective PIC. Although the functional relevance of the TATA-box mutation became 
evident in terms of in vitro transcription no influence on TBP recruitment was observed. 
However, the promoter template contains several DNA sequence elements to which TBP 
can bind unspecifically. Immunodepletion of TFIID (TBP together with TBP-associated 
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Figure 13: CTD ser-5 hypophosphorylation is dependent on a TATA box. PICs were formed on 
immobilized MRG5-promoter templates with a wildtype (TATA WT, lanes 4 and 5) or mutated TATA box 
(TATA MT, lanes 2 and 3) and after washing analyzed by immunoblot or for their transcription potential 
(TXN). Reactions were formed under basal conditions (lanes 2 and 4) or in the presence of the activator 
GAL4-VP16 (lanes 3 and 5). A reaction with column material without an attached promoter template 
served as specificity control for the used antibodies (beads w/o DNA, lane 6).  
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factors (TAFs)) did not lead to an establishment of CTD ser-5 hypophosphorylation in 
PICs formed under basal conditions (Fig. 20, compare lanes 3 and 4). A PIC formation 
assay performed with a TFIID-depleted nuclear extract into which recombinantly 
expressed TBP was added back restored establishment of CTD ser-5 
hypophosphorylation during PIC formation (Fig. 20, compare lanes 1 and 3), indicating 
that TBP but not TAFs are essential for establishment of CTD ser-5 
hypophosphorylation.  
C.2.2.3. CTD ser-5 hypophosphorylation is established close to the transcription 
start site 
In order to figure out in which region of the promoter DNA template CTD ser-5 
hypophosphorylation was established I performed a chromatin-immunoprecipitation 
restriction digest immunoprecipitation (CRIP) assay (Schluesche et al., 2007), which was 
designed as depicted in Fig. 14A: A PIC was formed on radiolabelled MRG5-promoter 
DNA templates containing five activator binding sites (GAL sites) upstream of a 
modified ML core promoter.   PICs were formed with nuclear extracts treated with an 
isotype antibody or immunodepleted for MED15 (removes all Mediator populations), 
MED25 (removes the VP16 interacting Mediator) or for NC2. Formed PICs were 
crosslinked with formaldehyde and the templates were then subjected to a restriction 
digest with restriction enzymes as indicated in figure 14B. Afterwards an 
immunoprecipitation was carried out with a CTD ser-5 phosphate specific monoclonal 
antibody. After protein removal with proteinase K DNA fragments that co-
immunoprecipitated with the crosslinked proteins were analyzed on a native PAGE gel 
by autoradiography. As shown in figure 14C the CTD ser-5 phosphorylation is found 
primarily close to the transcription start site whereas flanking DNA fragments have a 
lower ratio. Restriction digests with different enzymes confirmed this observation (Fig. 
14D). Of note removal of NC2 increased the amount of CTD ser-5 phosphorylation. This 
confirmed the result of a similar immobilized template assay experiment (Fig. 8). This 
finding further supports the notion that CTD ser-5 hypophosphorylation is established 
only on RNAPII that is associated with an transcription competent PIC. 
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Figure 14: CTD ser-5 phosphorylation is established close to the transcription start site during PIC 
formation. A, Scheme of a CRIP (crosslink-restriction-immunoprecipitation) assay. B, Diagram indicating 
the position of the restriction sites on a MRG5-promoter template. C, PIC formation reactions were carried 
out as depicted in A in the presence of 1 µM ATP. Jurkat nuclear extracts were either mock-treated (ΔIso) 
or immunodepleted for all Mediator populations (ΔMED15), for the MED25 Mediator (ΔMED25) or for 
NC2α (ΔNC2). D, PICs were formed with Jurkat nuclear extract in the presence of GAL4-VP16 and 1 µM 
ATP and analyzed in CRIP assays with the indicated restriction enzymes. A Mediator-dependent CTD-Ser5 
phosphorylation was established during PIC formation predominantly on the DNA fragments containing 
the transcription start site. 
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C.2.2.4. CDK7 established CTD ser-5 hypophosphorylation but did not influence 
establishment of CTD ser-5 hyperphosphorylation in vitro  
CTD ser-5 phosphorylation has been attributed to the TFIIH associated kinase CDK7. 
Here I wished to analyze the contribution of TFIIH/CDK7 to CTD ser-5 hypo and 
hyperphosphorylation respectively. I prepared PICs with Jurkat nuclear extracts 
immunodepleted for CDK7, CDK8 or CDK9 in the presence of 1 µM ATP and found 
that depletion of CDK7, but not depletion of CDK8 or CDK9, resulted in a complete loss 
of CTD ser-5 hypophosphorylation (Fig. 15B, compare lane 6 to lanes 5, 7 and 8). The 
reduction in transcription observed could relate to either diminished CTD ser-5 
hypophosphorylation levels or to a co-depletion of TFIIH with CDK7. Remarkably, CTD 
ser-5 hyperphosphorylation was, if at all, marginally affected by the absence of CDK7 
(Figure 15B, compare lanes 9 and 10). This holds true for RNAPII bound to the template, 
as well as for the population that  dissociated from the promoter during the 20 minutes of 
transcription incubation (Fig. 15C, compare lanes 2 and 3). Note that levels of CTD ser-2 
phosphorylation were below detection level. CTD ser-2 phosphorylation could be 
detected in the RNAPII population dissociating from the promoter template during 
transcription incubation. However, this might represents a background, as the input 
sample gives rise to an equal amount of CTD ser-2 phosphorylation signal (Figure 15C, 
compare Input/Experiment ratio for CTD ser-2, 5 and 7P). If CDK8 was immunodepleted 
a reduction in CTD ser-5 hyperphosphorylation was observed (Fig. 15B, compare lanes 9 
and 11). As the CDK8 immunodepletion had removed most CDK8 from the nuclear 
extract this may mean that another kinase than CDK7 and CDK8 is involved in 
establishment of CTD ser-5 hyperphosphorylation. In summary CTD ser-5 
hypophosphorylation was established dependent on the TFIIH-associated kinase CDK7. 
CTD ser-5 hyperphosphorylation was established at least in part dependent on CDK8.  
 
 
 
 
 
 
Results 
 85 
 
 
 
 
 
 
 
Figure 15: CTD ser-5 hypophosphorylation, but not CTD ser-5 and -7 hyperphosphorylation, is 
dependent on CDK7. A, Reaction scheme. B, Immobilized template assays were carried out on MRG5- 
promoter templates with nuclear extracts that were mock-treated (ΔIso) or immunodepleted for CDK7 
(ΔCDK7), CDK8 (ΔCDK8) or CDK9 (ΔCDK9) respectively. PICs were after extensive washing either 
analyzed directly by immunoblot (PIC) or were subjected to a second incubation under in vitro 
transcription conditions and then analyzed (PIC+TXN).  In vitro transcription reactions (TXN) were carried 
out in parallel under the same conditions as in the immobilized template assays. C, RNAPII that either ran 
off or dissociated from the promoter template during transcription was analyzed by immunoblot.  
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C.3. Biochemical characterization of RNAP II CTD ser-7 phosphorylation.  
The Eick laboratory discovered that ser-7 of a consensus repeat of the CTD of RNAPII is 
a phosphorylation site in vivo (Chapman et al., 2007). Furthermore it could be established 
that CTD ser-7 phosphorylation is observed at messenger RNA (mRNA) coding genes 
and required for the recruitment of the integrator complex to genes coding for the U2 
snRNA (Chapman et al., 2007; Egloff et al., 2007). Starting from there I asked whether 
CTD ser-7 phosphorylation is generated in an inducible model gene system by the tet-
VP16 activator in vivo and whether CTD ser-7 phosphorylation can be recapitulated in an 
immobilized promoter template assay in vitro.   
C.3.1. CTD ser-7 phosphorylation is detected in vivo and in vitro upon transcription 
initiation 
To characterize CTD ser-7 phosphorylation in vivo, I used the previously described EBV-
based CMV reporter gene system (Uhlmann et al., 2007). I monitored CTD ser-5 and -7 
phosphorylation before (transcription off) and after induction of the reportergene with 
doxycycline by chromatin immunoprecipitation (ChIP). In order to be able to normalize 
the amount of CTD modification to the amount of RNAPII, I also monitored the amount 
of RNAPII associated with the promoter, the start of the coding region and the control 
region oriP. The epitope recognized by the RNAPII N20 antibody is located outside the 
CTD of RNAPII. Induction of transcription in the reporter gene system correlated with 
increased recruitment of RNAPII and an increase in CTD ser-5 and 7 phosphorylation of 
the RNAPII CTD. Note that RNAPII was detected in the non-transcribed oriP region 
above background level (Fig 16, isotype IP) but this RNAPII population was not 
phosphorylated at CTD ser-5 or -7 upon addition of doxycycline. This in vivo experiment 
confirmed the results of the in vitro experiments presented in the previous chapter. 
Establishment of CTD ser-7 phosphorylation correlates to transcription initiation in vitro 
and in vivo.  
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Figure 16: CTD ser-5 and -7 phosphorylation does occur upon transcription initiation in vivo. 
Chromatin immunoprecipitation experiments were carried out with an isotype antibody (black bars) or 
antibodies specific for RNAPII (white bars), phosphorylated CTD ser-5 (blue bars) or CTD ser-7 (orange 
bars). Transcription was induced in the tet-VP16 system in CMV-vector transfected HeLa cells by addition 
of doxycycline to the cells as indicated. The oriP region served as a negative control for the ChIP 
experiment. The promoter (pro)-PCR amplicon included the TATA box, the luc amplicon was located 
immediately downstream of the transcription start site. The distance between TATA box and transcription 
start site in this system is 166 nucleotides.   
C.3.2. Establishment of CTD ser-7 phosphorylation can be recapitulated in vitro and 
the CTD ser-7 kinase is part of an isolated PIC 
As already discussed in context of CTD ser-5 phosphorylation in the previous section, 
CTD ser-7 phosphorylation was observed during PIC formation and transcription 
initiation. I observed CTD ser-7 hypophosphorylation on the high-mobility form of 
RNAPII Rpb1, which was established during PIC formation (Fig. 9B and 10A). The 
mechanisms responsible for establishment of CTD ser-5 and ser-7 hypophosphorylation 
appear to be distinct, since ser-5 hypophosphorylation was observed already before 
complex opening, whereas ser-7 hypophosphorylation appeared to be established after 
complex opening (Fig. 10A). Establishment of CTD ser-7 hypophosphorylation could be  
suppressed by immunodepletion of CDK7 (Fig. 15 and data not shown).  CTD ser-5 and 
ser-7 hyperphosphorylation were seen at the same stage of transcription initiation after 
incubation of a preformed PIC in the presence of 100 µM ATP or 100 µM NTP. 
Generation of CTD ser-5 and ser-7 hyperphosphorylation was insensitive to the 
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transcription inhibitor α-amanitin, indicating that this modification occurred before 
formation of the first phosphodiester bond (Fig 10B). Furthermore CTD ser-5/7 
hyperphosphorylation could be initiated in the presence of 100 µM ATP but not in the 
presence of 100 µM ATPγS, indicating that in addition to a kinase a ATPγS sensitive 
enzyme such as a helicase might be involved in this process (Eckstein, 1985). 
C.3.3. CTD ser-7 phosphorylation is dependent on Mediator 
In section C.2. I showed that CTD ser-5 hypophosphorylation is dependent on Mediator 
and CDK7. Here I asked whether Mediator is required for the establishment of 
CTD ser-5 and -7 hyperphosphorylation. Given the above results that CTD ser-5 and -7 
hyperphosphorylation did not correlate to processive transcription (Fig. 9B and 10B) I 
also included the negative cofactor 2 (NC2) into the analysis. I made use of the 
immobilized template assays in combination with Jurkat nuclear extracts that were either 
mock-treated with an isotype antibody (ΔIso) or immunodepleted for Mediator (ΔMed), 
NC2 (ΔNC2) or the combination of both factors (ΔMED/ΔNC2). PICs were formed with 
the depleted extracts, washed extensively and then either analyzed directly by 
immunoblot (Fig. 17B, lanes 5 to 8) or subjected to a second incubation step under in 
vitro transcription conditions. CTD modifications established during the transcription 
incubation step were analyzed by immunoblot in two fractions: The first contained 
RNAPII that had not dissociated from the promoter template during the transcription 
incubation (Fig. 17B, lanes 9-12), the second contained RNAPII that had dissociated 
from the promoter template during the transcription reaction (Fig. 17C, lanes 2-5). 
Importantly this type of analysis can not discriminate between RNAPII that was engaged 
in productive transcription and RNAPII that dissociated in a non-productive fashion from 
the promoter template. Under the used assay conditions RNAPII was associated with the 
promoter template even in the absence of Mediator. However the amount of RNAPII 
recruited in the absence of Mediator was lower than in the presence of Mediator. In the 
course of the in vitro transcription reaction (second incubation step) PIC associated 
RNAPII was partially hyperphosphorylated at CTD ser-5 and -7. RNAPII did partially 
dissociate from the promoter template during the transcription reaction and also the 
dissociated RNAPII population was found to be hyperphosphorylated at 
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CTD ser-5 and -7 (Fig. 17B/C). This experiment further demonstrated that NC2 had no 
influence on establishment of CTD ser-5/7 hyperphosphorylation. It indicates however 
that Mediator might be required for CTD ser-5/7 hyperphosphorylation. 
 
 
 
 
Figure 17: CTD ser-5 and -7 hyperphosphorylation is Mediator dependent. A, Reaction scheme B, 
Immobilized template assays were carried out on MRG5 promoter templates with mock-treated (ΔIso), 
Mediator depleted (ΔMED), NC2 depleted (ΔNC2) or Mediator/NC2 depleted (ΔMEDΔNC2) Jurkat 
nuclear extract. PICs were extensively washed and either analyzed directly or subjected to a second 
incubation under in vitro transcription conditions in the presence of 100 µM NTPs. CTD phosphorylation 
was analyzed on the template bound RNAPII population C, as well as on the RNAPII population that 
dissociated from the template during the second incubation step. 
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C.3.4. Mediator is required for CTD ser-5 and -7 hyperphosphorylation 
In order to further investigate whether Mediator is required for CTD ser-5/7 
hyperphosphorylation I performed in addition to the assay presented in the previous 
chapter an alternative assay. I assembled standard in vitro transcription reactions using 
either isotype-depleted (ΔIso) or Mediator-depleted Jurkat nuclear extract (ΔMED) and 
performed standard in vitro transcription reactions. But instead of analyzing the RNA at 
the end of the reaction I loaded the whole reaction on a SDS-PAGE and analyzed it by 
immunoblot. As a reference I also loaded transcription reactions on the SDS-PAGE that 
had not been incubated with NTPs (To situation). Thus I was able to determine the 
amount of CTD phosphorylation that was established during the transcription reaction by 
comparing the two situations (To vs. NTP incubated). This allowed me to detect the 
differences in the CTD phosphorylation status between a mock-depleted nuclear extract 
(ΔIso) and an Mediator-depleted (ΔMED) nuclear extract. In lanes 1 and 2 of figure 18B 
reaction mixtures prepared with mock- or Mediator-depleted nuclear extract were loaded 
onto the SDS-PAGE gel without any incubation, in order to monitor the amount of CTD 
ser-5/7 phosphorylation present at the beginning of the reaction (To). In the presence of a 
promoter template and incubation with 100 µM NTPs establishment of CTD ser-5/7 
hyperphosphorylation was diminished in the absence of Mediator (Fig. 18B, lanes 5 and 
6). Although a 10 fold excess (w/w) of poly(dG:dC) competitor DNA over promoter 
template DNA was present in the reaction CTD ser-5/7 hyperphosphorylation was 
maximal in the presence of a promoter DNA-template. Incubation with 100 µM ATP 
alone allowed for CTD ser-5/7 hyperphosphorylation (Fig. 18B, lanes 9 and 10) whereas 
incubation with 100 µM ATPγS did not led to CTD ser-5/7 hyperphosphorylation (Fig. 
18B, lanes 11 and 12). ATPγS is a nucleotide analogue that can be used by kinases, but 
not ATPases such as helicases (Stelzer et al., 1994; Tazi et al., 1993). Therefore a 
helicase might be involved in the establishment of CTD ser-5/7 hyperphosphorylation. 
The experiment depicted in figure 9 points in the same direction. In summary 
establishment of CTD ser-5 and -7 hyperphosphorylation was dependent on Mediator, 
DNA and an ATPase in this assay. Next I wanted to investigate whether a particular 
Mediator species is required for establishment of CTD ser-5 and -7 
hyperphosphorylation. To do so, I used mock-treated and Mediator depleted nuclear  
Results 
 91 
 
 
Figure 18: CTD ser-5 and -7 hyperphosphorylation are Mediator and DNA dependent. A, Standard in 
vitro transcription reactions were carried out as depicted in the scheme, but instead of analyzing the RNA, 
the complete reactions were analyzed by SDS-PAGE and immunoblot. B, Reactions were carried out either 
with mock-treated (ΔIso) or Mediator depleted (ΔMED) nuclear extract. Some reactions were carried out in 
the absence of promoter-DNA, in some reactions poly(dG:dC) DNA was omitted, which was added in a 10 
fold excess over the promoter DNA fragment. The second transcription incubations were carried out in the 
presence of 100 µM NTPs, 100 µM ATP or 100 µM ATPγS as indicated. In lanes 1 and 2 reactions were 
loaded without incubation at 30°C and NTP addition (To). B, SDS-PAGE in vitro transcription assays were 
carried out as depicted in A. Mediator-depleted (ΔMED) Jurkat nuclear extract was supplemented with 
immunoprecipitations carried out with isotype-, MED15-, MED25-, CDK8- and MED1-specific antibodies 
(lanes 4-8 respectively). The MED15 lanes serves as an indicator for the amount of Mediator complex 
added back to the respective reactions.  
Results 
 92 
 
extract in a SDS-PAGE in vitro transcription assay. Reactions containing Mediator-
depleted nuclear extracts were supplemented with various Mediator species which were 
immunoprecipitated from nuclear extracts with the respective antibodies (Fig. 18C, lanes 
4 to 8). Complementation of the reaction with isotype IP beads (Fig. 18C, lane 4) led to 
establishment of significant less CTD ser-7 phosphorylation than in the reference reaction 
(Fig. 18C, lane 3). Complementation of the Mediator-depleted nuclear extract with 
immunoprecipitated MED15-, MED25-, CDK8 or MED1- Mediator complexes restored 
the amount of CTD ser-5 and -7 hyperphosphorylation established during the in vitro 
transcription reaction.  Thus all tested Mediator subpopulations had the potential to 
facilitate CTD ser-5 and -7 hyperphosphorylation in vitro.  
C.3.5. Mediator preparations are associated with a kinase activity towards RNAPII 
CTD ser-5 but not with a kinase activity towards CTD ser-7 
Since  I found CTD ser-7 phosphorylation to be dependent on Mediator I tested whether 
the CTD ser-7 kinase is associated with Mediator. I performed in vitro kinase assays 
using GST-CTD as a substrate. For the kinase assay I used either immunoprecipitated  
Mediator (immunoprecipitated with the monoclonal MED15 antibody 6C9) or Mediator 
that associated with GST-VP16 or GST-H2 columns in pulldown experiments (Fig. 19B 
and 19C respectively). In vitro kinase assay reactions with immunoprecipitated Mediator 
were assembled and either analyzed without any incubation (Fig. 19B, lane 1, To) or 
incubated according to the scheme indicated in Fig. 19A. Presence of 
immunoprecipitated Mediator in the reaction led to an increase in CTD ser-5 
phosphorylation on RNAPII (which was co-precipitated with the Mediator complex) as 
well as on the GST-CTD substrate (Fig 19B, compare lanes 1 and 2). No increase in the 
amount of CTD ser-7 phosphorylation was detected. In a second experiment Mediator 
was enriched by GST-VP16 or GST-H2 pulldown experiments from Jurkat nuclear 
extracts. As control served a pulldown with a GST-H2 mutant (GST-H2mt) column 
(Ikeda et al., 2002). In vitro kinase assay reactions were assembled and either analyzed 
without any incubation (Fig. 19C, lanes 1 to 3, To) or incubated with 100 µM NTPs 
under in vitro transcription conditions as indicated in the scheme in Fig. 19A. The GST-
VP16 pulldown contains kinase activities that led to establishment of CTD ser-7 
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phosphorylation on the co-precipitated RNAPII as well as to slight ser-7 phosphorylation 
of GST-CTD. CTD ser-5 phosphorylation was observed on RNAPII as well as on GST-
CTD for both the GST-VP16 and the GST-H2 pulldown, but importantly, not with the 
control GST-H2mt pulldown. In summary, a CTD ser-7 kinase activity was precipitated 
with a GST-VP16 pulldown, but no detectable CTD ser-7 kinase activity was co-
precipitated with MED15 or GST-H2.  Consistent with this finding is that 
immunodepletion of the Mediator-associated kinase CDK8 abolished CTD ser-5 
hyperphosphorylation in part (Fig. 15B). 
 
 
Figure 19: Mediator is associated with CTD ser-5 but not ser-7 kinase activity. A, Schematic 
representation of this in vitro kinase assay carried out under in vitro transcription conditions. B, In vitro 
kinase assay reaction with GST-CTD as a substrate supplemented with immunoprecipitated Mediator. C, In 
vitro kinase assay with GST-CTD as substrate supplemented with a GST-VP16, GST-H2 or a GST-H2mt 
pulldown. To: Immunoblot of the reaction without incubation, TXN: Immunoblot of the reaction after 
incubation as indicated in A.  
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C.3.6. CTD ser-7 kinase activity is independent on TBP and a TATA box 
Next I determined whether the general transcription factor TFIID has any influence on 
the CTD ser-5/7 hyperphosphorylation activity. To do so I used immobilized template 
assays on major-late promoter templates in combination with either mock-depleted (ΔIso) 
or TBP-depleted (ΔTBP) Jurkat nuclear extracts. In addition to TBP the TBP-associated 
factors (TAFs) were removed from TBP-depleted nuclear extracts (Fig 20B, compare 
lanes 1 and 2). In order to analyze whether CTD ser-7 hyperphosphorylation is dependent  
 
 
Figure 20: CTD ser-5 hypophosphorylation was dependent on TBP but not on TAFs; 
CTD ser-5 and -7 hyperphosphorylation was independent of TBP and TAFs. A, Reaction scheme. B, 
Immobilized template assays were carried out on major-late promoter templates in combination with mock-
treated (ΔIso) or TBP-depleted (ΔTBP) nuclear extract. Recombinant human TBP (rTBP) was added to 
TBP-depleted nuclear extract as indicated. The amount of added rTBP was chosen such that the amount of 
endogenous TBP present in the initial extract was resembled. The activator GAL4-VP16 was present in the 
indicated reactions all other reactions were performed under basal conditions. Input: 20% input was loaded   
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on TBP or TFIID (TBP plus TAFs) I reconstituted some of the TBP/TAF depleted 
nuclear extract with recombinant human TBP (rTBP). The amount of added TBP equaled 
the amounts of TBP that were present in the nuclear extract before TBP/TAF depletion. 
Although the TBP/TAF-depletion was not complete few TBP was recruited to PICs 
formed with TBP/TAF-depleted extract (Fig. 20B, lane 4). In vitro transcription 
experiments (TXN) confirmed that most transcription relevant TBP was removed from 
the nuclear extract (Fig. 20B, compare transcription (TXN) in lanes 6 and 9 to that 
observed in lanes 7 and 10). In vitro transcription could be reconstituted by adding 
recombinant human TBP to TBP/TAF-depleted nuclear extracts (Fig. 20B, lanes 8 and 
11). This experiment showed in addition that CTD ser-5 hypophosphorylation was 
dependent on TBP but not on TAFs (Fig. 20B, lanes 3-5). This result is in agreement with 
the previous finding that a mutated TATA-box did abolish the appearance of CTD ser-5 
hypophosphorylation during PIC formation (Fig. 13). Establishment of CTD ser-5 and -7 
hyperphosphorylation on preformed PICs during the transcription incubation with 
100 µM NTPs was not affected by the absence of TBP and TAFs (Fig. 20B, lanes 6-11). 
Again, establishment of CTD ser-5 and -7 hyperphosphorylation occurred independent of 
productive transcription. Interestingly, Mediator, TFIIB and CDK7 were recruited to the 
promoter template in the basal situation even in the absence of TBP and TAFs. However 
this was not sufficient of initiate transcription (Fig. 20B, lanes 3-5). In summary I found 
establishment of CTD ser-5 hypophosphorylation during basal PIC formation to be 
critically dependent on TBP but independent of TAF presence. Furthermore PIC 
associated CTD ser-5 and -7 hypophosphorylation correlated with the transcription 
potential of the respective PIC. In contrast CTD ser-5 and ser-7 hyperphosphorylation 
were established independent of TBP/TAFs and productive transcription in this assay.  
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C.3.7. PIC analysis by mass spectrometry 
As described earlier, I could show that the CTD ser-7 kinase activity is part of a purified 
PIC assembled on an immobilized promoter template (Fig. 9B). Given that the CTD ser-7 
kinase activity appeared to be dependent on a ATPase (Fig. 9B) and was not associated in 
its active form with Mediator complexes (Fig. 19) I reasoned that the ser-7 kinase activity 
might be active only in the context of a larger protein network, e.g. a PIC. During 
classical column chromatography the CTD ser-7 kinase complex might disintegrate and 
therefore loose its activity.  The laboratory of Gerhard Mittler at the Max-Planck Institute 
for Immunobiology in Freiburg I performed for me a mass spectrometric analysis of an in 
vitro formed PIC. I screened the resulting protein list manually for kinases and could 
identify 13 kinases. These kinases were grouped into three categories: (i) Kinases which 
had been reported in the literature to posses the ability to phosphorylate RNAPII or GST-
CTD as a substrate, (ii) kinases which were functionally linked to the transcription 
processes and (iii) kinases which did not fit into one of the other two groups. In this thesis 
the seven PIC associated kinases identified in the first group were tested for their ability 
to contribute to CTD hyperphosphorylation at ser-5 and -7. The first group comprised the 
kinases DNA-PK, CDK1, CDK11, CKI, CKII, CDK7 and CDK9. Investigation of the 
kinases identified in the other two groups takes place in an ongoing project.  
C.3.8. CDK7, CDK8 and CDK9 are not CTD Ser-7 kinases 
In order to test the transcription related kinases CDK7, 8 and 9 for their contribution to 
CTD ser-5/7 hyperphosphorylation during an in vitro transcription reaction I used the 
immobilized template assay in combination with immunodepleted nuclear extracts. The 
immunoblot confirmed that all kinases were depleted to a significant degree (Fig 15B, 
lanes 1-4). Analysis of the PICs in the presence of 1 µM ATP revealed that CDK7 was 
responsible for the CTD ser-5 and -7 hypophosphorylation during PIC formation (Fig. 
15B, lanes 5 to 8 and data not shown). In a subsequent step washed PICs were incubated 
for 20 min under in vitro transcription conditions in the presence of 100 µM NTPs. At the 
end of the transcription incubation RNAPII was analyzed in two fractions. First, RNAPII 
that remained associated to the promoter template was analyzed (Fig. 15B, lanes 9-12) 
and second, RNAPII that had dissociated during the second incubation was analyzed by 
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immunoblot (Fig. 15C, lanes 2-5). In the absence of CDK7, I observed a significant 
reduction in CTD ser-5 hypophosphorylation during PIC formation, but moderate if any 
reduction in CTD ser-5 and -7 hyperphosphorylation. Absence of CDK8 led to a 
reproducible decrease in CTD ser-5, but not ser-7 hyperphosphorylation established 
during transcription initiation. The data do not provide evidence for an involvement of 
CDK7, CDK8 or CDK9 in CTD ser-7 hyperphosphorylation.  
C.3.9. Evidence that DNA-PK, CKI, and CKII are not CTD ser-7 kinases in a PIC 
To determine the contribution of DNA-protein kinase (DNA-PK), casein kinase (CKI) 
and casein kinase 2 (CKII) to CTD ser-5/7 hyperphosphorylation I made use of the 
DNA-PK specific inhibitor wortmannin, the CKI specific inhibitor D4476 and the CKII 
specific inhibitor TBB (4,5,6,7-tetrabromobenzotriazole). I prepared PICs with Jurkat 
nuclear extracts in the presence of GAL4-VP16 and 1 µM ATP on immobilized major-
late promoter templates, washed the PICs and either analyzed them directly by 
immunoblot (Fig. 21 lane 1) or subjected them to a second incubation in in vitro 
transcription buffer supplemented with 100 µM NTPs and the indicated inhibitors (Fig. 
21, lanes 2-5 and 6-16). Roscovitine, an inhibitor of CDK1, CDK2 and CDK5 led to a 
slight reduction of CTD ser-7 hyperphosphorylation upon transcription initiation (Fig. 21, 
compare lanes 6 to 15 and 16). The DNA-PK inhibitor wortmannin was able to suppress 
the appearance of post-translationally modified TBP species that migrated with an up to 
10 kDa higher molecular weight than unmodified TBP (Fig. 21, compare lanes 6 to 11 
and 12). This experiment suggests that CTD ser-5 and -7 hyperphosphorylation is not 
significantly mediated by CKI, CKII, DNA-PK and CDK9 (CDK9 is inhibited by DRB; 
lanes 13 and 14). However the predominantly CDK1, CDK2 and CDK5-specific inhibitor 
roscovitine led to a decrease in CTD ser-7 hyperphosphorylation.  
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Figure 21: Effects of the kinase inhibitors D4476, TBB, wortmannin, DRB and roscovitine on 
CTD ser-5 and -7 hyperphosphorylation. A, Reaction scheme. B, PICs were formed on major-late 
promoter templates in the presence of 1 µM ATP, washed extensively and then subjected to a second 
incubation step in transcription buffer containing no inhibitors (lanes 2 and 6) or the kinase inhibitors 
D4476 (0.5, 5, 50 µM, lanes 3-5); TBB (1, 10 and 100 µM, lanes 7-9); wortmannin (0.1, 1 and 10 µM, 
lanes 10-12); DRB (50, 100 µM, lanes 13 and 14) or roscovitine (10, 100 µM, lanes 15 and 16). PIC: 
Immunoblotanalysis of a PIC that had not been subjected to the second incubation step. The TBP post-
translational modifications led to an apparent shift of about 10 kDa in molecular weight in SDS-PAGE 
gels. 
 
C.3.10. CDK1 phosphorylates GST-CTD substrates at ser-5 and -7, but is 
dispensable for CTD ser-5 and -7 hyperphosphorylation in the PIC context 
CDK1 as well as a CDK1-related kinase, CDK11 were identified in the mass 
spectrometric PIC analysis. In addition roscovitine showed in the above and several 
additional experiments the propensity to inhibit CTD ser-7 hyperphosphorylation. In 
order to determine whether CDK1 could be the PIC-associated CTD ser-7 kinase I 
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performed in vitro kinase assays with immunoprecipitated CDK1 and the CDK1-related 
kinase CDK11. A GST-CTD fusion protein was offered as substrate. CDK1 was able to 
phosphorylate GST-CTD at ser-5 and -7 whereas CDK11 showed no activity toward 
GST-CTD ser-5 or -7 (Fig. 22A). Note that the monoclonal CTD ser-7 antibody did 
recognize plain recombinant GST-CTD. Extensive λ-phosphatase treatment did not 
abolish this recognition. Jurkat nuclear extract was used as a positive control in this assay 
(Fig 22A, lane 5). A CDK1 immunoprecipitation led to a modest increase in GST-CTD 
ser-7 phosphorylation and a robust phosphorylation at GST-CTD ser-5 (Fig. 22A, lane 2). 
CDK11 did not facilitate GST-CTD ser-5 or -7 phosphorylation (Fig. 22A, lane 3). Also 
the combination of both kinases in one kinase assay reaction did not boost 
phosphorylation activity towards CTD ser-5 and -7 (Fig. 22A, lane 4). Thus CDK1,  a 
kinase that is recruited to an in vitro formed PIC in a Mediator-independent fashion (Fig. 
13) showed the tendency to phosphorylate GST-CTD at ser-5 and -7. In parallel to the 
PIC mass spectrometric analysis I tried to purify the CTD ser-7 kinase by classical 
column chromatography. On a DE52 column the CTD ser-7 phosphorylation activity 
towards GST-CTD could be spitted into two activities as determined by an in vitro kinase 
assay with the respective column fractions on GST-CTD as substrate (Fig. 22B). One 
fraction contained an activity towards GST-CTD ser-5 and -7 and a second peak 
contained predominant a kinase activity towards GST-CTD ser-7 (Fig. 22B, fractions A 
and D/E respectively). While characterizing CTD ser-5/7 hyperphosphorylation I never 
observed one hyperphosphorylated state in the absence of the other. Therefore I focused 
on the activity in fraction A. Immunoblot analysis revealed that CDK1 is present in 
fraction A (Fig. 22B, lane 4). In order to further investigate CDK1 as potential 
CTD ser-5 and -7 hyperphosphorylation kinase in the PIC context I immunodepleted the 
kinase from Jurkat nuclear extract and performed immobilized template assays on major-
late promoter templates (Fig. 22C). Immunodepletion of CDK1 abolished CTD ser-5 and 
-7 phosphorylation as well as the in vitro transcription potential of the PIC (Fig. 22C, 
compare lanes 3 and 4). However, in the course of the study it became evident that most 
of the Mediator complex was co-depleted by the polyclonal CDK1 antibody which was 
used for the CDK1 depletion (compare MED15 and MED25 recruitment to the PIC in 
lane 3  
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Figure 22: CDK1 phosphorylates GST-CTD at ser-5 and -7 but appears not to be the PIC associated 
kinase responsible for CTD ser-5 or 7 hyperphosphorylation. A, In vitro kinase assay with GST-CTD as 
substrate. CDK1 or CDK11 immunoprecipitations were probed for their potential to phosphorylate GST-
CTD at ser-5 and -7 (lanes 2 and 3 respectively). Jurkat nuclear extract served as a positive control (lane 5). 
B, In vitro kinase assay probing DE52 column fractions for their CTD ser-5 and -7 phosphorylation activity 
towards GST-CTD. C, Immobilized template assay on major-late promoter templates. PICs were formed 
with mock-treated (ΔIso) or CDK1-depleted (ΔCDK1) Jurkat nuclear extract as indicated. PICs were 
formed in the presence of the activator GAL4-VP16 and 1 µM ATP, washed afterwards and subjected to a 
second incubation in in vitro transcription buffer containing 100 µM NTPs. The DNA-bound proteins were 
analyzed by immunoblot, in addition the in vitro transcription potential of the respective PICs was probed 
(TXN). PIC formation reactions were supplemented with DE52 fractions A and D, as well as with an 
isotype or a Mediator (MED) immunoprecipitation (IP) as indicated.        
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and 4 as well as the amount of MED15 and MED25 present in the input nuclear extracts, 
lane 1 and 2). On the other hand, Mediator immunoprecipitations did not co-precipitate 
CDK1 in detectable quantities. To dissect whether the defect in CTD ser-5 and -7 
hyperphosphorylation was due to the absence of Mediator or CDK1, I reconstituted the 
CDK1 depleted nuclear extract with DE52 fraction A, which contained CDK1 (Fig. 22C, 
lane 5). Adding back CDK1 from this fraction to the PIC formation reaction did not 
restore the CTD ser-5/7 hyperphosphorylation activity. Next, immunoprecipitated 
Mediator, that was not associated with appreciable levels of CDK1, was added-back into 
a CDK1-depleted nuclear extract and an immobilized template assay was performed on 
major late promoter templates. Mediator, although added-back in excess to the PIC 
formation reaction, fully restored the CTD ser-5 and -7 hyperphosphorylation activity and 
also restored the in vitro transcription potential of the nuclear extract (Fig. 22C, lane 8). 
Thus, although CDK1 is able to phosphorylate GST-CTD at ser-5 and to a lesser extent at 
ser-7 in an in vitro kinase assay (Fig. 22A) I did not find convincing evidence that CDK1 
is the major PIC associated kinase responsible for CTD ser-7 hyperphosphorylation upon 
transcription initiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 102 
D. Discussion 
D.1. Mediator Modules 
Several distinct Mediator subpopulations can be isolated from nuclear extracts. This 
finding could reflect two scenarios: (i) a particular set of target genes is regulated by a 
particular Mediator subpopulation or (ii) the Mediator subpopulations present in a nuclear 
extract are generated sequentially at a promoter during transcription initiation. In this 
scenario one would expect that Mediator acts in a similar fashion for all Mediator-
responsive genes.  
D.1.1. Characterization of the CDK8 Mediator subpopulation 
The Tjian laboratory discovered that two basic classes of Mediator complexes can be 
distinguished in vitro: A small Mediator termed ‘cofactor required for Sp1 activation’ 
(CRSP),  which  stimulates transcription strongly and a large Mediator termed ‘activator-
recruited cofactor-L’ (ARC-L) which is transcriptionally inactive. The main difference 
between the two complexes is the presence of a CDK8 Mediator module (CDK8, cyclin 
C, MED12, MED13). It is present in the ARC-L but not in CRSP complex (Taatjes et al., 
2002). CDK8 has been reported to phosphorylate and thereby inactivate the 
cyclin H/CDK7 kinase module of TFIIH (Akoulitchev et al., 2000). A genome wide 
ChIP-on-chip study in yeast found the CDK8-Mediator and RNAPII to be located at 
promoter regions of inactive genes in vivo (Andrau et al., 2006). In combination with the 
above molecular mechanism a model results in which the CDK8-module of Mediator 
keeps a RNAPII holoenzyme complex in a poised state allowing rapid activation of the 
respective gene upon loss of the inhibitory CDK8-Mediator module. Loss of the CDK8-
module or CDK8-Mediator in vivo has been shown to dependent on PARP-1 (Pavri et al., 
2005). Tom Uhlmann, a former graduate student in the lab, showed that the CDK8-
module is lost in a tet-VP16 inducible model gene system upon transcription initiation at 
the promoter (Uhlmann et al., 2007). Regarding CDK8 function this study was guided by 
the following questions: Does the CDK8 module dissociate from Mediator upon 
transcription initiation and can this be recapitulated in vitro? Has the CDK8 module any 
positive function in transcription initiation? I found that the CDK8 module together with 
the tail subunit MED15 did dissociate from an in vitro formed PIC upon incubation with 
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nucleotides (Fig. 4B and 9B). CKII is known to be associated with transcription 
complexes in vitro, as it is required for in vitro transcription from downstream promoter 
element (DPE) containing promoters (Lewis et al., 2005). The CKII specific kinase 
inhibitor TBB did prevent partially post-translational modification and/or dissociation of 
CDK8 upon transcription initiation (Fig 4C). Further investigation will be required to 
determine whether dissociation of the CDK8 module from a PIC is triggered by CKII. It 
turned out that only a small fraction of all Mediators in a nuclear extract were associated 
with CDK8 (Fig. 3A). Immunodepletion of CDK8 from a nuclear extract did not reduce 
the in vitro transcription potential of a nuclear extract. In addition I showed that CDK8 is 
responsible in part for the establishment of CTD ser-5 hyperphosphorylation upon 
transcription initiation (Fig. 15B). Both findings provide evidence that neither CDK8 or 
CDK8-mediated CTD ser-5 hyperphosphorylation have essential positive functions in 
transcription initiation in vitro. 
D.1.2. Further characterization of MED25 
The MED25 Mediator is essential for VP16-mediated gene activation (Mittler et al., 
2003). A basal Mediator has been described which acts similar to a general transcription 
factor in a nuclear extract in vitro transcription system (Mittler et al., 2001). On this 
background I wished to determine whether a basal Mediatorfunction is associated with 
MED25 or a MED25 Mediator. I found that immunoprecipitated MED25, even if washed 
under stringent conditions, is sufficient to support VP16-activated transcription in vitro. 
In addition I find that a MED15 immunodepletion removes all MED25 from a nuclear 
extract. I conclude that the basal Mediator function is physically associated with a 
MED25 immunoprecipitation and that all MED25 present in a nuclear extract is 
physically associated with Mediator.   
D.1.3. Characterization of the human equivalent of the yeast reinitiation Mediator 
It has been shown that after a first round of in vitro transcription a scaffold complex is 
formed at promoter template in the yeast system. This  scaffold or reinitiation complex 
contains factors like TBP and the Mediator complex. Other factors such as TFIIB and 
CDK7 were reported to dissociate from the PIC upon addition of ATP or NTPs to a PIC 
(Yudkovsky et al., 2000). When I incubated preformed and washed PICs with ATP or 
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NTP I observed a partial dissociation of the PIC in human nuclear extracts. As reported 
for the yeast system, I observed dissociation of TFIIB and CDK7. Interestingly, TBP 
appeared to be post-translationally modified during this process (Fig. 4B/C, Fig. 9). 
Appearance of the post-translational modification can be suppressed by the inhibitor 
wortmannin (Fig. 21), which is specific for DNA-PK. DNA-PK is a immobilized 
promoter template associated kinase in vitro (Peterson et al., 1992).  Furthermore a 
DNA-PK phosphorylation sites have been discovered in TBP (Chibazakura et al., 1997). 
The TBP post-translational modification was established in the presence of 100 µM ATP, 
but not in the presence of 100 µM ATPγS, an ATP analogue that can be used by kinases 
but not by helicases (Stelzer et al., 1994; Tazi et al., 1993), indicating that also a helicase 
might be involved in the process leading to post-translational modification of TBP. 
DNA-PK is a kinase that is not conserved from yeast to man. In the yeast nuclear extract 
in vitro transcription system multiple round transcription is observed, whereas this is not 
the case in the human nuclear extract in vitro transcription system. The post-translational 
modification of template associated TBP may provide an explanation for this difference. 
Similar to the TBP modification, the PIC dissociation appears to be dependent on a 
helicase. Very little TFIIB dissociation was observed if a PIC was incubated with 100 
µM ATPγS. Incubation of a PIC with 100 µM ATP or 100 µM NTPs led to TFIIB 
dissociation Fig 9B. PIC dissociation and TBP post-translational modification also 
occurred if CDK7, CDK8 or CDK9 were depleted from nuclear extracts (Fig. 15B). In 
the yeast system it was reported that Mediator remains associated with the DNA 
promoter template, however the analysis in that study put emphasis on the head subunits 
MED6, MED17 and MED20 (Yudkovsky et al., 2000). Upon addition of 100 µM ATP or 
NTP to preformed PICs the tail subunit MED15 as well as the CDK8 module subunit 
CDK8 did dissociate from immobilized promoter templates, whereas the middle submit 
MED7 remained associated with the  promoter templates (Fig. 4B/C, Fig. 9B). An 
interesting question for the future will be whether the middle/head scaffold Mediator, that 
remains associated with an immobilized promoter template after transcription initiation is 
sufficient to recruit GTFs such as TFIIB and TFIIH for another round of transcription, or 
whether the tail region is required for that to happen. In summary PIC dissociation upon 
transcription initiation appeared to be dependent on a yet to be identified ATPase such as 
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a helicase. Furthermore I found that the head/middle part of Mediator remained 
associated to the promoter template upon transcription initiation whereas the tail and 
CDK8 module were dissociating.  
D.2. Basal Mediator 
Gerhard Mittler, a former graduate student in the laboratory, discovered that Mediator 
acts like to a basal transcription factor in a nuclear extract in vitro transcription system 
(Mittler et al., 2001). In the minimal in vitro transcription system composed of 
recombinant or highly purified proteins many regulatory mechanisms are neglected due 
to the simplicity of the system. In comparison in the nuclear extract in vitro transcription 
system several additional transcription regulatory mechanism are in place and therefore it 
represents the more physiological transcription system. For instance, the minimal 
transcription system acts independently of RNAPII CTD phosphorylation, whereas in the 
nuclear extract transcription system this mode of regulation can be recapitulated 
(Serizawa et al., 1993). In the course of this work the Roeder laboratory published that 
Mediator is required in the nuclear extract transcription system for efficient recruitment 
of TFIIB to the PIC. In this article it was demonstrated that the Mediator requirement can 
be overcome by adding excessive amounts of recombinant TFIIB to a Mediator-deficient 
nuclear extract (Baek et al., 2006). Starting from these points I investigated how Mediator 
is involved in GTF recruitment and what influence Mediator has on RNAPII CTD 
phosphorylation. As discussed in more detail below, I found that Mediator is essential for 
TFIIB and TFIIH recruitment and that Mediator is also required for the establishment of 
several CTD ser-5 and -7 phosphorylation states.   
 D.2.1. Basal Mediator is required for TFIIB and TFIIH recruitment in a nuclear 
extract in vitro transcription system 
In the literature two models have been proposed to explain the recruitment of general 
transcription factors to a promoter to form a functional PIC. The first model represents an 
extrapolation from the situation found with recombinant and purified transcription 
factors. In this in vitro transcription system there is evidence that the GTFs and RNAPII 
are recruited sequentially in the following order: TFIID > TFIIA > TFIIB > 
RNAPII/TFIIF > TFIIE > TFIIH. The second model, the so called holoenzyme pathway, 
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is based on research carried out with crude nuclear extract transcription systems and 
states that a PIC is recruited to a promoter in two bulk segments: the TFIID/TFIIA 
complex and the holoenzyme consisting of RNAPII, Mediator, the SWI/SNF complex, 
TFIIB, TFIIE, TFIIF and TFIIH (reviewed in (Thomas and Chiang, 2006)). A study by 
the Roeder lab argued that also in the nuclear extract in vitro transcription system the 
sequential assembly model applies (Baek et al., 2006). Notably, a basal Mediator 
complex is not required for GTF recruitment in the recombinant/purified in vitro 
transcription system. On this background I investigated the nature of the GTF-recruitment 
limiting mechanism in the nuclear extract transcription system.  
D.2.1.1. What kind of mechanism could limit TFIIB and TFIIH recruitment to a    
promoter in the nuclear extract transcription system? 
Recruitment of TFIIB and TFIIH to a PIC appears to be inhibited in a nuclear extract 
transcription system. Despite a large excess of these GTFs, in particular of TFIIB, present 
in a nuclear extract, Mediator was absolutely required for their recruitment (Fig. 6B) to 
an PIC. One possibility is that in a nuclear extract transcription system a negative acting 
factor competes with TBP for TATA-box binding. Therefore it could be reasoned that 
Mediator helps TBP to bind properly to the TATA box. Thereby appropriate binding sites 
for TFIIB and TFIIH recruitment are generated within the PIC. After figuring out that 
TFIIB recruitment to a PIC is indeed limited – directly or indirectly - by a factor present 
in the nuclear extract (Fig. 6C) I incubated a promoter DNA-template with recombinant 
TBP, and subsequently incubated it with either mock-depleted or Mediator deficient 
nuclear extract. In case TBP-binding would be the GTF-recruitment limiting mechanism 
one would expect in this case Mediator-independent recruitment of TFIIB to the PIC. 
However, this is not the case, TFIIB recruitment was still Mediator-dependent (Fig. 6B). 
Remarkably, TFIID and Mediator recruitment followed a much faster kinetic than the 
recruitment of TFIIB  to a PIC (Fig. 11B). Obviously generating the GTF binding surface 
within the PIC is a slow process. One could envision that Mediator is required to bring 
TBP in a position or confirmation that allows TFIIB recruitment to the PIC, e.g. by 
dissociating TBP from TAFs. However, prebinding of recombinant TBP to the  promoter 
DNA template should alleviate the Mediator-requirement for TFIIB in that case, which 
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was not the case (Fig. 6B, lanes 12 and 13). For this reason the TFIIB/TFIIH-recruitment 
limiting mechanism may act downstream of functional TBP recruitment to the TATA-
box. Another possibility is that the GTF-binding sites within the PIC are physically 
blocked by a negative acting protein or complex that has to be displaced by Mediator in 
order to allow GTF recruitment. In genetic screens two factors turned up as suppressors 
of MED17 (Srb4) Mediator mutations: mutations in alleles belonging to the NC2 and the 
CCR4-NOT complexes (Lee et al., 1998). It is well described that NC2 affects and 
competes with TFIIA and TFIIB for recruitment to a PIC if recombinant proteins are used 
(Goppelt et al., 1996). Testing whether NC2 imposes the Mediator-requirement on basal 
transcription revealed that NC2 competes with TFIIB for recruitment to the PIC but also 
that basal transcription was Mediator-dependent even if a NC2-deficient nuclear extract 
was used (Fig. 8A/B). Interestingly, if TFIIB recruitment was limited by increased 
amounts of NC2 also the recruitment of the TFIIH component CDK7 was impaired (Fig. 
8B, lanes 7 and 8). NC2 appears to be a fine-tuning mechanism for TFIIB and TFIIH 
recruitment, but is not the major TFIIB/TFIIH-recruitment limiting factor that is 
counteracted by Mediator in basal in vitro transcription (Fig. 8A/B).  
A recent publication claimed that adding the DSIF heterodimer to a in vitro transcription 
system consisting of recombinant and purified transcription factors leads to a Mediator 
requirement for basal in vitro transcription. Importantly the used transcription system did 
not contain pTEFb or CDK9 which are required to overcome the transcription block 
imposed by DSIF 20 to 50 nucleotides downstream of the transcription start site (Malik et 
al., 2007). It will be interesting to address in further investigations whether the CCR4-
NOT complex or the DSIF complex are components of the TFIIB-recruitment limiting 
mechanism. Furthermore it will be interesting to further purify the TFIIB-recruitment 
limiting factor from the 0.1M P11 column fraction (Fig. 6C).  
D.2.1.2. TFIIB recruitment to a PIC is slow  
What is the nature of the TFIIB/TFIIH-recruitment limiting mechanism? A remarkable 
feature of TFIIB recruitment to the PIC was its slow recruitment during PIC formation in 
comparison to recruitment of TFIID, activator and Mediator (Fig. 11). This may indicate 
that the TFIIB binding site within the PIC has to be generated by an ATPase such as a 
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helicase. However PIC formation in the presence of 1 µM of the helicase inhibitor ATPγS 
does not lead to reduced TFIIB recruitment (Fig. 9 and 10A). The kinase inhibitor H8 
was found to inhibit CTD ser-5 and -7 phosphorylation of the RNAPII CTD during PIC 
formation (Fig. 9 and 10A). In yeast TFIIB recruitment to a in vitro formed PIC was 
found to be dependent on the RNAPII CTD (Ranish et al., 1999). However, TFIIB 
recruitment was in the assay system used in this study independent of CTD ser-5 and -7 
hypophosphorylation or a kinase that is sensitive to H8 (Fig. 9  and 10A).  
D.2.1.3. Recruitment of GTFs in the context of the holoenzyme 
Mediator was recruited to an in vitro formed PIC even in a TBP-depleted nuclear extract. 
Strikingly TFIIB and TFIIH component CDK7 were found to be associated with the 
promoter template even in the absence of promoter bound TBP arguing that they were 
recruited in the context of a holoenzyme complex (Fig. 20, lanes 3-5). Significant 
amounts of TFIIB were also recruited to a promoter template that contained a mutated 
TATA-box and therefore did not provide a functional TBP binding site as it is required 
for functional PIC formation (Fig. 13). In support of this notion it was found in yeast that 
TFIIB is recruited by GAL4-VP16 to a DNA template that does not contain a promoter 
(Ranish et al., 1999). If a promoter template was incubated with recombinant 
TBP/rTFIIB prior to the PIC formation reaction that was carried out with nuclear extract, 
additional endogenous TFIIB was recruited to the promoter template in a Mediator-
dependent fashion (Fig. 6B; rTFIIB contains a His-tag, and therefore has higher 
molecular weight than the endogenous TFIIB). One possibility is that in a nuclear
extract transcription system only the Mediator-recruited TFIIB is transcriptionally active, 
but not the TFIIB that had been bound to the TATA-TBP complex during the 
preincubation step. The sequential assembly model would predict that successful 
recruitment of one GTF is sufficient to recruit the following GTF. However I observed 
that prebinding of large amounts of rTFIIB to a promoter template – TPB complex did 
not led to increased TFIIH recruitment (Fig. 6B). On the other hand, if TFIIB recruitment 
was limited due to an increased amount of NC2 or the B2-RNA during PIC formation, 
also TFIIH recruitment was diminished (Fig. 8B and 12B respectively). Notably, I did not 
find any evidence that a holoenzyme complex containing the GTFs TFIIB, TFIIE, TFIIH 
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and TFIIF in conjunction with Mediator and RNAPII is present as a preformed entity in a 
nuclear extract or that such a complete holoenzyme is recruited to the PIC in one piece.  
E.g. TFIIB was not found to be associated with Mediator in measurable quantities in a 
nuclear extract (Fig. 6B, lanes 1 and 2, Fig. 12A, lanes 1 and 2). Taken together this 
results indicate that the holoenzyme does not exist as a pre-formed entity, but is rather 
created in a slow process during PIC formation.  
D.2.2. Basal Mediator is required to establish several CTD phosphorylation states 
As will be discussed in the next chapter in detail, I found that a particular form of 
CTD ser-5 phosphorylation correlated with the transcription potential of a PIC. Basal 
in vitro transcription in the nuclear extract system is sensitive to the kinase inhibitor H8, 
whereas transcription in the system composed of recombinantly expressed and purified 
transcription factors is not (Serizawa et al., 1993; Stelzer et al., 1994). Furthermore the 
first description of Mediator provided evidence that Mediator stimulates the kinase 
activity of the TFIIH associated kinase CDK7 (Kim et al., 1994). I found that CDK7 
mediates CTD ser-5 hypo- but not CTD ser-5 hyperphosphorylation (Fig. 15B) and also 
could show that CTD ser-5 hypophosphorylation is Mediator-dependent (Fig. 8A). In 
addition to this CDK7-dependent mechanism Mediator is also required for the 
establishment of CTD ser-5 and -7 hyperphosphorylation, which is generated in a CDK7-
independent fashion (Fig. 15B). In summary, establishment of various kinds of CTD 
phosphorylation is a basal Mediator function.  
D.3. Two distinct modes of CTD ser-5 phosphorylation  
Two kinases have been identified in conjunction with transcription as RNAPII CTD ser-5 
kinases: CDK7 and CDK8. CDK7 is described as a factor that supports transcription 
whereas CDK8 is described as a factor that inhibits transcription (Hengartner et al., 
1998). CTD ser-5 phosphorylation is generally believed to be predominantly associated 
with the low-mobility IIo form of Rpb1. However a  recent study by the Fisher laboratory 
revealed that highly specific inhibition of CDK7 in a human cell line had no effect on the 
amount of CTD ser-5 hyperphosphorylation observed in the lysate of inhibitor treated 
cells (Larochelle et al., 2007). Also upon inactivation of CDK7 in D. melongaster only a 
modest drop in total CTD ser-5 phosphorylation was observed (Schwartz et al., 2003) in 
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vivo.  I discovered that CTD ser-5 phosphorylation comes in two distinct classes as CTD 
ser-5 hypo- and hyperphosphorylation (CTD ser-5 phosphorylation of the IIa and IIo 
form of RNAPII Rpb1 respectively). Appearance of CTD ser-5 hypophosphorylation was 
dependent on CDK7, TFIIB, TBP, a TATA box, and Mediator, was established before 
complex opening by the TFIIH associated helicase and did correlate to the transcription 
potential of a given PIC (see chapter C.2). However a recent study challenged the view 
that the CDK7 kinase activity is critically required for transcription to occur in yeast 
(Kanin et al., 2007). I observed that a fraction of CTD ser-5 hyperphosphorylation, that 
occurred upon transcription initiation in vitro, could be linked to CDK8 (Fig. 15B). CTD 
ser-5 hypophosphorylation was entirely independent of CDK8. My data provide evidence 
for the notion that another kinase then CDK7 and CDK8 participates in establishing CTD 
ser-5  hyperphosphorylation upon transcription initiation. CTD ser-5 and -7 
hyperphosphorylation could not be separated in any experiment and might therefore be 
linked or established by the same mechanism. However, CTD ser-7 hypophosphorylation 
is preceded by CTD ser-5 hypophosphorylation, arguing that each of these two marks is 
established by a distinct mechanism (Fig. 10A). In summary I provide evidence that CTD 
ser-5 phosphorylation occurs in two distinct modes, of which one, CTD ser-5 
hypophosphorylation is established in a tightly controlled fashion, whereas the other, 
CTD ser-5 hyperphosphorylation, appears to be established independent of TBP or the 
transcription potential of a PIC. Based on this data one can envision the following model: 
CTD ser-5 hypophosphorylation is established only at bona fide transcription start sites if 
all factors are recruited to the PIC and thus marks an transcription competent PIC. CTD 
ser-5 hyperphosphorylation is then established to dissociate RNAPII from the PIC in 
order to start productive transcription. If however an RNAPII holoenzyme is bound to a 
non-promoter region, e.g. an accessible DNA region in an open reading frame, no 
functional PIC is formed and thus no CTD ser-5 hypophosphorylation established.  If 
now CTD ser-5 or -7 hyperphosphorylation is established, this RNAPII may be 
hyperphosphorylated and thereby dissociate in a non-productive fashion from the 
inappropriate binding site within the genome (Fig. 23). What could be the physiological 
function of CTD ser-5 hypophosphorylation? A recent study found that specific 
inhibition of yeast CDK7/Kin28 in vivo does not lead to diminished mRNA synthesis but 
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to decreased mRNA capping (Kanin et al., 2007). Also it was reported that the yeast 
homologue of the human MLL histone methyltransferase Set1 is recruited to promoters in 
a CDK7/Kin28-dependent fashion (Ng et al., 2003). In a genome-wide ChIP-on-chip 
study it was demonstrated that most transcription start sites of active genes are decorated 
with a highly localized peak of histone H3-lysine-4 trimethylation (Guenther et al., 
2007). The mechanism by which this precise localization is achieved is unknown. A 
possible mechanism would be that the histone methyltransferase is active only in 
combination with RNAPII that bears the CTD ser-5 hypophosphorylation mark and is 
devoid of CTD ser-7 phosphorylation. As soon as CTD ser-7 phosphorylation is 
established after complex opening the histone methyltransferase would be inactivated. 
The result would be a highly localized histone methylation mark.  
  
 
Figure 23: Model CTD phosphorylation (for details see text above) 
 
D.4. Characterization of CTD ser-7 phosphorylation 
The Eick laboratory raised monoclonal antibodies specific for the  RNAPII CTD 
phosphorylated at ser-7 and found that this modification is observed in vivo (Chapman et 
al., 2007). After figuring out that CTD ser-7 phosphorylation did appear upon 
transcription initiation in vivo (Fig. 16) and in vitro (Fig. 9), I set out to characterize and 
identify the kinase that mediates this modification.  
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D.4.1. Establishment of CTD ser-5 and -7 hyperphosphorylation is independent of 
processive transcription 
First I investigated whether CTD ser-7 phosphorylation is established in a transcription-
dependent fashion in vitro and found that this modification was established before 
formation of the first phosphodiester bond. Incubation of a PIC with 100 µM ATP under 
in vitro transcription conditions was sufficient to establish similar amounts of CTD ser-7 
hyperphosphorylation than were generated by incubation of PICs with 
100 µM NTPs. Incubation with NTPs, in contrast to incubation with ATP alone, does 
allow productive in vitro transcription to occur (Fig. 9). Also incubation of an in vitro 
transcription reaction with 100 µM NTPs in the presence of the transcription inhibitor α-
amanitin gave rise to the same levels of CTD ser-7 hyperphosphorylation as in the 
uninhibited situation (Fig. 10B). α-Amanitin is known to inhibit transcription before 
formation of the second phosphodiester bond (de Mercoyrol et al., 1989). In support of 
this notion it has been reported previously that CTD hyperphosphorylation occurs before 
the formation of the first phosphodiester bond (Laybourn and Dahmus, 1990). 
Immunodepletion of CDK7 or TBP in a nuclear extract did abolish CTD ser-5 
hypophosphorylation but left the amount of generated CTD ser-7 hyperphosphorylated 
RNAPII unaltered as compared to the mock-depleted situation. In both cases the amount 
of transcript produced by the immunodepleted PICs was reduced (Fig. 15B and 20B 
respectively). Thus, CTD ser-7 phosphorylation was established at an early stage of 
transcription initiation and did not show any correlation to the amount of processive 
transcription from the respective PIC. Appearance of CTD ser-5 hyperphosphorylation 
generally correlated with the establishment of CTD ser-7 hyperphosphorylation. 
Immunodepletion of CDK8 led to a reduction in CTD ser-5 but not CTD ser-7 
hyperphosphorylation (Fig. 15B). CTD ser-5 and -7 hyperphosphorylation was observed 
in a double-strand DNA-dependent fashion. Presence of the poly(dG:dC) DNA polymer 
in an in vitro transcription reaction that lacks template DNA still led to the establishment 
of CTD ser-5 and -7 hyperphosphorylation (Fig. 18B). The amount of established CTD 
ser-5 and -7 hyperphosphorylation did not increase much if a major-late promoter 
template was included into the reaction (Fig. 18B). I conclude that the protein kinase that 
establishes these modifications acts in a DNA but not promoter-dependent fashion. 
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Establishment of CTD ser-5 and -7 hyperphosphorylation could be triggered by 
incubating a PIC with 100 µM ATP but not by incubation with 100 µM ATPγS. ATPγS 
is an ATPase inhibitor but can be used by kinases as a substrate (Eckstein, 1985). 
Therefore it is likely that the CTD ser-7 hyperphosphorylation kinase is functionally 
linked to an ATPase such as a helicase (Fig 9B and Fig. 18B). It has been reported that 
hyperphosphorylation of the CTD of RNAPII leads to dissociation of a RNAPII-Mediator 
complex (Max et al., 2007; Svejstrup et al., 1997).  Taking this into account it is possible 
that CTD ser-5 and -7 hyperphosphorylation leads to a dissociation of the PIC. 
Dissociation of a DNA-bound Mediator RNAPII complex could have two consequences: 
Productive transcription is initiated or RNAPII dissociates from the DNA in a non-
productive fashion. In the future it will be interesting to determine whether presence of 
CTD ser-5 hypophosphorylation in combination with CTD ser-5 and ser-7 
hyperphosphorylation leads to productive transcription whereas presence of CTD ser-5 
and -7 hyperphosphorylation only leads to non-productive dissociation of RNAPII from 
DNA as depicted in Fig. 23. 
D.4.2. Establishment of CTD ser-5 and -7 hyperphosphorylation is Mediator-
dependent 
Immunodepletion of Mediator in nuclear extracts led to a loss of CTD ser-5 and -7 
hyperphosphorylation in both, the immobilized template assay as well as in an SDS-
PAGE in vitro transcription assay (Fig. 17 and 18B respectively). CTD ser-5 and -7 
hyperphosphorylation could be restored in a Mediator-depleted nuclear extract by adding 
back Mediator immunoprecipitated with antibodies against the MED15, MED25, CDK8 
or MED1 Mediator subunits. Mediator preparations did phosphorylate a GST-CTD 
substrate at ser-5 but did not increase GST-CTD ser-7 phosphorylation in an in vitro 
kinase assay (Fig. 19). Therefore Mediator is not associated with the active form of the 
CTD ser-7 hyperphosphorylating kinase. This could be explained by the fact that 
additional factors are required for the activation of the CTD ser-7 kinase. Alternatively 
the CTD ser-7 kinase might not be physically associated with Mediator outside the PIC. 
In the future it will be necessary to determine how Mediator triggers the kinase activity 
responsible for CTD ser-7 hyperphosphorylation. It will be interesting to determine 
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whether this kinase also contributes to establishment of CTD ser-5 hyperphosphorylation 
upon transcription initiation.  
D.4.3. Characterization of the kinase responsible for CTD ser-7 phosphorylation  
In order to identify the CTD ser-7 kinase I made use of the fact that the functionally 
active kinase is part of an in vitro formed PIC. Mass spectrometric analysis of the isolated 
PIC identified 13 kinases as constituents of the PIC. In a first step I analyzed those seven 
kinases in detail which had been reported as CTD kinases in the literature. Given the 
functional characteristics of the CTD ser-7 kinase a particularly interesting candidate was 
DNA-protein kinase (DNA-PK). DNA-PK is able to phosphorylate short CTD peptides at 
ser-7 (Trigon et al., 1998). It forms a complex with the Ku80/Ku86 proteins which are 
DNA-helicases (Tuteja et al., 1994). I had observed that CTD ser-7 phosphorylation is 
established in a DNA- and helicase-dependent fashion (Fig. 18B). I probed DNA-PK 
directly in an immobilized promoter template assay with the inhibitor wortmannin and 
did not find a reduction in CTD ser-7 hyperphosphorylation (Fig. 21). Importantly, I 
observed that the DNA-PK inhibitor suppressed TBP post-translational modifications, 
that occurred in that type of assay (Fig. 21), indicating that the inhibitor was working 
properly. In parallel I started a biochemical purification of the CTD ser-7 kinase and 
found that CDK1 copurified with a kinase activity that was able to phosphorylate GST-
CTD at ser-5 and -7 (Fig. 22A). Also CDK1 was identified by mass spectrometry as a 
PIC associated kinase. This result could be confirmed by an immunoblot analysis of a 
PIC (Fig. 13). In addition the inhibitor roscovitine was able to suppress CTD ser-7 
hyperphosphorylation in an immobilized template assay (Fig. 21). A further investigation 
by immunodepletion of CDK1 was carried out. At first glance immunodepletion of 
CDK1 led to a loss of CTD ser-5 and -7 hyperphosphorylation in immobilized template 
assays and also led to a reduction in the transcription potential of the respective PICs 
(Fig. 22B). However it turned out that during the CDK1 immunodepletion with a 
polyclonal antiserum Mediator was co-depleted together with CDK1 (Fig 22C, compare 
lanes 1 and 2). Since immunoprecipitated Mediator was not associated with detectable 
amounts of CDK1 I conclude that the co-depletion of Mediator with CDK1 occurred due 
to an unspecific antibody cross-reaction and not due to a specific interaction between the 
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two components. To compensate for the loss of Mediator, I added back 
immunoprecipitated Mediator to a  CDK1-depleted nuclear extract. This treatment fully 
restored the ability of the PIC to hyperphosphorylate CTD ser-5 and -7. Also it did 
restore the in vitro transcription potential of the PIC. In contrast, add-back of the CDK1 
containing column chromatography fraction to a CDK1-depleted nuclear extract did not 
restore CTD ser-5 and -7 hyperphosphorylation (Fig. 22C). In the light of these results I 
conclude that CDK1 is unlikely to be the PIC associated kinase responsible for CTD 
ser-7 hyperphosphorylation. I tested all other CTD-kinases that were detected in the PIC 
either by immunodepletion (CDK7, CDK8, CDK9; Fig. 15), by probing the 
immunoprecipitated kinase in an in vitro kinase assay on GST-CTD (CDK11; Fig. 22A) 
or by using chemical inhibitors (CKI, CKII; Fig. 21). Furthermore I found that 
roscovitine is able to suppress the activity of the CTD ser-7 kinase in an immobilized 
template assay, but I could not gather convincing evidence that CDK1, a roscovitine 
sensitive kinase, is the PIC associated CTD ser-7 kinase. Other kinases that are sensitive 
to roscovitine are CDK2 and CDK5 (Filgueira de Azevedo et al., 2002). CDK2 could be 
detected as specific constituent of an in vitro formed PIC (Fig. 13). Further investigation 
will be required in this direction. In summary, the CTD ser-7 kinase activity appears to be 
connected to an ATPase activity and therefore it is possible that the PIC associated kinase 
responsible for CTD ser-7 hyperphosphorylation is active only in a complex with a 
helicase and DNA.  
 
 
 
 
 
 
 
 
 
 
 
References 
 116 
References 
 
Akoulitchev, S., Chuikov, S., and Reinberg, D. (2000). TFIIH is negatively regulated by 
cdk8-containing mediator complexes. Nature 407, 102-106. 
Albert, T.K., Grote, K., Boeing, S., Stelzer, G., Schepers, A., and Meisterernst, M. 
(2007). Global distribution of negative cofactor 2 subunit-alpha on human promoters. 
Proc Natl Acad Sci U S A 104, 10000-10005. 
Albright, S.R., and Tjian, R. (2000). TAFs revisited: more data reveal new twists and 
confirm old ideas. Gene 242, 1-13. 
Andrau, J.C., van de Pasch, L., Lijnzaad, P., Bijma, T., Koerkamp, M.G., van de Peppel, 
J., Werner, M., and Holstege, F.C. (2006). Genome-wide location of the coactivator 
mediator: Binding without activation and transient Cdk8 interaction on DNA. Mol Cell 
22, 179-192. 
Andrau, J.C., Van Oevelen, C.J., Van Teeffelen, H.A., Weil, P.A., Holstege, F.C., and 
Timmers, H.T. (2002). Mot1p is essential for TBP recruitment to selected promoters 
during in vivo gene activation. The EMBO journal 21, 5173-5183. 
Asturias, F.J., Jiang, Y.W., Myers, L.C., Gustafsson, C.M., and Kornberg, R.D. (1999). 
Conserved structures of mediator and RNA polymerase II holoenzyme. Science 283, 985-
987. 
Baek, H.J., Kang, Y.K., and Roeder, R.G. (2006). Human Mediator enhances basal 
transcription by facilitating recruitment of transcription factor IIB during preinitiation 
complex assembly. J Biol Chem 281, 15172-15181. 
Baillat, D., Hakimi, M.A., Naar, A.M., Shilatifard, A., Cooch, N., and Shiekhattar, R. 
(2005). Integrator, a multiprotein mediator of small nuclear RNA processing, associates 
with the C-terminal repeat of RNA polymerase II. Cell 123, 265-276. 
Bengal, E., Flores, O., Krauskopf, A., Reinberg, D., and Aloni, Y. (1991). Role of the 
mammalian transcription factors IIF, IIS, and IIX during elongation by RNA polymerase 
II. Molecular and cellular biology 11, 1195-1206. 
Black, J.C., Choi, J.E., Lombardo, S.R., and Carey, M. (2006). A mechanism for 
coordinating chromatin modification and preinitiation complex assembly. Mol Cell 23, 
809-818. 
Blazek, E., Mittler, G., and Meisterernst, M. (2005). The mediator of RNA polymerase II. 
Chromosoma 113, 399-408. 
Borggrefe, T., Davis, R., Erdjument-Bromage, H., Tempst, P., and Kornberg, R.D. 
(2002). A complex of the Srb8, -9, -10, and -11 transcriptional regulatory proteins from 
yeast. J Biol Chem 277, 44202-44207. 
References 
 117 
Bourbon, H.M. (2008). Comparative genomics supports a deep evolutionary origin for 
the large, four-module transcriptional mediator complex. Nucleic acids research 36, 
3993-4008. 
Bregman, D.B., Pestell, R.G., and Kidd, V.J. (2000). Cell cycle regulation and RNA 
polymerase II. Front Biosci 5, D244-257. 
Buratowski, S. (2003). The CTD code. Nature structural biology 10, 679-680. 
Burley, S.K., and Roeder, R.G. (1996). Biochemistry and structural biology of 
transcription factor IID (TFIID). Annual review of biochemistry 65, 769-799. 
Byers, S.A., Price, J.P., Cooper, J.J., Li, Q., and Price, D.H. (2005). HEXIM2, a 
HEXIM1-related protein, regulates positive transcription elongation factor b through 
association with 7SK. J Biol Chem 280, 16360-16367. 
Chadick, J.Z., and Asturias, F.J. (2005). Structure of eukaryotic Mediator complexes. 
Trends in biochemical sciences 30, 264-271. 
Chang, M., and Jaehning, J.A. (1997). A multiplicity of mediators: alternative forms of 
transcription complexes communicate with transcriptional regulators. Nucleic acids 
research 25, 4861-4865. 
Chapman, R.D., Heidemann, M., Albert, T.K., Mailhammer, R., Flatley, A., Meisterernst, 
M., Kremmer, E., and Eick, D. (2007). Transcribing RNA polymerase II is 
phosphorylated at CTD residue serine-7. Science 318, 1780-1782. 
Chen, H.H., Wang, Y.C., and Fann, M.J. (2006). Identification and characterization of the 
CDK12/cyclin L1 complex involved in alternative splicing regulation. Molecular and 
cellular biology 26, 2736-2745. 
Chen, H.H., Wong, Y.H., Geneviere, A.M., and Fann, M.J. (2007). CDK13/CDC2L5 
interacts with L-type cyclins and regulates alternative splicing. Biochemical and 
biophysical research communications 354, 735-740. 
Chibazakura, T., Watanabe, F., Kitajima, S., Tsukada, K., Yasukochi, Y., and Teraoka, 
H. (1997). Phosphorylation of human general transcription factors TATA-binding protein 
and transcription factor IIB by DNA-dependent protein kinase--synergistic stimulation of 
RNA polymerase II basal transcription in vitro. European journal of biochemistry / FEBS 
247, 1166-1173. 
Chicca, J.J., 2nd, Auble, D.T., and Pugh, B.F. (1998). Cloning and biochemical 
characterization of TAF-172, a human homolog of yeast Mot1. Molecular and cellular 
biology 18, 1701-1710. 
Cisek, L.J., and Corden, J.L. (1989). Phosphorylation of RNA polymerase by the murine 
homologue of the cell-cycle control protein cdc2. Nature 339, 679-684. 
References 
 118 
Coin, F., and Egly, J.M. (1998). Ten years of TFIIH. Cold Spring Harbor symposia on 
quantitative biology 63, 105-110. 
Conaway, R.C., and Conaway, J.W. (1993). General initiation factors for RNA 
polymerase II. Annual review of biochemistry 62, 161-190. 
Cook, P.R. (1999). The organization of replication and transcription. Science 284, 1790-
1795. 
Cox, J.M., Hayward, M.M., Sanchez, J.F., Gegnas, L.D., van der Zee, S., Dennis, J.H., 
Sigler, P.B., and Schepartz, A. (1997). Bidirectional binding of the TATA box binding 
protein to the TATA box. Proc Natl Acad Sci U S A 94, 13475-13480. 
Cramer, P., Bushnell, D.A., Fu, J., Gnatt, A.L., Maier-Davis, B., Thompson, N.E., 
Burgess, R.R., Edwards, A.M., David, P.R., and Kornberg, R.D. (2000). Architecture of 
RNA polymerase II and implications for the transcription mechanism. Science 288, 640-
649. 
Dasgupta, A., Darst, R.P., Martin, K.J., Afshari, C.A., and Auble, D.T. (2002). Mot1 
activates and represses transcription by direct, ATPase-dependent mechanisms. Proc Natl 
Acad Sci U S A 99, 2666-2671. 
Davis, J.A., Takagi, Y., Kornberg, R.D., and Asturias, F.A. (2002). Structure of the yeast 
RNA polymerase II holoenzyme: Mediator conformation and polymerase interaction. 
Mol Cell 10, 409-415. 
Davis, J.L., Kunisawa, R., and Thorner, J. (1992). A presumptive helicase (MOT1 gene 
product) affects gene expression and is required for viability in the yeast Saccharomyces 
cerevisiae. Molecular and cellular biology 12, 1879-1892. 
de Mercoyrol, L., Job, C., and Job, D. (1989). Studies on the inhibition by alpha-amanitin 
of single-step addition reactions and productive RNA synthesis catalysed by wheat-germ 
RNA polymerase II. The Biochemical journal 258, 165-169. 
Deng, L., Ammosova, T., Pumfery, A., Kashanchi, F., and Nekhai, S. (2002). HIV-1 Tat 
interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association 
with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol 
Chem 277, 33922-33929. 
Dichtl, B., Blank, D., Ohnacker, M., Friedlein, A., Roeder, D., Langen, H., and Keller, 
W. (2002). A role for SSU72 in balancing RNA polymerase II transcription elongation 
and termination. Mol Cell 10, 1139-1150. 
Dignam, J.D., Lebovitz, R.M., and Roeder, R.G. (1983). Accurate transcription initiation 
by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic 
acids research 11, 1475-1489. 
References 
 119 
Dotson, M.R., Yuan, C.X., Roeder, R.G., Myers, L.C., Gustafsson, C.M., Jiang, Y.W., 
Li, Y., Kornberg, R.D., and Asturias, F.J. (2000). Structural organization of yeast and 
mammalian mediator complexes. Proc Natl Acad Sci U S A 97, 14307-14310. 
Dvir, A., Conaway, R.C., and Conaway, J.W. (1997). A role for TFIIH in controlling the 
activity of early RNA polymerase II elongation complexes. Proc Natl Acad Sci U S A 94, 
9006-9010. 
Eckstein, F. (1985). Nucleoside phosphorothioates. Annual review of biochemistry 54, 
367-402. 
Egloff, S., O'Reilly, D., Chapman, R.D., Taylor, A., Tanzhaus, K., Pitts, L., Eick, D., and 
Murphy, S. (2007). Serine-7 of the RNA polymerase II CTD is specifically required for 
snRNA gene expression. Science 318, 1777-1779. 
Elmlund, H., Baraznenok, V., Lindahl, M., Samuelsen, C.O., Koeck, P.J., Holmberg, S., 
Hebert, H., and Gustafsson, C.M. (2006). The cyclin-dependent kinase 8 module 
sterically blocks Mediator interactions with RNA polymerase II. Proc Natl Acad Sci U S 
A 103, 15788-15793. 
Esnault, C., Ghavi-Helm, Y., Brun, S., Soutourina, J., Van Berkum, N., Boschiero, C., 
Holstege, F., and Werner, M. (2008). Mediator-dependent recruitment of TFIIH modules 
in preinitiation complex. Mol Cell 31, 337-346. 
Espinoza, C.A., Allen, T.A., Hieb, A.R., Kugel, J.F., and Goodrich, J.A. (2004). B2 RNA 
binds directly to RNA polymerase II to repress transcript synthesis. Nat Struct Mol Biol 
11, 822-829. 
Faro-Trindade, I., and Cook, P.R. (2006). Transcription factories: structures conserved 
during differentiation and evolution. Biochemical Society transactions 34, 1133-1137. 
Filgueira de Azevedo, W., Jr., Gaspar, R.T., Canduri, F., Camera, J.C., Jr., and Freitas da 
Silveira, N.J. (2002). Molecular model of cyclin-dependent kinase 5 complexed with 
roscovitine. Biochemical and biophysical research communications 297, 1154-1158. 
Flores, O., Maldonado, E., and Reinberg, D. (1989). Factors involved in specific 
transcription by mammalian RNA polymerase II. Factors IIE and IIF independently 
interact with RNA polymerase II. J Biol Chem 264, 8913-8921. 
Gebara, M.M., Sayre, M.H., and Corden, J.L. (1997). Phosphorylation of the carboxy-
terminal repeat domain in RNA polymerase II by cyclin-dependent kinases is sufficient to 
inhibit transcription. Journal of cellular biochemistry 64, 390-402. 
Geisberg, J.V., Moqtaderi, Z., Kuras, L., and Struhl, K. (2002). Mot1 associates with 
transcriptionally active promoters and inhibits association of NC2 in Saccharomyces 
cerevisiae. Molecular and cellular biology 22, 8122-8134. 
References 
 120 
Gilfillan, S., Stelzer, G., Kremmer, E., and Meisterernst, M. (2003). Purification and 
transcription repression by negative cofactor 2. Methods in enzymology 370, 467-479. 
Goppelt, A., Stelzer, G., Lottspeich, F., and Meisterernst, M. (1996). A mechanism for 
repression of class II gene transcription through specific binding of NC2 to TBP-
promoter complexes via heterodimeric histone fold domains. The EMBO journal 15, 
3105-3116. 
Guenther, M.G., Levine, S.S., Boyer, L.A., Jaenisch, R., and Young, R.A. (2007). A 
chromatin landmark and transcription initiation at most promoters in human cells. Cell 
130, 77-88. 
Guo, Z., and Stiller, J.W. (2004). Comparative genomics of cyclin-dependent kinases 
suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs. BMC 
genomics 5, 69. 
Hahn, S. (2004). Structure and mechanism of the RNA polymerase II transcription 
machinery. Nat Struct Mol Biol 11, 394-403. 
Hawkes, N.A., and Roberts, S.G. (1999). The role of human TFIIB in transcription start 
site selection in vitro and in vivo. J Biol Chem 274, 14337-14343. 
Hengartner, C.J., Myer, V.E., Liao, S.M., Wilson, C.J., Koh, S.S., and Young, R.A. 
(1998). Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-
dependent kinases. Mol Cell 2, 43-53. 
Hengartner, C.J., Thompson, C.M., Zhang, J., Chao, D.M., Liao, S.M., Koleske, A.J., 
Okamura, S., and Young, R.A. (1995). Association of an activator with an RNA 
polymerase II holoenzyme. Genes & development 9, 897-910. 
Hernandez, N. (1993). TBP, a universal eukaryotic transcription factor? Genes & 
development 7, 1291-1308. 
Hirose, Y., and Manley, J.L. (2000). RNA polymerase II and the integration of nuclear 
events. Genes & development 14, 1415-1429. 
Hoey, T., Weinzierl, R.O., Gill, G., Chen, J.L., Dynlacht, B.D., and Tjian, R. (1993). 
Molecular cloning and functional analysis of Drosophila TAF110 reveal properties 
expected of coactivators. Cell 72, 247-260. 
Holstege, F.C., Fiedler, U., and Timmers, H.T. (1997). Three transitions in the RNA 
polymerase II transcription complex during initiation. The EMBO journal 16, 7468-7480. 
Holstege, F.C., van der Vliet, P.C., and Timmers, H.T. (1996). Opening of an RNA 
polymerase II promoter occurs in two distinct steps and requires the basal transcription 
factors IIE and IIH. The EMBO journal 15, 1666-1677. 
References 
 121 
Hu, D., Mayeda, A., Trembley, J.H., Lahti, J.M., and Kidd, V.J. (2003). CDK11 
complexes promote pre-mRNA splicing. J Biol Chem 278, 8623-8629. 
Hu, X., Malik, S., Negroiu, C.C., Hubbard, K., Velalar, C.N., Hampton, B., Grosu, D., 
Catalano, J., Roeder, R.G., and Gnatt, A. (2006). A Mediator-responsive form of 
metazoan RNA polymerase II. Proc Natl Acad Sci U S A 103, 9506-9511. 
Ikeda, K., Stuehler, T., and Meisterernst, M. (2002). The H1 and H2 regions of the 
activation domain of herpes simplex virion protein 16 stimulate transcription through 
distinct molecular mechanisms. Genes Cells 7, 49-58. 
Imbalzano, A.N., Zaret, K.S., and Kingston, R.E. (1994). Transcription factor (TF) IIB 
and TFIIA can independently increase the affinity of the TATA-binding protein for 
DNA. J Biol Chem 269, 8280-8286. 
Ito, M., Yuan, C.X., Malik, S., Gu, W., Fondell, J.D., Yamamura, S., Fu, Z.Y., Zhang, X., 
Qin, J., and Roeder, R.G. (1999). Identity between TRAP and SMCC complexes 
indicates novel pathways for the function of nuclear receptors and diverse mammalian 
activators. Mol Cell 3, 361-370. 
Johnson, K.M., Wang, J., Smallwood, A., and Carey, M. (2004). The immobilized 
template assay for measuring cooperativity in eukaryotic transcription complex assembly. 
Methods in enzymology 380, 207-219. 
Kahle, A., Feng, Y., and M, A.N. (2005). Isolation and characterization of the human 
Cdc2L1 gene promoter. Gene 344, 53-60. 
Kaiser, K., and Meisterernst, M. (1996). The human general co-factors. Trends in 
biochemical sciences 21, 342-345. 
Kaiser, K., Stelzer, G., and Meisterernst, M. (1995). The coactivator p15 (PC4) initiates 
transcriptional activation during TFIIA-TFIID-promoter complex formation. The EMBO 
journal 14, 3520-3527. 
Kamada, K., Shu, F., Chen, H., Malik, S., Stelzer, G., Roeder, R.G., Meisterernst, M., 
and Burley, S.K. (2001). Crystal structure of negative cofactor 2 recognizing the TBP-
DNA transcription complex. Cell 106, 71-81. 
Kang, J.S., Kim, S.H., Hwang, M.S., Han, S.J., Lee, Y.C., and Kim, Y.J. (2001). The 
structural and functional organization of the yeast mediator complex. J Biol Chem 276, 
42003-42010. 
Kanin, E.I., Kipp, R.T., Kung, C., Slattery, M., Viale, A., Hahn, S., Shokat, K.M., and 
Ansari, A.Z. (2007). Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 
does not impair global mRNA synthesis. Proc Natl Acad Sci U S A 104, 5812-5817. 
Kim, J.L., Nikolov, D.B., and Burley, S.K. (1993a). Co-crystal structure of TBP 
recognizing the minor groove of a TATA element. Nature 365, 520-527. 
References 
 122 
Kim, M.K., and Nikodem, V.M. (1999). hnRNP U inhibits carboxy-terminal domain 
phosphorylation by TFIIH and represses RNA polymerase II elongation. Molecular and 
cellular biology 19, 6833-6844. 
Kim, Y., Geiger, J.H., Hahn, S., and Sigler, P.B. (1993b). Crystal structure of a yeast 
TBP/TATA-box complex. Nature 365, 512-520. 
Kim, Y.J., Bjorklund, S., Li, Y., Sayre, M.H., and Kornberg, R.D. (1994). A multiprotein 
mediator of transcriptional activation and its interaction with the C-terminal repeat 
domain of RNA polymerase II. Cell 77, 599-608. 
Ko, T.K., Kelly, E., and Pines, J. (2001). CrkRS: a novel conserved Cdc2-related protein 
kinase that colocalises with SC35 speckles. Journal of cell science 114, 2591-2603. 
Komarnitsky, P., Cho, E.J., and Buratowski, S. (2000). Different phosphorylated forms of 
RNA polymerase II and associated mRNA processing factors during transcription. Genes 
& development 14, 2452-2460. 
Kretzschmar, M., Meisterernst, M., and Roeder, R.G. (1993). Identification of human 
DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA 
polymerase II. Proc Natl Acad Sci U S A 90, 11508-11512. 
Kretzschmar, M., Stelzer, G., Roeder, R.G., and Meisterernst, M. (1994). RNA 
polymerase II cofactor PC2 facilitates activation of transcription by GAL4-AH in vitro. 
Molecular and cellular biology 14, 3927-3937. 
Krishnamurthy, S., He, X., Reyes-Reyes, M., Moore, C., and Hampsey, M. (2004). Ssu72 
Is an RNA polymerase II CTD phosphatase. Mol Cell 14, 387-394. 
Lariviere, L., Geiger, S., Hoeppner, S., Rother, S., Strasser, K., and Cramer, P. (2006). 
Structure and TBP binding of the Mediator head subcomplex Med8-Med18-Med20. Nat 
Struct Mol Biol 13, 895-901. 
Lariviere, L., Seizl, M., van Wageningen, S., Rother, S., van de Pasch, L., Feldmann, H., 
Strasser, K., Hahn, S., Holstege, F.C., and Cramer, P. (2008). Structure-system 
correlation identifies a gene regulatory Mediator submodule. Genes & development 22, 
872-877. 
Larochelle, S., Batliner, J., Gamble, M.J., Barboza, N.M., Kraybill, B.C., Blethrow, J.D., 
Shokat, K.M., and Fisher, R.P. (2006). Dichotomous but stringent substrate selection by 
the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol 13, 
55-62. 
Larochelle, S., Merrick, K.A., Terret, M.E., Wohlbold, L., Barboza, N.M., Zhang, C., 
Shokat, K.M., Jallepalli, P.V., and Fisher, R.P. (2007). Requirements for Cdk7 in the 
assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in 
human cells. Mol Cell 25, 839-850. 
References 
 123 
Laybourn, P.J., and Dahmus, M.E. (1990). Phosphorylation of RNA polymerase IIA 
occurs subsequent to interaction with the promoter and before the initiation of 
transcription. J Biol Chem 265, 13165-13173. 
Lee, H.K., Park, U.H., Kim, E.J., and Um, S.J. (2007). MED25 is distinct from 
TRAP220/MED1 in cooperating with CBP for retinoid receptor activation. The EMBO 
journal 26, 3545-3557. 
Lee, T.I., Wyrick, J.J., Koh, S.S., Jennings, E.G., Gadbois, E.L., and Young, R.A. (1998). 
Interplay of positive and negative regulators in transcription initiation by RNA 
polymerase II holoenzyme. Molecular and cellular biology 18, 4455-4462. 
Lee, T.I., and Young, R.A. (2000). Transcription of eukaryotic protein-coding genes. 
Annual review of genetics 34, 77-137. 
Lewis, B.A., Sims, R.J., 3rd, Lane, W.S., and Reinberg, D. (2005). Functional 
characterization of core promoter elements: DPE-specific transcription requires the 
protein kinase CK2 and the PC4 coactivator. Mol Cell 18, 471-481. 
Li, Y., Bjorklund, S., Jiang, Y.W., Kim, Y.J., Lane, W.S., Stillman, D.J., and Kornberg, 
R.D. (1995). Yeast global transcriptional regulators Sin4 and Rgr1 are components of 
mediator complex/RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 92, 
10864-10868. 
Lin, P.S., Dubois, M.F., and Dahmus, M.E. (2002). TFIIF-associating carboxyl-terminal 
domain phosphatase dephosphorylates phosphoserines 2 and 5 of RNA polymerase II. J 
Biol Chem 277, 45949-45956. 
Liu, Y., Kung, C., Fishburn, J., Ansari, A.Z., Shokat, K.M., and Hahn, S. (2004). Two 
cyclin-dependent kinases promote RNA polymerase II transcription and formation of the 
scaffold complex. Molecular and cellular biology 24, 1721-1735. 
Long, J.J., Leresche, A., Kriwacki, R.W., and Gottesfeld, J.M. (1998). Repression of 
TFIIH transcriptional activity and TFIIH-associated cdk7 kinase activity at mitosis. 
Molecular and cellular biology 18, 1467-1476. 
Loyer, P., Trembley, J.H., Grenet, J.A., Busson, A., Corlu, A., Zhao, W., Kocak, M., 
Kidd, V.J., and Lahti, J.M. (2008). Characterization of cyclin L1 and L2 interactions with 
CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. J Biol 
Chem 283, 7721-7732. 
Lu, H., Zawel, L., Fisher, L., Egly, J.M., and Reinberg, D. (1992). Human general 
transcription factor IIH phosphorylates the C-terminal domain of RNA polymerase II. 
Nature 358, 641-645. 
Luse, D.S., and Jacob, G.A. (1987). Abortive initiation by RNA polymerase II in vitro at 
the adenovirus 2 major late promoter. J Biol Chem 262, 14990-14997. 
References 
 124 
Maldonado, E., Shiekhattar, R., Sheldon, M., Cho, H., Drapkin, R., Rickert, P., Lees, E., 
Anderson, C.W., Linn, S., and Reinberg, D. (1996). A human RNA polymerase II 
complex associated with SRB and DNA-repair proteins. Nature 381, 86-89. 
Malik, S., Baek, H.J., Wu, W., and Roeder, R.G. (2005). Structural and functional 
characterization of PC2 and RNA polymerase II-associated subpopulations of metazoan 
Mediator. Molecular and cellular biology 25, 2117-2129. 
Malik, S., Barrero, M.J., and Jones, T. (2007). Identification of a regulator of 
transcription elongation as an accessory factor for the human Mediator coactivator. Proc 
Natl Acad Sci U S A 104, 6182-6187. 
Malik, S., Gu, W., Wu, W., Qin, J., and Roeder, R.G. (2000). The USA-derived 
transcriptional coactivator PC2 is a submodule of TRAP/SMCC and acts synergistically 
with other PCs. Mol Cell 5, 753-760. 
Malik, S., and Roeder, R.G. (2003). Isolation and functional characterization of the 
TRAP/mediator complex. Methods in enzymology 364, 257-284. 
Mandal, S.S., Chu, C., Wada, T., Handa, H., Shatkin, A.J., and Reinberg, D. (2004). 
Functional interactions of RNA-capping enzyme with factors that positively and 
negatively regulate promoter escape by RNA polymerase II. Proc Natl Acad Sci U S A 
101, 7572-7577. 
Maniatis, T., and Reed, R. (2002). An extensive network of coupling among gene 
expression machines. Nature 416, 499-506. 
Marshall, N.F., Peng, J., Xie, Z., and Price, D.H. (1996). Control of RNA polymerase II 
elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem 271, 
27176-27183. 
Marshall, N.F., and Price, D.H. (1995). Purification of P-TEFb, a transcription factor 
required for the transition into productive elongation. J Biol Chem 270, 12335-12338. 
Max, T., Sogaard, M., and Svejstrup, J.Q. (2007). Hyperphosphorylation of the C-
terminal repeat domain of RNA polymerase II facilitates dissociation of its complex with 
mediator. J Biol Chem 282, 14113-14120. 
Meinhart, A., and Cramer, P. (2004). Recognition of RNA polymerase II carboxy-
terminal domain by 3'-RNA-processing factors. Nature 430, 223-226. 
Meinhart, A., Kamenski, T., Hoeppner, S., Baumli, S., and Cramer, P. (2005). A 
structural perspective of CTD function. Genes & development 19, 1401-1415. 
Meisterernst, M., Roy, A.L., Lieu, H.M., and Roeder, R.G. (1991). Activation of class II 
gene transcription by regulatory factors is potentiated by a novel activity. Cell 66, 981-
993. 
References 
 125 
Meisterernst, M., Stelzer, G., and Roeder, R.G. (1997). Poly(ADP-ribose) polymerase 
enhances activator-dependent transcription in vitro. Proc Natl Acad Sci U S A 94, 2261-
2265. 
Merino, A., Madden, K.R., Lane, W.S., Champoux, J.J., and Reinberg, D. (1993). DNA 
topoisomerase I is involved in both repression and activation of transcription. Nature 365, 
227-232. 
Mermelstein, F., Yeung, K., Cao, J., Inostroza, J.A., Erdjument-Bromage, H., Eagelson, 
K., Landsman, D., Levitt, P., Tempst, P., and Reinberg, D. (1996). Requirement of a 
corepressor for Dr1-mediated repression of transcription. Genes & development 10, 
1033-1048. 
Mittler, G., Kremmer, E., Timmers, H.T., and Meisterernst, M. (2001). Novel critical role 
of a human Mediator complex for basal RNA polymerase II transcription. EMBO reports 
2, 808-813. 
Mittler, G., Stuhler, T., Santolin, L., Uhlmann, T., Kremmer, E., Lottspeich, F., Berti, L., 
and Meisterernst, M. (2003). A novel docking site on Mediator is critical for activation 
by VP16 in mammalian cells. The EMBO journal 22, 6494-6504. 
Moreland, R.J., Tirode, F., Yan, Q., Conaway, J.W., Egly, J.M., and Conaway, R.C. 
(1999). A role for the TFIIH XPB DNA helicase in promoter escape by RNA polymerase 
II. J Biol Chem 274, 22127-22130. 
Muldrow, T.A., Campbell, A.M., Weil, P.A., and Auble, D.T. (1999). MOT1 can activate 
basal transcription in vitro by regulating the distribution of TATA binding protein 
between promoter and nonpromoter sites. Molecular and cellular biology 19, 2835-2845. 
Myer, V.E., and Young, R.A. (1998). RNA polymerase II holoenzymes and 
subcomplexes. J Biol Chem 273, 27757-27760. 
Myers, L.C., Gustafsson, C.M., Bushnell, D.A., Lui, M., Erdjument-Bromage, H., 
Tempst, P., and Kornberg, R.D. (1998). The Med proteins of yeast and their function 
through the RNA polymerase II carboxy-terminal domain. Genes & development 12, 45-
54. 
Naar, A.M., Taatjes, D.J., Zhai, W., Nogales, E., and Tjian, R. (2002). Human CRSP 
interacts with RNA polymerase II CTD and adopts a specific CTD-bound conformation. 
Genes & development 16, 1339-1344. 
Ng, H.H., Robert, F., Young, R.A., and Struhl, K. (2003). Targeted recruitment of Set1 
histone methylase by elongating Pol II provides a localized mark and memory of recent 
transcriptional activity. Mol Cell 11, 709-719. 
Noble, C.G., Hollingworth, D., Martin, S.R., Ennis-Adeniran, V., Smerdon, S.J., Kelly, 
G., Taylor, I.A., and Ramos, A. (2005). Key features of the interaction between Pcf11 
CID and RNA polymerase II CTD. Nat Struct Mol Biol 12, 144-151. 
References 
 126 
Nonet, M.L., and Young, R.A. (1989). Intragenic and extragenic suppressors of 
mutations in the heptapeptide repeat domain of Saccharomyces cerevisiae RNA 
polymerase II. Genetics 123, 715-724. 
Odom, D.T., Zizlsperger, N., Gordon, D.B., Bell, G.W., Rinaldi, N.J., Murray, H.L., 
Volkert, T.L., Schreiber, J., Rolfe, P.A., Gifford, D.K., et al. (2004). Control of pancreas 
and liver gene expression by HNF transcription factors. Science 303, 1378-1381. 
Ohkuma, Y. (1997). Multiple functions of general transcription factors TFIIE and TFIIH 
in transcription: possible points of regulation by trans-acting factors. Journal of 
biochemistry 122, 481-489. 
Ohkuma, Y., Sumimoto, H., Hoffmann, A., Shimasaki, S., Horikoshi, M., and Roeder, 
R.G. (1991). Structural motifs and potential sigma homologies in the large subunit of 
human general transcription factor TFIIE. Nature 354, 398-401. 
Orphanides, G., Lagrange, T., and Reinberg, D. (1996). The general transcription factors 
of RNA polymerase II. Genes & development 10, 2657-2683. 
Orphanides, G., and Reinberg, D. (2002). A unified theory of gene expression. Cell 108, 
439-451. 
Ossipow, V., Tassan, J.P., Nigg, E.A., and Schibler, U. (1995). A mammalian RNA 
polymerase II holoenzyme containing all components required for promoter-specific 
transcription initiation. Cell 83, 137-146. 
Pavri, R., Lewis, B., Kim, T.K., Dilworth, F.J., Erdjument-Bromage, H., Tempst, P., de 
Murcia, G., Evans, R., Chambon, P., and Reinberg, D. (2005). PARP-1 determines 
specificity in a retinoid signaling pathway via direct modulation of mediator. Mol Cell 
18, 83-96. 
Pereira, L.A., Klejman, M.P., and Timmers, H.T. (2003). Roles for BTAF1 and Mot1p in 
dynamics of TATA-binding protein and regulation of RNA polymerase II transcription. 
Gene 315, 1-13. 
Peters, A.H., and Schubeler, D. (2005). Methylation of histones: playing memory with 
DNA. Current opinion in cell biology 17, 230-238. 
Peterson, S.R., Dvir, A., Anderson, C.W., and Dynan, W.S. (1992). DNA binding 
provides a signal for phosphorylation of the RNA polymerase II heptapeptide repeats. 
Genes & development 6, 426-438. 
Peterson, S.R., Jesch, S.A., Chamberlin, T.N., Dvir, A., Rabindran, S.K., Wu, C., and 
Dynan, W.S. (1995). Stimulation of the DNA-dependent protein kinase by RNA 
polymerase II transcriptional activator proteins. J Biol Chem 270, 1449-1454. 
Phatnani, H.P., and Greenleaf, A.L. (2006). Phosphorylation and functions of the RNA 
polymerase II CTD. Genes & development 20, 2922-2936. 
References 
 127 
Price, D.H. (2000). P-TEFb, a cyclin-dependent kinase controlling elongation by RNA 
polymerase II. Molecular and cellular biology 20, 2629-2634. 
Price, D.H. (2008). Poised polymerases: on your mark...get set...go! Mol Cell 30, 7-10. 
Proudfoot, N.J., Furger, A., and Dye, M.J. (2002). Integrating mRNA processing with 
transcription. Cell 108, 501-512. 
Ranish, J.A., Yudkovsky, N., and Hahn, S. (1999). Intermediates in formation and 
activity of the RNA polymerase II preinitiation complex: holoenzyme recruitment and a 
postrecruitment role for the TATA box and TFIIB. Genes & development 13, 49-63. 
Reyes-Reyes, M., and Hampsey, M. (2007). Role for the Ssu72 C-terminal domain 
phosphatase in RNA polymerase II transcription elongation. Molecular and cellular 
biology 27, 926-936. 
Roberts, S.G., Ha, I., Maldonado, E., Reinberg, D., and Green, M.R. (1993). Interaction 
between an acidic activator and transcription factor TFIIB is required for transcriptional 
activation. Nature 363, 741-744. 
Roeder, R.G., and Rutter, W.J. (1969). Multiple forms of DNA-dependent RNA 
polymerase in eukaryotic organisms. Nature 224, 234-237. 
Rossi, F., Labourier, E., Forne, T., Divita, G., Derancourt, J., Riou, J.F., Antoine, E., 
Cathala, G., Brunel, C., and Tazi, J. (1996). Specific phosphorylation of SR proteins by 
mammalian DNA topoisomerase I. Nature 381, 80-82. 
Rossignol, M., Keriel, A., Staub, A., and Egly, J.M. (1999). Kinase activity and 
phosphorylation of the largest subunit of TFIIF transcription factor. J Biol Chem 274, 
22387-22392. 
Roy, R., Schaeffer, L., Humbert, S., Vermeulen, W., Weeda, G., and Egly, J.M. (1994). 
The DNA-dependent ATPase activity associated with the class II basic transcription 
factor BTF2/TFIIH. J Biol Chem 269, 9826-9832. 
Safer, B., Yang, L., Tolunay, H.E., and Anderson, W.F. (1985). Isolation of stable 
preinitiation, initiation, and elongation complexes from RNA polymerase II-directed 
transcription. Proc Natl Acad Sci U S A 82, 2632-2636. 
Sato, S., Tomomori-Sato, C., Banks, C.A., Sorokina, I., Parmely, T.J., Kong, S.E., Jin, J., 
Cai, Y., Lane, W.S., Brower, C.S., et al. (2003). Identification of mammalian Mediator 
subunits with similarities to yeast Mediator subunits Srb5, Srb6, Med11, and Rox3. J Biol 
Chem 278, 15123-15127. 
Schaeffer, L., Roy, R., Humbert, S., Moncollin, V., Vermeulen, W., Hoeijmakers, J.H., 
Chambon, P., and Egly, J.M. (1993). DNA repair helicase: a component of BTF2 (TFIIH) 
basic transcription factor. Science 260, 58-63. 
References 
 128 
Schluesche, P., Stelzer, G., Piaia, E., Lamb, D.C., and Meisterernst, M. (2007). NC2 
mobilizes TBP on core promoter TATA boxes. Nat Struct Mol Biol 14, 1196-1201. 
Schwartz, B.E., Larochelle, S., Suter, B., and Lis, J.T. (2003). Cdk7 is required for full 
activation of Drosophila heat shock genes and RNA polymerase II phosphorylation in 
vivo. Molecular and cellular biology 23, 6876-6886. 
Serizawa, H., Conaway, J.W., and Conaway, R.C. (1993). Phosphorylation of C-terminal 
domain of RNA polymerase II is not required in basal transcription. Nature 363, 371-374. 
Serizawa, H., Tsuchihashi, Z., and Mizumoto, K. (1997). The RNA polymerase II 
preinitiation complex formed in the presence of ATP. Nucleic acids research 25, 4079-
4084. 
Shi, J., and Nelson, M.A. (2005). The cyclin-dependent kinase 11 interacts with NOT2. 
Biochemical and biophysical research communications 334, 1310-1316. 
Singh, B.N., and Hampsey, M. (2007). A transcription-independent role for TFIIB in 
gene looping. Mol Cell 27, 806-816. 
Stelzer, G., Goppelt, A., Lottspeich, F., and Meisterernst, M. (1994). Repression of basal 
transcription by HMG2 is counteracted by TFIIH-associated factors in an ATP-dependent 
process. Molecular and cellular biology 14, 4712-4721. 
Sterner, D.E., and Berger, S.L. (2000). Acetylation of histones and transcription-related 
factors. Microbiol Mol Biol Rev 64, 435-459. 
Svejstrup, J.Q., Li, Y., Fellows, J., Gnatt, A., Bjorklund, S., and Kornberg, R.D. (1997). 
Evidence for a mediator cycle at the initiation of transcription. Proc Natl Acad Sci U S A 
94, 6075-6078. 
Svejstrup, J.Q., Wang, Z., Feaver, W.J., Wu, X., Bushnell, D.A., Donahue, T.F., 
Friedberg, E.C., and Kornberg, R.D. (1995). Different forms of TFIIH for transcription 
and DNA repair: holo-TFIIH and a nucleotide excision repairosome. Cell 80, 21-28. 
Taatjes, D.J., Naar, A.M., Andel, F., 3rd, Nogales, E., and Tjian, R. (2002). Structure, 
function, and activator-induced conformations of the CRSP coactivator. Science 295, 
1058-1062. 
Taatjes, D.J., and Tjian, R. (2004). Structure and function of CRSP/Med2; a promoter-
selective transcriptional coactivator complex. Mol Cell 14, 675-683. 
Takagi, Y., Calero, G., Komori, H., Brown, J.A., Ehrensberger, A.H., Hudmon, A., 
Asturias, F., and Kornberg, R.D. (2006). Head module control of mediator interactions. 
Mol Cell 23, 355-364. 
References 
 129 
Tazi, J., Kornstadt, U., Rossi, F., Jeanteur, P., Cathala, G., Brunel, C., and Luhrmann, R. 
(1993). Thiophosphorylation of U1-70K protein inhibits pre-mRNA splicing. Nature 363, 
283-286. 
Thomas, M.C., and Chiang, C.M. (2006). The general transcription machinery and 
general cofactors. Critical reviews in biochemistry and molecular biology 41, 105-178. 
Thompson, C.M., Koleske, A.J., Chao, D.M., and Young, R.A. (1993). A multisubunit 
complex associated with the RNA polymerase II CTD and TATA-binding protein in 
yeast. Cell 73, 1361-1375. 
Timmers, H.T., and Sharp, P.A. (1991). The mammalian TFIID protein is present in two 
functionally distinct complexes. Genes & development 5, 1946-1956. 
Tora, L. (2002). A unified nomenclature for TATA box binding protein (TBP)-associated 
factors (TAFs) involved in RNA polymerase II transcription. Genes & development 16, 
673-675. 
Trembley, J.H., Hu, D., Slaughter, C.A., Lahti, J.M., and Kidd, V.J. (2003). Casein 
kinase 2 interacts with cyclin-dependent kinase 11 (CDK11) in vivo and phosphorylates 
both the RNA polymerase II carboxyl-terminal domain and CDK11 in vitro. J Biol Chem 
278, 2265-2270. 
Trigon, S., Serizawa, H., Conaway, J.W., Conaway, R.C., Jackson, S.P., and Morange, 
M. (1998). Characterization of the residues phosphorylated in vitro by different C-
terminal domain kinases. J Biol Chem 273, 6769-6775. 
Tsutsui, T., Umemura, H., Tanaka, A., Mizuki, F., Hirose, Y., and Ohkuma, Y. (2008). 
Human mediator kinase subunit CDK11 plays a negative role in viral activator VP16-
dependent transcriptional regulation. Genes Cells. 
Tuteja, N., Tuteja, R., Ochem, A., Taneja, P., Huang, N.W., Simoncsits, A., Susic, S., 
Rahman, K., Marusic, L., Chen, J., et al. (1994). Human DNA helicase II: a novel DNA 
unwinding enzyme identified as the Ku autoantigen. The EMBO journal 13, 4991-5001. 
Uhlmann, T., Boeing, S., Lehmbacher, M., and Meisterernst, M. (2007). The VP16 
activation domain establishes an active mediator lacking CDK8 in vivo. J Biol Chem 
282, 2163-2173. 
van Werven, F.J., van Bakel, H., van Teeffelen, H.A., Altelaar, A.F., Koerkamp, M.G., 
Heck, A.J., Holstege, F.C., and Timmers, H.T. (2008). Cooperative action of NC2 and 
Mot1p to regulate TATA-binding protein function across the genome. Genes & 
development 22, 2359-2369. 
Wada, T., Takagi, T., Yamaguchi, Y., Ferdous, A., Imai, T., Hirose, S., Sugimoto, S., 
Yano, K., Hartzog, G.A., Winston, F., et al. (1998a). DSIF, a novel transcription 
elongation factor that regulates RNA polymerase II processivity, is composed of human 
Spt4 and Spt5 homologs. Genes & development 12, 343-356. 
References 
 130 
Wada, T., Takagi, T., Yamaguchi, Y., Watanabe, D., and Handa, H. (1998b). Evidence 
that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent 
transcription in vitro. The EMBO journal 17, 7395-7403. 
Wang, W., Carey, M., and Gralla, J.D. (1992). Polymerase II promoter activation: closed 
complex formation and ATP-driven start site opening. Science 255, 450-453. 
Wilson, C.J., Chao, D.M., Imbalzano, A.N., Schnitzler, G.R., Kingston, R.E., and Young, 
R.A. (1996). RNA polymerase II holoenzyme contains SWI/SNF regulators involved in 
chromatin remodeling. Cell 84, 235-244. 
Wittenberg, C., and Reed, S.I. (2005). Cell cycle-dependent transcription in yeast: 
promoters, transcription factors, and transcriptomes. Oncogene 24, 2746-2755. 
Woodard, R.L., Anderson, M.G., and Dynan, W.S. (1999). Nuclear extracts lacking 
DNA-dependent protein kinase are deficient in multiple round transcription. J Biol Chem 
274, 478-485. 
Wu, S.Y., Zhou, T., and Chiang, C.M. (2003). Human mediator enhances activator-
facilitated recruitment of RNA polymerase II and promoter recognition by TATA-
binding protein (TBP) independently of TBP-associated factors. Molecular and cellular 
biology 23, 6229-6242. 
Xie, J., Collart, M., Lemaire, M., Stelzer, G., and Meisterernst, M. (2000). A single point 
mutation in TFIIA suppresses NC2 requirement in vivo. The EMBO journal 19, 672-682. 
Yamaguchi, Y., Wada, T., Watanabe, D., Takagi, T., Hasegawa, J., and Handa, H. 
(1999). Structure and function of the human transcription elongation factor DSIF. J Biol 
Chem 274, 8085-8092. 
Yu, V.P., Baskerville, C., Grunenfelder, B., and Reed, S.I. (2005). A kinase-independent 
function of Cks1 and Cdk1 in regulation of transcription. Mol Cell 17, 145-151. 
Yudkovsky, N., Ranish, J.A., and Hahn, S. (2000). A transcription reinitiation 
intermediate that is stabilized by activator. Nature 408, 225-229. 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
 131 
Abbreviations 
 
ATP  adenosine 5’-triphosphate 
ATPγS  adenosine 5’-O-(3-thio)triphosphate 
BRE  TFIIB recognition element 
BSA  bovine serum albumin 
CAK  cyclin-dependent kinase activating kinase 
Cat. no. catalogue number 
ChIP  chromatin immunoprecipitation 
CKI  casein kinase I 
CKII  casein kinase II 
CRIP  crossling-restriction digest immunoprecipitation assay 
CTD  C-terminal domain of the largest subunit of RNAPII Rpb1 
D4476  4-(4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-
  2-yl)benzamide 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DNA-PK DNA protein kinase 
dNTP  deoxynucleotide triphosphate 
DPE  downstream promoter element 
DTT  dithiothreitol 
EDTA  ethylenediamine tetraacetic acid 
EGTA  ethylenebis(oxyethylenenitrilo)tetraacetic acid 
Fig.  figure 
GTF  general transcription factor 
GST  gluthathione S-transferase 
H8  N-[2-(Methylamino)ethyl]-5-isoquinolinesulfonamide hydrochloride 
Hepes  N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
His  hexahistidine tag 
INR  initiator element 
IP  immunoprecipitation 
Abbreviations 
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ML  major-late 
NC2  negative cofactor 2 
NEX  nuclear extract 
PC  positive cofactor 
PCR  polymerase chain reaction 
PIC  preinitiationcomplex 
RNA  ribonucleic acid 
RNAPII RNA polymerase II 
SDS  sodium dodecysulphate 
SDS-PAGE sodium dodecysulphate polyacrylamide gel electrophoresis 
ser  serine 
TAF  TBP-associated factor 
TBB  4,5,6,7-tetrabromobenzotriazole 
TBP  TATA binding protein 
Tris  Tris(hydroxymethyl)aminomethane 
TXN  transcription 
VP16  virion protein 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
